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Foreword 
Cancer in Aboriginal and Torres Strait Islander peoples of Australia: an overview is one of a series 
of reports commissioned by Cancer Australia and developed in collaboration with the 
Australian Institute of Health and Welfare.  
This report provides, for the first time, a comprehensive summary of population-level cancer 
statistics across a number of states and territories in Australia for Aboriginal and Torres 
Strait Islander peoples alongside comparative figures for non-Indigenous Australians. It 
aims to document key cancer statistics to inform health professionals, policy makers, health 
planners, educators, researchers and the broader public of relevant data to understand and 
work towards reducing the impact of cancer for Indigenous Australians.  
On average, per day, around two Aboriginal and Torres Strait Islander people are diagnosed 
with cancer and there is just over one cancer-related death.  
Importantly, this report identifies significant differences between Indigenous Australians 
and their non-Indigenous counterparts. While incidence rates for cancer overall were 
marginally higher for Indigenous peoples, mortality and survival differences between the 
two population groups were more marked with cancer mortality rates 1.5 times higher and 
survival percentages 1.3 times lower for Aboriginal and Torres Strait Islander peoples.  
This report also looks at the 10 most commonly diagnosed cancers as well as the 10 most 
commonly reported causes of cancer deaths for Aboriginal and Torres Strait Islander peoples 
of Australia, accounting for over 60% of cancers in these groups. Lung cancer was both the 
most commonly diagnosed cancer and the leading cause of cancer deaths for this population 
group. Differences between gender and across age groups are also identified. 
In addition, data for survival, prevalence, hospitalisations and burden of disease from cancer 
contextualises the impact of cancer on this population group, and information about 
hospitalisations and expenditure provides an overview of the impact on the health system.  
The work of the Australian Institute of Health and Welfare informs and supports the 
development of policy and programs for Australia through the provision of relevant, timely 
and high-quality information. The Institute collaborates with the Australian, state and 
territory governments and non-governmental organisations in undertaking its mission to 
provide authoritative information and statistics to promote better health and wellbeing.  
Cancer Australia works to reduce the impact of cancer and improve the wellbeing of those 
diagnosed by ensuring that evidence informs cancer prevention, screening, diagnosis, 
treatment and supportive care. This report provides a foundational, evidence-based resource 
upon which to inform Cancer Australia’s work in improving cancer outcomes for Aboriginal 
and Torres Strait Islander peoples. The report also highlights the significant burden of 
disease that cancer places on Aboriginal and Torres Strait Islander peoples and underscores 
the concerted action required across the research and health service sectors to address the 
cancer needs of this community.  
 
David Kalisch       Helen Zorbas, AO 
Director        CEO 
Australian Institute of Health and Welfare   Cancer Australia 
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Summary 
Cancer in Aboriginal and Torres Strait Islander peoples of Australia: an overview provides a 
summary of statistics on cancer in Aboriginal and Torres Strait Islander peoples of Australia.  
Cancer incidence and mortality rates are higher for Indigenous Australians 
In 2004–2008, Indigenous Australians had a higher rate of new cancer cases diagnosed than 
non-Indigenous Australians (461 compared with 434 per 100,000) using age-standardised 
data. Lung cancer was the most commonly diagnosed cancer for Indigenous Australians. 
In 2007–2011, the age-standardised cancer mortality rate was higher for Indigenous 
Australians than for non-Indigenous Australians (252 compared with 172 per 100,000). Lung 
cancer was the leading cause of cancer death for Indigenous Australians. 
Cancer survival is lower for Indigenous Australians 
Indigenous Australians diagnosed with cancer between 1999 and 2007 had a 40% chance of 
surviving for at least 5 years, which was lower than non-Indigenous Australians (52%). 
Fewer cancer-related hospitalisations occurred for Indigenous Australians 
From 2006–07 to 2010–11, Indigenous Australians were less likely to be hospitalised for a 
principal diagnosis of cancer compared with other Australians (113 compared with 170 per 
10,000), although they had longer hospitalisations than other Australians (9.6 compared with 
7.7 days on average). 
Higher prevalence of cancer-related modifiable risk factors 
Aboriginal and Torres Strait Islander peoples have higher rates of certain lifestyle risk 
factors, which can partly explain some cancer incidence and mortality patterns such as: 
 Liver cancer: Indigenous Australians are 3 times as likely to develop, and 3.3 times as 
likely to die from liver cancer and had a lower chance of surviving another 1 year (21% 
compared with 33%) than non-Indigenous Australians. Higher rates of risky alcohol 
consumption and higher prevalence of hepatitis B infection in this population group 
may be contributing factors. 
 Cervical cancer: Indigenous females are 2.8 times as likely to develop and 3.9 times as 
likely to die from cervical cancer and had a lower chance of surviving another 5 years 
(51% compared with 67%) than non-Indigenous females. A contributing factor in the 
higher rates in Indigenous females could be lower rates of cervical screening for this 
population group.  
 Lung cancer: Indigenous Australians are 1.9 times as likely to develop and die from lung 
cancer as non-Indigenous Australians. A contributing factor may be the higher 
prevalence of smoking among Indigenous Australians than non-Indigenous Australians 
(38% compared with 18%). 
 Breast cancer in females: Indigenous females diagnosed with breast cancer in 2003–2007 
had a 100% higher risk of dying from any cause by 2010 than non-Indigenous females. 
The poorer prognosis could be at least partly explained by the lower participation of 
Indigenous females in breast cancer screening (36%) than non-Indigenous females (54%). 
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Data at a glance 
Cancer in Aboriginal and Torres Strait Islander peoples of Australia: an overview provides a 
summary of national statistics on cancer in Aboriginal and Torres Strait Islander peoples of 
Australia. The following table presents summary data on incidence, mortality, 
hospitalisation and survival for Aboriginal and Torres Strait Islander peoples for selected 
cancers. Data presented are restricted to those states and territories for which information on 
Indigenous status is considered of sufficient completeness for reporting (see chapters 3, 4, 5 
and 7 for further information). Comparisons throughout this section are made between 
Indigenous Australians and their non-Indigenous counterparts (or other Australians for 
hospitalisation). 
Age-standardised rates(a) for incidence, mortality, hospitalisation and 5-year crude survival(b) for 
selected cancers, Indigenous Australians  
Cancer site/type 
Incidence
(c)
 
2004–2008 
Mortality 
2007–2011 
Hospitalisation 
2006–07 to 2010–11 
Survival 
1999–2007 
Lung (C33–C34)     
 Indigenous 79.8 63.6 12.3 7.4 
 Non-Indigenous 43.0 33.2 7.9 10.7 
Breast in females (C50)     
 Indigenous 82.1 27.5 13.7 69.9 
 Non-Indigenous 103.6 21.4 20.4 81.3 
Bowel (C18–C20)     
 Indigenous 47.8 13.4 7.8 46.8  
 Non-Indigenous 58.8 16.2 12.7 52.9 
Prostate (C61)     
 Indigenous 105.2 30.6 11.8 62.5 
 Non-Indigenous 147.6 29.9 29.1 72.0 
Unknown primary site/Secondary site (C77–C80)
(d)
     
 Indigenous 23.6 15.7 14.3 6.6 
 Non-Indigenous 12.2 9.6 16.8 8.3 
Cervix (C53)     
 Indigenous 18.0  7.1 4.8 51.2 
 Non-Indigenous 6.5 1.8 1.6 67.2 
Liver (C22)     
 Indigenous 15.3  17.2 3.1 n.p. 
 Non-Indigenous 5.1 5.2 1.5 12.1 
All cancers combined
(e)
     
 Indigenous 460.8 251.7 113.0 40.2 
 Non-Indigenous 434.4 172.4 170.1 51.9 
(a) Rates were directly age-standardised to the Australian population as at 30 June 2001 and are expressed per 100,000 population for 
incidence and mortality and per 10,000 population for hospitalisations. 
(b) Data for 5-year crude survival, expressed as a percentage.  
(c) Incidence refers to the number of new cases diagnosed during a given period. 
(d) For incidence the applicable code is C80 (unknown primary site) and for hospitalisation the applicable codes are C77–C79 (secondary site). 
(e) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, with the exception of those C44 codes that indicate basal cell 
and squamous cell carcinoma of the skin. 
Source: AIHW Australian Cancer Database 2009 and 2007, AIHW National Mortality Database and AIHW National Hospital Morbidity Database. 
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Overview 
The following pages present key findings for leading cancers affecting Aboriginal and Torres 
Strait Islander peoples. Comparisons throughout this section are made between Aboriginal 
and Torres Strait Islander peoples and non-Indigenous Australians (or other Australians for 
hospitalisation) using the latest available data. 
Lung cancer 
Indigenous Australians were 1.9 times as likely to develop, 1.9 times as likely to die from, 
and 1.6 times as likely to be hospitalised for, lung cancer. Indigenous Australians had a 
lower chance of surviving 5 years following a diagnosis of lung cancer (7% compared with 
11%). 
Demographics 
Indigenous Australians had higher mortality rates among all age groups, higher incidence 
rates among those aged 45 and older, higher hospitalisation rates among those aged under 
75 and a lower chance of surviving another 5 years after a lung cancer diagnosis among 
those aged 50 to 69.  
Indigenous males and females had higher incidence, mortality and hospitalisation rates. 
Indigenous Australians had higher incidence rates among those living in all remoteness 
areas, and higher hospitalisation rates among those living in Inner regional, Outer regional and 
Remote and very remote areas. 
Modifiable risk factors 
The higher rates of lung cancer in Indigenous Australians could be explained by the higher 
prevalence of smoking (38% compared with 18% in 2010 after age-standardisation) in this 
population group than non-Indigenous Australians (Roder 2005; AIHW 2011a;  
Cunningham et al. 2008).  
Breast cancer in females 
Indigenous females were 20% less likely to be diagnosed with, and 30% less likely to be 
hospitalised for, breast cancer but were 1.3 times more likely to die from breast cancer.  
Indigenous females diagnosed with breast cancer in 2003–2007 had a 2 times higher risk of 
dying from any cause by 2010, after adjusting for age, sex and geographic remoteness. 
Demographics 
Indigenous females had lower incidence rates among those aged under 65, lower 
hospitalisation rates among those aged under 75 and a lower chance of surviving another  
5 years after a breast cancer diagnosis among all age groups. 
 xiv   
Indigenous females had a lower incidence rate among those living in Remote and very remote 
areas, and a lower chance of surviving another 5 years after a breast cancer diagnosis among 
those living in Inner regional, Outer regional and Remote and very remote areas.  
Screening behaviour 
The lower incidence, but higher mortality rates, of breast cancer in Indigenous females could 
be explained in part by the lower participation in breast cancer screening (36% in Indigenous 
females compared with 54% in non-Indigenous females aged 50–69 in 2010–2011 in screening 
through BreastScreen Australia), meaning that breast cancers are diagnosed at a later stage 
where treatment is not as effective (Roder 2005). 
Bowel cancer 
Indigenous Australians were 20% less likely to be diagnosed with, 20% less likely to die 
from, and 40% less likely to be hospitalised for, bowel cancer. Indigenous Australians had a 
lower chance of surviving 5 years following a diagnosis of bowel cancer (47% compared with 
53%). 
Demographics 
Indigenous Australians had lower incidence rates of bowel cancer among those aged less 
than 45 and those aged between 55 and 74, and lower mortality rates among those aged  
75 and older.  
Indigenous males and females had lower hospitalisation rates, and Indigenous males had 
lower incidence rates, for bowel cancer. 
Indigenous Australians had lower hospitalisation rates among those living in all remoteness 
areas. Indigenous Australians had lower incidence rates and a lower chance of surviving 
another 5 years after a bowel cancer diagnosis among those living in Remote and very remote 
areas. 
Screening behaviour 
The lower incidence rates in Indigenous Australians could be partly explained by the lower 
participation in bowel cancer screening. Of the Australian population aged 50, 55 and 65, 
1.5% identified as Indigenous in the 2011 Census, but only 0.6% of National Bowel Cancer 
Screening Program participants in 2011–12 identified as Indigenous, indicating that not all 
eligible Indigenous Australians participated in this program (or chose not to identify). 
Cervical cancer 
Indigenous females were 2.8 times as likely to develop, 3.9 times as likely to die from, and 3 
times as likely to be hospitalised for, cervical cancer. Indigenous Australians had a lower 
chance of surviving 5 years following a diagnosis of cervical cancer (51% compared with 
67%). 
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Demographics 
Indigenous females had higher incidence and hospitalisation rates for cervical cancer among 
those aged under 75, and higher mortality rates among those aged under 65.  
Indigenous females had higher incidence rates and hospitalisation rates among those living 
in all remoteness areas, and a lower chance of surviving another 5 years among those living 
in Remote and very remote areas.  
Modifiable risk factors 
The higher rates of cervical cancer in Indigenous females could be explained in part by the 
higher prevalence of chronic infections, such as the human papilloma virus (HPV), and 
potentially from lower participation in cancer screening which detects precancerous lesions 
and infection with HPV (Roder 2005; Cunningham et al. 2008).  
Liver cancer 
Indigenous Australians were 3 times as likely to develop, 3.3 times as likely to die from and  
2.1 times as likely to be hospitalised for, liver cancer. Indigenous Australians had a lower 
chance of surviving 1 year following a diagnosis of liver cancer (21% compared with 33%). 
Demographics 
Indigenous Australians had higher incidence and mortality rates among those aged 45 and 
older and higher hospitalisation rates among those aged 45 to 74. 
Indigenous males and females had higher incidence, mortality and hospitalisation rates. 
Indigenous Australians had higher hospitalisation rates among those living in all remoteness 
areas, and higher incidence rates among those living in Major cities, Outer regional and Remote 
and very remote areas. 
Modifiable risk factors 
The higher rates of liver cancer in Indigenous Australians could be explained by the higher 
prevalence of smoking, risky alcohol consumption and chronic infections  
(Roder 2005; Cunningham et al. 2008).  
Prostate cancer 
Indigenous Australians were 30% less likely to be diagnosed with prostate cancer, and 60% 
less likely to be hospitalised for prostate cancer. Indigenous Australians had a lower chance 
of surviving 5 years following a diagnosis of prostate cancer (63% compared with 72%). 
Demographics 
Indigenous Australians had lower hospitalisation rates among all age groups and lower 
incidence rates among all age groups except those aged 75 and older.  
Indigenous Australians living in all remoteness areas had lower incidence and 
hospitalisation rates. 
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Cancer of unknown primary site 
Indigenous Australians were 1.9 times more likely to be diagnosed with, and 1.6 times more 
likely to die from, cancer of unknown primary site.  
Demographics 
Indigenous Australians had higher incidence and mortality rates among those aged 45 to 74. 
Indigenous males and females had higher incidence and mortality rates.  
Indigenous Australians living in Major cities, Outer regional and Remote and very remote areas 
had higher incidence rates.  
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1 Introduction 
This report provides a summary of national statistics on cancer in Aboriginal and Torres 
Strait Islander peoples of Australia. It aims to increase understanding of how this disease 
affects the Aboriginal and Torres Strait Islander population, to inform decision making and 
the development and evaluation of programs and policies. It is directed at a wide audience, 
including health professionals, policy makers, health planners, educators, researchers, 
consumers and the general public. 
For this report, Aboriginal and Torres Strait Islander peoples is the preferred term for referring 
to Aboriginal and Torres Strait Islanders collectively as it recognises the distinct cultures, 
languages and homelands of Australia’s Indigenous communities. However, the term 
Indigenous Australians is sometimes used in place of Aboriginal and Torres Strait Islander peoples 
to improve presentation when comparing cancer statistics with other population groups and 
in presenting information in tables or graphs.  
Demographic characteristics 
Preliminary analysis of the 2011 Census of Population and Housing data suggests that 3% of 
the Australian population identified as being of Aboriginal and/or Torres Strait Islander 
origin (see Box 1.1 for more information).  
Box 1.1: How do changes in the level of Indigenous identification affect cancer 
counts?  
Preliminary analysis of the 2011 Census of Population and Housing data suggests that the 
proportion of the Australian population identifying as being of Aboriginal or Torres Strait 
Islander origin has risen since the 2006 Census. The observed increases may be due to 
population growth, improved identification and a decrease in the belief that identifying can 
have negative repercussions (ABS 2012b).  
The Australian Bureau of Statistics (ABS) recommends that 2011 preliminary Indigenous 
population estimates released in 2012 should not be used for reporting; instead data based 
on the 2006 Census should continue to be used until final population estimates and 
projections are released (ABS 2012a). Final 2011 population estimates for Aboriginal and 
Torres Strait Islander peoples will be released in August 2013 and revised estimates for 
previous and future years will be released by April 2014. While preliminary population 
estimates are available and presented in this section, following on ABS recommendations 
population estimates and projections based on 2006 Census data are used in this report. 
Changes over time in the accuracy of identification of Aboriginal and Torres Strait Islander 
Australians will impact on cancer incidence, mortality and hospitalisation rates as both the 
numerator and denominator used to calculate rates will change. Therefore rates presented 
in this report using estimated populations derived from the 2006 Census should be 
interpreted with this in mind.  
The Indigenous population has a younger overall age structure than the non-Indigenous 
population (Figure 1.1). In 2011, Aboriginal and Torres Strait Islander people aged under 15 
constitute 36% of the Indigenous population, whereas this age group represents 18% of the 
non-Indigenous population. Those aged 65 and over comprise only 3% of the Indigenous 
population, compared with 14% of the non-Indigenous population (ABS 2013).  
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Indigenous     Non-Indigenous 
 
Source: ABS 2013. 
Figure 1.1: Age structure, by sex and Indigenous status, Australia, 2011 
Indigenous population estimates from the 2011 Census are not yet available by remoteness 
areas, therefore the latest available data by remoteness is sourced from the 2006 Census. The 
Indigenous population is more likely to live in remote areas of Australia than non-
Indigenous Australians. In 2006, about one-quarter of Aboriginal and Torres Strait Islander 
peoples lived in remote areas of Australia (9% in Remote and 15% in Very remote areas). The 
remaining three-quarters lived in Major cities (32%), Inner regional areas (21%) and Outer 
regional areas (22%) (Table 1.1). 
Table 1.1: Geographical distribution of the Australian population by Indigenous status, per cent, 
2006  
Remoteness area Indigenous Non-Indigenous 
Major cities 32.1 69.4 
Inner regional 21.4 19.7 
Outer regional 21.9 9.2 
Remote 9.3 1.3 
Very remote 15.4 0.4 
Total
(a)
 100.0 100.0 
(a) The percentages may not add up to total due to rounding. 
Source: ABS 2008. 
Data interpretation 
This report uses the term cancer to refer to tumours that are invasive (that is, malignant), and 
excludes benign or non-invasive tumours. The original site in which a cancerous tumour 
forms is referred to as the primary cancer site, while the spread of cancerous cells to another 
(that is, secondary) site is referred to as metastasis. In general, data in this report are 
presented by primary site, but data in chapters 7 and 8 also include data on metastasis. 
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The report refers to a number of different disease classifications including ICD-10 
(International Statistical Classification of Diseases and Related Health Problems, tenth 
revision) and ICD-10-AM (International Statistical Classification of Diseases and Related 
Health Problems, tenth revision, Australian modification). See Appendix A for further 
information on the use of these codes.  
This report also presents information on the number of cancer cases and deaths, together 
with age-standardised rates. The use of age-standardised rates takes into account differences 
in the age structure and size of the population. This is especially important with regard to 
cancer since the risk of many cancers rises with age. Rates have been standardised to the 
Australian population at 30 June 2001 and are generally expressed per 100,000 population 
unless otherwise specified. See Appendix B for further information.  
Confidence intervals (at the 95% level) are shown in graphs and in tables. CIs can be used as 
a guide when considering whether differences in rates may be a result of chance variation. 
Where CIs do not overlap, the difference between rates is regarded as greater than would be 
attributable to chance. A narrow CI indicates good precision or little random error and, 
conversely, a wider CI indicates poorer precision. See Appendix B for further information.  
In some cases, data based on a small number of cases may need to be suppressed in order to 
maintain data confidentially and to avoid publishing statistics of very low reliability. The 
table or figure where this is applicable notes such cases.  
The quality of cancer data can vary according to the availability of source data. In Australia, 
all states and territories have legislation that makes cancer a notifiable disease and cancer 
data is relatively complete (see Appendix C). However, a range of factors influence key 
cancer measures, such as incidence, mortality and survival (Black et al. 1998; WCRF & AICR 
2007) including: 
 characteristics of those diagnosed with cancer (such as age, sex, race, ethnicity, 
socioeconomic status, presence of additional illness and behaviour, including awareness 
of cancer symptoms and compliance with treatment) 
 the nature of the tumours (such as stage at diagnosis, site of tumour, structure of the 
tumour and extent of disease) 
 health-care system and cancer control (such as availability of and access to screening, 
early detection, changes to treatment facilities and supportive care, quality of treatment 
and follow-up care) 
 completeness of cancer registrations, death registrations and estimated residential 
populations (including the level of Indigenous identification). 
Due to these factors, data presented in this report should be interpreted with care and used 
as a guide.  
Aboriginal and Torres Strait Islander peoples may have poor access to health-care services 
due to financial, language, cultural or geographical barriers (Queensland Health 2006; 
Stumpers & Thomson 2009). In addition, Indigenous Australians may be less likely to 
participate in cancer screening and other prevention programs than non-Indigenous 
Australians (Roder 2005; Burns et al. 2010). Therefore, when Aboriginal and Torres Strait 
Islander peoples in Australia present for diagnosis, they may have a more advanced stage of 
cancer and can have a number of additional diagnoses (Moore et al. 2010). Aboriginal and 
Torres Strait Islander peoples in Australia can also have a lower uptake of cancer treatment 
(Cunningham et al. 2008). 
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Box 1.2: Terminology used throughout this report 
 The term cancer is used to refer to tumours which are invasive. 
 The term significant refers to a statistically significant difference, where 95% CIs do not 
overlap. Such differences may or may not be significant from a practical or clinical 
perspective. Note that while rates for Indigenous and non-Indigenous Australians may 
differ, the smaller size of the Indigenous population has led to broader CIs that may 
overlap. 
Population groups used throughout this report: 
 Aboriginal and Torres Strait Islander peoples or Indigenous Australians refers to those 
people who identify as being of Aboriginal and/or Torres Strait Islander descent. 
 Non-Indigenous Australians refers to people who have declared they are not of 
Aboriginal or Torres Strait Islander descent. 
 Other Australians includes people who have declared that they are not of Aboriginal or 
Torres Strait Islander descent and others who have not stated their Indigenous status. 
 Total Australians includes Aboriginal and Torres Strait Islander peoples of Australia, 
non-Indigenous Australians and others who have not stated their Indigenous status. 
Data sources 
This report uses the most up-to-date data available. The registration of cancer is a dynamic 
process in that existing records may be modified if new information is received. It can take 
some time for the necessary information to be become available and to be finalised before 
being provided to the AIHW. Once the AIHW receives the data, further time is needed to 
process and finalise them into a national data set. As a result, the statistics in the main 
chapters refer to different years ranging from 2011 to earlier periods, depending on the data 
process (see Table 1.2 for information on years reported by data source). 
A key data source for this report was the 2009 Australian Cancer Database (ACD). The ACD 
contains information on all new cases of primary, invasive cancer diagnosed in Australia, 
excluding basal and squamous cell carcinomas of the skin. State and territory cancer 
registries collect data from a number of sources, such as pathology and haematology 
laboratories, hospitals and death registrations, and these data are supplied annually to the 
AIHW. The 2009 data files for NSW and the ACT were not available for inclusion in the 2009 
version of the ACD. As a consequence, this report does not use 2009 cancer data as the most 
recent national incidence data available for inclusion were for 2008.  
The Registries of Births, Deaths and Marriages, the ABS and the National Coronial 
Information System provided the mortality data used in this report, and these data are 
maintained in the National Mortality Database (NMD). Death information presented in this 
report relates to the year of death, except for data from the most recent year available 
(namely, 2011) where year of registration is used. Generally, for the most part, the year of 
death and year of registration correspond, but deaths that occur at the end of the year often 
do not get registered until the following year due to a lag in processing. Therefore, the 
number of deaths registered for the most recent year is used as an estimate to account for 
these deaths. 
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This report uses several other data sources, including the National Death Index (NDI), the 
National Hospital Morbidity Database and the 2008 GLOBOCAN database. See Appendix C 
for information on each data source, including data quality statements. 
Quality of Indigenous status data 
The quality of information on Indigenous status varies among these data sources by 
jurisdiction and year of collection. In some areas, data presented are restricted to those states 
and territories where information on Indigenous status is considered of sufficient 
completeness for reporting (see Table 1.2 for a summary). This report presents incidence data 
by Indigenous status for four jurisdictions, mortality data for five jurisdictions and hospitals 
data for six jurisdictions. Each chapter provides details of the Indigenous status data quality. 
Table 1.2: Availability of cancer data by Indigenous status 
Data source Measure NSW Vic Qld WA SA Tas ACT NT 
Missing 
data
(a)
 
Australian Cancer database (2009 
version, reporting years 2004–2008) 
Incidence         12% 
National Mortality Database (reporting 
years 2007–2011) 
Mortality         0.8% 
National Hospital Morbidity Database
(b)
 
(2006–07 to 2010–11 financial years) 
Hospitalisation          11% 
BreastScreen Australia
(c)
 (2 years  
2010–2011) 
Breast screening         n.a. 
National Bowel Cancer Screening 
Program
(c)
 (July 2011 and June 2012) 
Bowel screening         n.a. 
National Cervical Screening Program Cervical screening         n.a. 
(a) Missing data refers to the per cent of records with unknown Indigenous status.  
(b) The Northern Territory data by Indigenous status considered acceptable for analysis purposes are restricted to public hospitals only. 
(c) Information on the BreastScreen Australia and National Bowel Cancer Screening Program require people to self-report and therefore some 
Aboriginal and Torres Strait Islander people may choose to not identify. 
Source: AIHW Australian Cancer Database 2009, AIHW National Mortality Database, AIHW National Hospital Morbidity Database,  
AIHW 2012e, AIHW 2013b, AIHW 2013d and AIHW 2013f. 
What is missing from the picture? 
The ACD currently does not contain information on the stage of cancer at diagnosis, 
presence of co-morbidity, treatment or frequency of recurrence of cancer after treatment 
(AIHW 2012b). Some pilot projects are underway to collect these data with the aim of 
extending the method to national data collection (CA 2010). 
Reliable national data on the incidence and mortality of cancer for Aboriginal and Torres 
Strait Islander peoples are not available. Further, information on cervical screening by 
Indigenous status are not reported, as there are no national mechanisms for collecting 
Indigenous status on pathology or cytology forms. There are also no nationally coordinated 
approaches to collecting national primary health-care data on cancer by Indigenous status. 
As part of the National Indigenous Reform Agreement, National best practice guidelines for 
collecting Indigenous status in health data sets have been developed to improve the collection of 
baseline Indigenous status information (AIHW 2013g). Further, Federal, state and territory 
governments are reviewing practices for collecting pathology information (AIHW 
forthcoming 2013), including introducing a standard question on Indigenous status. They are 
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also developing Key Performance Indicators for Indigenous-specific primary health-care 
services (Council of Australian Governments 2011). 
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2 Risk factors 
Understanding what causes cancer is important to enable successful prevention, detection 
and treatment of the disease. For most cancers, the causes are not fully understood. However 
some factors are well-recognised as contributing to the development of cancer. These factors 
include genetic, lifestyle and environmental factors (Figure 2.1). While some risk factors 
cannot be changed, others, mainly those relating to behaviours and lifestyles, are modifiable, 
and improvements in these areas could be beneficial in lowering cancer rates.  
 
Note: Based on information published in IARC 2008 and WCRF & AICR 2007. 
Figure 2.1: Risk factors for cancer  
Aboriginal and Torres Strait Islander peoples 
Compared with their non-Indigenous counterparts, Indigenous Australians as a group are 
more socially disadvantaged and this contributes to their poorer health status. On average, 
they have higher rates of unemployment, lower educational attainment and live in more 
overcrowded households (AIHW 2012b; AIHW 2013a). 
Data suggests that Aboriginal and Torres Strait Islander peoples have risk factors relevant to 
cancer, including tobacco smoking, risky alcohol consumption, poor diet, low levels of 
physical activity and high levels of infection such as Hepatitis B (Condon 2004; Cunningham 
et al. 2008). The high prevalence of these risk factors could play a part in the higher cancer 
incidence and mortality rates observed in this population group (Cunningham et al. 2008). 
Cancers associated with risk factors that are of particular concern for Aboriginal and Torres 
Strait Islander peoples are listed in the boxes below, divided into lifestyle (and potentially 
modifiable) factors, biomedical factors and other factors.  
 
 
 
 
Biomedical factors 
•Genetic susceptibility 
•Hormonal factors in 
females 
Lifestyle factors 
•Smoking 
•Alcohol consumption 
•Diet 
•Physcial inactivity and 
obesity 
•Chronic infections 
Environmental 
factors 
•Sunlight 
•Radiation 
•Occupational exposure 
•Pollution 
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Lifestyle factors 
 
 
 
 
 
Smoking and passive smoking 
Smoking is a major cause of cancer in humans, and is responsible for one in 
five of all deaths in Aboriginal and Torres Strait Islander peoples in Australia 
(Vos et al. 2007). Indigenous Australians generally take up smoking at an 
earlier age, continue to smoke for longer and make fewer quitting attempts 
than non-Indigenous Australians (CCA 2007).  
In 2010, Indigenous Australians were 2.2 times as likely as non-Indigenous 
Australians to smoke tobacco (38% compared with 18% after  
age-standardisation). Further, among current smokers, on average Indigenous 
Australians smoked 46 cigarettes more per week (147) than non-Indigenous 
Australians (101) (AIHW 2011a). 
Evidence indicates that active and for some cases, passive smoking, can cause 
cancers of the following sites: 
 • bladder 
• cervix 
• kidney 
• larynx 
• liver 
• lung 
• myeloid leukaemia 
• nasal cavity and nasal sinuses 
• oral cavity (lip, mouth, tongue) 
• oesophagus 
• pancreas 
• pharynx 
• stomach. 
 
 Alcohol consumption 
Alcohol consumption is an important risk factor for cancer with the risk 
increasing with the amount of alcohol consumed (IARC 2008). It is associated 
with an estimated 6% of the total burden of disease for Aboriginal and Torres 
Strait Islander people in Australia (Vos et al. 2007).  
In 2010, 23% of Indigenous Australians compared with 16% of non-Indigenous 
Australians had more than four standard drinks at least once a week, and 30% 
compared with 20% had on average more than two standard drinks per day, 
which means Indigenous Australians were about 1.5 times as likely to drink 
alcohol at risky levels on both single occasions and during their lifetime 
(AIHW 2011a).  
Cancers associated with alcohol consumption include those of the: 
 • bowel 
• breast (females) 
• larynx 
• liver 
• oesophagus 
• oral cavity (lip, mouth, tongue) 
• pharynx. 
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 Diet 
Good nutrition contributes to quality of life, helps maintain a healthy body 
weight and reduces the risk of chronic diseases such as cancer. Alternatively, 
poor diets are associated with many chronic diseases that are a major cause of 
death (AIHW 2012a). 
In 2004–05, Indigenous Australians were about 7 times as likely as non-
Indigenous Australians to report no usual daily vegetable consumption (5% 
compared with 0.8%) and twice as likely to report no usual daily fruit 
consumption (13% compared with 7%) (AIHW 2011b). Fruit and vegetables 
were reported to be less accessible for approximately two-thirds of Indigenous 
Australians living in regional and remote areas of Australia (ABS 2009b; 
AIHW 2011b). 
Evidence suggests that high intake of particular foods (such as processed meat 
and foods that are high in fat) may be associated with an increased risk of 
cancers of the: 
 • bowel 
• breast 
• kidney 
• oesophagus 
• pancreas 
• prostate 
• stomach 
• uterus. 
 
 Obesity and physical inactivity 
Obesity is defined as abnormal or excessive fat accumulations that may impair 
health and a body mass index of 30 and over.  
Physical activity is an important part of a healthy lifestyle. Doing little or no 
physical activity increases an individual's risk of being overweight or obese, 
and is associated with a higher risk of developing cancer (AIHW 2012b).  
In 2004–2005, Indigenous Australians were 1.8 times more likely to be obese 
than non-Indigenous Australians. Approximately 29% of adult Indigenous 
Australians were classified as overweight, and 31% as obese (AIHW 2011b). 
Indigenous Australians were also more likely to be sedentary and less 
physically active than non-Indigenous Australians. In 2004–05, approximately 
half (51%) of Indigenous Australians reported their exercise level as sedentary 
compared to a third (33%) of non-Indigenous Australians (AIHW 2011b). 
Obesity and lack of physical activity is thought to increase the risk of cancers 
of the: 
 • bowel 
• breast (females) 
• endometrium 
• gall bladder 
• kidney 
• oesophagus 
• ovary 
• pancreas. 
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 Chronic infections 
Chronic infections, such as hepatitis B virus (HBV) and human papilloma 
virus (HPV) can cause cancer.  
HBV infection occurs among Indigenous Australians at a higher rate than  
non-Indigenous Australians. In 2005, Indigenous Australians were 7 times as 
likely to have HBV compared with non-Indigenous Australians (DoHA 2010).  
Recent research has found that about half of the total liver cancer mortality can 
be attributed to HBV infection (Lozano et al. 2012).  
Cancers associated with chronic infections are thought to include those of the:  
 • bladder 
• cervix 
• blood or bone marrow 
(leukaemias) 
• liver 
• lung 
• lymphatic system (lymphomas) 
• nasopharynx and oropharynx 
• oral cavity (lip, mouth, tongue) 
• stomach. 
Biomedical factors 
 Reproductive and hormonal factors 
Reproductive hormones are thought to influence the risk of developing some 
cancers. For women, the risk can be related to early pregnancies and to 
multiple pregnancies (Roder 2005).  
In 2010, Indigenous women had a higher birth rate than non-Indigenous 
women (2.6 compared with 1.9 babies), and on average had children at a 
younger age (median age of 24.6 compared with 30.7, respectively) (ABS 2011).  
Cancers that are associated with reproductive and hormonal factors include 
those of the: 
 • breast 
• endometrium  
• ovary. 
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Other factors 
 Participation in cancer screening 
Australia has three national population cancer screening programs 
(BreastScreen Australia, the National Cervical Screening Program and the 
National Bowel Cancer Screening Program), directed at reducing illness and 
death from cancer through early detection and effective follow-up treatment. 
Finding cancers early can mean that the cancers are less advanced, which for 
some cancers may be associated with increased treatment options (NBOCC 
2009) and improved survival (AIHW & NBCC 2007). 
Indigenous Australians have lower participation in screening programs than 
non-Indigenous Australians. Over 2010 and 2011, participation in screening 
through BreastScreen Australia by Indigenous women in the target age group 
(50–69 years) was lower at 36% than their non-Indigenous counterparts (54%) 
(AIHW 2013b). Of the Australian population aged 50, 55 and 65, 1.5% 
identified as Indigenous in the 2011 Census, but only 0.6% of National Bowel 
Cancer Screening Program participants in 2011–12 identified as Indigenous, 
indicating that not all eligible Indigenous Australians participated in this 
program or chose not to identify (AIHW 2013f). Of particular concern, research 
in cervical cancer screening has found that Indigenous Australians participate 
in screening at a lower rate than non-Indigenous Australians (Coory et al. 
2002; Binns & Condon 2006), but have higher incidence and mortality rates of 
cervical cancer (Condon 2004; Condon et al. 2005; Roder 2005; Stumpers & 
Thomson 2009). 
Invasive cancers that could be prevented or detected earlier by participating in 
national population screening programs include those of the: 
 • bowel 
• breast 
• cervix. 
 
 Area of residence 
People living in rural and remote areas tend to be less healthy, have higher 
mortality rates and lower levels of education, income and employment than 
their city counterparts (AIHW 2012b). Further, the cost of basic nutritious food 
can be 30% higher in rural and remote areas than in urban and metropolitan 
areas (Harrison et al. 2010). The availability of quality fresh fruit and 
vegetables and better food choices decreases in remote communities while the 
cost rises (AIHW 2012a). 
In 2006, approximately one-quarter (24%) of Aboriginal and Torres Strait 
Islander peoples lived in remote or very remote areas of Australia (ABS 2008). 
For these Aboriginal and Torres Strait Islander peoples, there can be issues 
with accessing preventive, diagnostic and curative health-care services 
because of geographical barriers (Stumpers & Thomson 2009).  
Research suggests that the further a person’s residential address is from major 
treatment centres, the poorer their cancer outcome (CA 2009).  
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3 Incidence of cancer 
Key findings 
Between 2004 and 2008 in New South Wales, Queensland, Western Australia and the 
Northern Territory: 
 3,875 Aboriginal and Torres Strait Islander people were diagnosed with cancer. 
 Indigenous Australians were more likely to be diagnosed with cancer at a younger age 
than non-Indigenous Australians. 
 The age-standardised incidence rate for all cancers combined was significantly higher 
for: 
– Indigenous Australians compared with non-Indigenous Australians (461 and 434 per 
100,000, respectively) 
– Indigenous males than for Indigenous females (549 compared with 400 per 100,000) 
– Indigenous females than for non-Indigenous females (400 compared with 361 per 
100,000) 
– Indigenous Australians living in Outer regional areas compared with non-Indigenous 
Australians living in these areas (285 compared with 243 per 100,000). 
 The most commonly diagnosed cancers for Aboriginal and Torres Strait Islander peoples 
were cancers of the lung (603 cases), breast in females (438), bowel (348), prostate (291) 
and unknown primary site (167). 
 Indigenous Australians were 3 times as likely to be diagnosed with liver cancer, 2.8 times 
as likely to be diagnosed with cervical cancer, 1.9 times as likely to be diagnosed with 
lung cancer and 1.9 times as likely to be diagnosed with cancer of unknown primary site 
as their non-Indigenous counterparts. 
About incidence 
 Incidence is the number of new primary cancers and not a recurrence of a previous 
primary cancer (IARC 2004). 
 The main data source was the 2009 ACD.  
 Data provided is for new primary invasive cancer cases diagnosed in Aboriginal and 
Torres Strait Islander peoples during 2004–2008. 
 Information in the ACD on Indigenous status is only considered of sufficient 
completeness for reporting for New South Wales, Queensland, Western Australia and 
the Northern Territory.  
 Comparisons have been made throughout with non-Indigenous Australians, with the 
analysis excluding those for whom Indigenous status was not given. The overall level 
of missing data on Indigenous status was 12% (Table 3.1). 
 The Australian Standard Geographical Classification Remoteness Area (ASGC RA) 
(ABS 2006) was used to make comparisons by remoteness status (see Appendix A for 
more details). 
 More detailed data are available in Cancer in Aboriginal and Torres Strait Islander peoples 
of Australia: supplementary data tables on the AIHW website. 
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All cancers combined 
In 2004–2008, in the four jurisdictions analysed, 3,875 Aboriginal and Torres Strait Islander 
people were diagnosed with cancer (Table 3.1). This means, on average, about two 
Indigenous Australians were diagnosed with cancer every day in these states and territories.  
During the same period, the age-standardised incidence rate of all cancers combined for 
Indigenous Australians was 461 cases per 100,000 persons, which was significantly higher 
than the rate for non-Indigenous Australians (434 per 100,000).  
Table 3.1: Incidence of all cancers combined(a) by Indigenous status, New South Wales, 
Queensland, Western Australia and the Northern Territory, 2004–2008 
Indigenous status Number  Per cent ASR
(b)
 95% CI 
Indigenous 3,875 1.1 460.8 443.8–478.2 
Non-Indigenous 292,949 86.8 434.4 432.8–436.0 
Not stated 40,494 12.0 . . . . 
Total 337,318 100.0 494.1 492.4–495.8 
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, with the exception of those C44 codes that indicate basal 
cell and squamous cell carcinoma of the skin. 
(b) Rates were directly age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
Source: AIHW Australian Cancer Database 2009. 
Age 
Indigenous Australians were diagnosed with cancer at a younger age than non-Indigenous 
Australians (Table 3.2). The higher relative proportion of new cases among Indigenous 
Australians aged less than 55 is likely to be due to the relatively younger age structure in this 
population group and the lower overall life expectancy (AIHW 2012b). 
The age-specific incidence rates for all cancers combined increased with age for both groups 
and were generally higher for Indigenous Australians than non-Indigenous Australians in all 
age groups except for those aged less than 45 (Table 3.2). The incidence rate for Indigenous 
Australians within this younger age category was significantly lower than that of  
non-Indigenous Australians (42 compared with 63 per 100,000). 
Sex 
The number of new cancer cases diagnosed among Aboriginal and Torres Strait Islander 
peoples was equally distributed among males and females (Table 3.2). However the  
age-standardised incidence rate for all cancers combined was significantly higher for 
Aboriginal and Torres Strait Islander males than for their female counterparts (549 compared 
with 400 per 100,000). 
Indigenous females had a significantly higher age-standardised incidence rate than their 
non-Indigenous counterparts (400 compared with 361 per 100,000) (Table 3.2). Indigenous 
males also had a higher rate than their non-Indigenous counterparts, but the difference was 
not significant. 
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A smaller proportion of Indigenous Australians diagnosed with cancer lived in Major cities 
compared with non-Indigenous Australians (29% compared with 65%), and a greater 
proportion lived in Remote and very remote areas (27% compared with 2%) (Table 3.2). 
The age-standardised incidence rate for all cancers combined was significantly higher for 
Indigenous Australians living in Outer regional areas compared with their non-Indigenous 
counterparts (285 compared with 243 per 100,000). Among Indigenous Australians, the 
highest incidence rate was for those living in Outer regional areas (285 per 100,000), 
significantly higher than the rate for Remote and very remote areas (245 per 100,000).  
Table 3.2: Incidence of all cancers combined(a) by Indigenous status, age group, sex and remoteness 
area, New South Wales, Queensland, Western Australia and the Northern Territory, 2004–2008 
 
Indigenous  Non-Indigenous 
Number  Per cent  Rate
(b)
 95% CI  Number  Per cent  Rate
(b)
 95% CI 
Age groups (years) 
<45 763 19.7 42.2 39.2–45.3  24,793 8.5 62.5 61.7–63.3 
45–54 815 21.0 435.8 406.4–466.8  35,028 12.0 393.6 389.5–397.7 
55–64 975 25.2 968.7 908.8–1,031.4  65,690 22.4 929.9 922.8–937.1 
65–74 836 21.6 1,870.4 1,745.8–2,001.6  75,797 25.9 1,719.2 1,707.0–1,731.5 
75+ 486 12.5 2,380.3 2,173.3–2,601.6  91,640 31.3 2,354.9 2,339.7–2,370.2 
Sex 
Males 1,931 49.8 549.1 519.1–580.1  165,103 56.3 524.7 522.2–527.3 
Females 1,944 50.2 399.9 379.8–420.8  127,846 43.6 361.0 359.0–363.0 
Remoteness area 
Major cities 1,139 29.4 269.3 253.2–286.1  191,504 65.4 252.5 251.2–253.8 
Inner 
regional 734 18.9 258.5 239.3–278.7  65,285 22.3 256.7 254.3–259.1 
Outer 
regional  924 23.8 284.6 265.9–304.3  29,175 10.0 243.0 239.7–246.2 
Remote and 
very remote 1,059 27.3 245.3 230.1–261.3  5,661.54 1.9 260.0 252.8–267.3 
Not stated 19 0.5 . . . .  1,323 0.5 252.5 . . 
Total 3,875 100.0 460.8 443.8–478.2  292,949 100.0 434.4 432.8–436.0 
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, with the exception of those C44 codes that indicate basal cell 
and squamous cell carcinoma of the skin. 
(b) The rates for age groups (years) are expressed per 100,000 population. The rates for sex, remoteness area and the total were directly  
age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
Source: AIHW Australian Cancer Database 2009. 
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Cancer type 
The 10 most commonly diagnosed cancers among Aboriginal and Torres Strait Islander 
peoples accounted for 63% of all cancers diagnosed within this population (Table D3.1). The 
top 10 cancer incidence rankings for Indigenous Australians differed from those for  
non-Indigenous Australians and all Australians (Table 3.3, online supplementary Table 
G3.2). Cancer types that were ranked higher in the Indigenous population than in the  
non-Indigenous population include: 
 lung cancer (ranked first compared with fourth) 
 cervical cancer (ranked seventh compared with twenty-second) 
 liver cancer (ranked ninth compared with eighteenth). 
Table 3.3: The 10 most commonly diagnosed cancers in Aboriginal and Torres Strait Islander 
peoples, New South Wales, Queensland, Western Australia and the Northern Territory, 2004–2008 
 Indigenous  Non-Indigenous 
Cancer site/type Number Ranking  Number Ranking 
Lung (C33–C34) 603 1  28,998 4 
Breast in females(C50) 438 2  35,851 3 
Bowel (C18–C20)  348 3  39,725 2 
Prostate (C61) 291 4  47,404 1 
Unknown primary site (C77–C80) 167 5  8,329 7 
Non-Hodgkin lymphoma (C82–C85) 125 6  10,945 6 
Cervix (C53) 121 7  2,185 22 
Uterus (C54–C55) 120 8  5,243 13 
Liver (C22) 118 9  3,429 18 
Pancreas (C25) 110 10  7,046 8 
All cancers combined
(a)
 3,875 . .  292,949 . . 
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, with the exception of those C44 codes that indicate basal cell 
and squamous cell carcinoma of the skin. 
Notes 
1. Full list of cancer types can be found in online supplementary Table G3.1. 
2. Top 10 rankings of Indigenous, non-Indigenous and all Australians can be found in online supplementary Table G3.2. 
Source: AIHW Australian Cancer Database 2009. 
Comparison of the age-standardised incidence rates for the 10 most common cancers 
indicates that Indigenous Australians (Figure 3.1): 
 were 3 times as likely to develop liver cancer, 2.8 times as likely to develop cervical 
cancer, 1.9 times as likely to develop lung cancer, 1.9 times as likely to develop cancer of 
unknown primary site and 1.5 times as likely to develop pancreatic cancer as non-
Indigenous Australians 
 were less likely to develop breast cancer in females (rate ratio of 0.8), bowel (0.8) and 
prostate cancers (0.7) as non-Indigenous Australians.  
The high prevalence of risk factors, such as smoking, risky alcohol consumption and higher 
levels of chronic infections may explain the higher rates of liver, cervical and lung cancer. 
The lower rates of breast cancer in females, bowel and prostate cancer could be related to the 
lower participation in screening (Roder 2005; Cunningham et al. 2008). 
 16 Cancer in Aboriginal and Torres Strait Islander peoples of Australia: an overview 
 
Notes 
1. Rates were directly age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
2. Breast cancer is for females only. UPS stands for unknown primary site. NHL stands for non-Hodgkin lymphoma. 
3. Figure is ordered based on top 10 cancer incidence numbers for Indigenous Australians. 
4. The data for this figure are shown in Table D3.1. 
Source: AIHW Australian Cancer Database 2009. 
Figure 3.1: Age-standardised incidence rates of the 10 most commonly diagnosed cancers in 
Aboriginal and Torres Strait Islander peoples, New South Wales, Queensland, Western Australia 
and the Northern Territory, 2004–2008 
Age 
Consistent with the overall findings, the age-specific incidence rate for Indigenous 
Australians, compared with non-Indigenous Australians (Figure 3.2), was: 
 significantly higher for lung and liver cancers among all age groups except those aged 
less than 45; for cervical cancer among all age groups except those aged 75 and older; 
and for cancer of unknown primary site among those aged 45 to 74 
 significantly lower for prostate cancer among all age groups except those aged 75 and 
older; breast cancer in females among all age groups except those aged 65 and older; and 
bowel cancer among those aged less than 45 and those aged between 55 and 74. 
Other cancers where Indigenous Australians had significantly higher age-specific incidence 
rates than non-Indigenous Australians include uterine cancer among those aged 45–54 and 
pancreatic cancer among those aged 45 to 64. 
Sex 
Consistent with the overall findings, the age-standardised incidence rate (Figure 3.3) was: 
 significantly higher for Indigenous males than non-Indigenous males for liver cancer, 
lung cancer and cancer of unknown primary site; and for Indigenous females than non-
Indigenous females for liver cancer, cervical cancer, lung cancer and cancer of unknown 
primary site 
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 significantly lower for Indigenous males than non-Indigenous males for bowel cancer 
and prostate cancer; and for Indigenous females than non-Indigenous females for breast 
cancer. 
Other cancers of interest include significantly higher rates of uterine cancer and pancreatic 
cancer in Indigenous females. Within the Indigenous population, Indigenous males had 
significantly higher rates of liver cancer and lung cancer than Indigenous females. 
Remoteness 
Consistent with the overall findings, the age-standardised incidence rate for Indigenous 
Australians compared with non-Indigenous Australians (Figure 3.4) was significantly: 
 higher for those living in all remoteness areas for lung and cervical cancers 
 higher for those living in Major cities, Outer regional and Remote and very remote areas for 
liver cancer and cancer of unknown primary site 
 lower for those living in all remoteness areas for prostate cancer, and for those living in 
Remote and very remote for breast cancer in females and bowel cancer. 
When comparing within the Indigenous population, Indigenous Australians living in Remote 
and very remote areas had significantly: 
 higher rate of cancer of unknown primary site and significantly lower rates of bowel and 
prostate cancers and breast cancer in females than those living in Major cities  
 lower rates of bowel and prostate cancers than those living in Inner regional and Outer 
regional areas. 
These results could suggest that Indigenous Australians living in Remote and very remote 
areas have poorer access to health-care services and are more likely to have cancers that are 
diagnosed at a later stage when the primary site is no longer apparent (Roder 2005; 
Cunningham et al. 2008).  
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Notes 
1. There are differences in the scale on the y-axis between cancer types. 
2. The rates are expressed per 100,000 population. 
3. The data for this figure are shown in Table D3.2. 
Source: AIHW Australian Cancer Database 2009. 
Figure 3.2: Age-specific incidence rates for the 10 most commonly diagnosed cancers in Aboriginal 
and Torres Strait Islander peoples, by age group, New South Wales, Queensland, Western 
Australia and the Northern Territory, 2004–2008 
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Notes 
1. There are differences in the scale on the y-axis between cancer types. 
2. Rates were directly age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
3. The data for this figure are shown in Table D3.3. 
Source: AIHW Australian Cancer Database 2009. 
Figure 3.3: Age-standardised incidence rates for the 10 most commonly diagnosed cancers in 
Aboriginal and Torres Strait Islander peoples, by sex, New South Wales, Queensland, Western 
Australia and the Northern Territory, 2004–2008 
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Notes 
1. MC stands for Major cities, IR stands for Inner regional, OR stands for Outer regional and R+VR stands for Remote and very remote. 
2. There are differences in the scale on the y-axis between cancer types. 
3. Rates were directly age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
4. The data for this figure are shown in Table D3.4. 
Source: AIHW Australian Cancer Database 2009. 
Figure 3.4: Age-standardised incidence rates for the 10 most commonly diagnosed cancers in 
Aboriginal and Torres Strait Islander peoples, by remoteness area, New South Wales, Queensland, 
Western Australia and the Northern Territory, 2004–2008 
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Clinical cancer groupings 
This section presents statistics on cancer incidence based on clinical cancer groupings. 
Cancer types are categorised into groups based on clinical categories. For example, prostate, 
testicular, bladder and kidney cancers are grouped as ‘urogenital cancers’ as these cancers 
are most often treated by an urologist. Similarly, all cancers of the female genital organs are 
grouped as ‘gynaecological cancers’ as these cancers are most often treated by a 
gynaecologist or gynaecological oncologist (see Appendix E).  
The three clinical cancer groupings with the highest number of cases for Aboriginal and 
Torres Strait Islander peoples in Australia were respiratory (631 cases), urogenital (487 cases) 
and upper gastrointestinal (479 cases) (Table 3.4). The proportional distributions differed 
significantly for Indigenous Australians and non-Indigenous Australians as follows:  
 Indigenous Australians were more likely than non-Indigenous Australians to be 
diagnosed with respiratory (16% compared with 11%), upper gastrointestinal  
(12% compared with 8%), gynaecological (9% compared with 4%) and head and neck 
(8% compared with 3%) cancers 
 Indigenous Australians were less likely than non-Indigenous Australians to be 
diagnosed with urogenital (13% compared with 22%), colorectal (10% compared with 
14%) and skin (2% compared with 9%) cancers. 
Table 3.4: Incidence of cancer, by Indigenous status and clinical grouping, New South Wales, 
Queensland, Western Australia and the Northern Territory, 2004–2008 
 Indigenous  Non-Indigenous 
Clinical cancer grouping (ICD-10 codes) Number  Per cent   Number  Per cent  
Respiratory (C33–C34, C37–C38, C45) 631 16.3   31,293 10.7 
Urogenital (C60–C68) 487 12.6   64,661 22.1 
Upper gastrointestinal (C15–C17, C22–C25) 479 12.4   22,562 7.7 
Breast (C50) 441 11.4   36,141 12.3 
Colorectal (C18–C21) 370 9.5   40,605 13.9 
Lymphohaematopoietic (C81–C85, C88, C90–C96, D45, D46, D47.1, D47.3) 369 9.5   29,094 9.9 
Gynaecological (C51–C59) 332 8.6   12,414 4.2 
Head and neck (C01–C14, C30–C32) 295 7.6   8,357 2.9 
Ill-defined and unknown primary sites (C26, C39, C48, C76–C79, C80) 186 4.8   9,465 3.2 
Thyroid and other endocrine (C73–C75) 105 2.7   5,931 2.0 
Skin (C00, C43, C44, C46) 89 2.3   25,207 8.6 
Neurological (C70–C72) 59 1.5   4,462 1.5 
Bone and other connective tissue (C40–C41, C47, C49) 26 0.7   1,946 0.7 
Eye (C69) 6 0.2   811 0.3 
Total
(a)
 3,875 100.0  292,949 100.0 
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, with the exception of those C44 codes that indicate basal cell 
and squamous cell carcinoma of the skin. 
Source: AIHW Australian Cancer Database 2009. 
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Excess cancer incidence 
Indigenous Australians are 1.1 times more likely to be diagnosed with cancer than  
non-Indigenous Australians (Table 3.1). Another way to detect the average slight  
over-representation of cancer in Indigenous Australians is to compare the number of 
observed cases with the expected cases if the non-Indigenous age-specific incidence rates 
were applied to the Indigenous population. A positive number (higher number of cases 
observed than expected) indicates an excess in cancer cases, while a negative number 
indicates that there were fewer cancer cases than expected (see Appendix B). Note that the 
numbers of excess cases for individual cancer types are not expected to sum to the number of 
excess case for all cancers. 
If the non-Indigenous incidence rate was applied to the Indigenous population, there would 
be an expected 3,662 new cancer cases, rather than the observed 3,875 cases (Table D3.5). This 
means that overall there were 213 excess cases of cancer among Aboriginal and Torres Strait 
Islander peoples than would be expected. The number of excess cancer cases varied by 
cancer type as follows (Figure 3.5): 
 Lung cancer accounted for the largest number of excess cases (315), followed by cancer 
of unknown primary site (91), liver cancer (77) and cervical cancer (75). 
 For breast cancer in females, bowel cancer, prostate cancer and non-Hodgkin lymphoma, 
there were less cancers observed among Indigenous Australians than would be expected 
if the non-Indigenous incidence rates applied.  
More detailed data on the number of excess cancer cases in Aboriginal and Torres Strait 
Islander peoples by cancer type, age group and sex are available in Cancer in Aboriginal and 
Torres Strait Islander peoples of Australia: supplementary data tables on the AIHW website.  
 
Notes 
1. Excess new cases are the observed new cases minus the expected new cases. 
2. Breast cancer is for females only. UPS stands for unknown primary site. NHL stands for non-Hodgkin lymphoma. 
3. All cancers includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, with the exception of those C44 codes that 
indicate basal cell and squamous cell carcinoma of the skin. 
4. Excess cases are derived by applying the age-specific rates from the non-Indigenous population to the age distribution of the Indigenous 
population. The numbers of excess cases for individual cancer types are not expected to sum to the number of excess case for all cancers. 
5. The data for this figure are shown in Table D3.5. 
Source: AIHW Australian Cancer Database 2009. 
Figure 3.5: Excess new cases for the 10 most commonly diagnosed cancers and for all cancers in 
Aboriginal and Torres Strait Islander peoples, New South Wales, Queensland, Western Australia 
and the Northern Territory, 2004–2008 
Excess cases
–200
–100
   0
 100
 200
 300
 400
Cancer type
Lung Breast Bow el Prostate UPS NHL Cervix Uterus Liver Pancreas All
cancers
  Cancer in Aboriginal and Torres Strait Islander peoples of Australia: an overview 23 
4 Mortality from cancer 
Key findings 
Between 2007 and 2011 in New South Wales, Queensland, Western Australia, South 
Australia and the Northern Territory: 
 2,197 Aboriginal and Torres Strait Islander people died from cancer (1,137 males and 
1,060 females). 
 Indigenous Australians died from cancer at a younger age than non-Indigenous 
Australians. 
 The age-standardised mortality rate for all cancers combined was: 
– 1.5 times as high for Indigenous Australians compared with non-Indigenous 
Australians (252 and 172 per 100,000, respectively) 
– higher for both Indigenous males and females than non-Indigenous males and 
females (1.4 and 1.6 times, respectively). 
 The most common causes of cancer death among Aboriginal and Torres Strait Islander 
peoples were cancers of the lung (549 deaths), liver (145), breast in females (140), 
unknown primary site (131) and bowel (118). 
 Indigenous Australians were 3.9 times as likely to die from cervical cancer, 3.3 times as 
likely to die from liver cancer, 2.3 times as likely to die from oesophageal cancer and 1.9 
times as likely to die from lung cancer as non-Indigenous Australians. 
 Cancer was recorded as an associated cause of death for 605 Aboriginal and Torres Strait 
Islander people; for 61% of these, cancer was the underlying cause of death. 
About mortality 
 The main data source was the National Mortality Database (NMD) (see Appendix C 
for more information).  
 Data provided are for deaths during 2007‒2011 for which the underlying cause of 
death was cancer. 
 Mortality data presented are based on the year of death, except in 2011 (the latest 
available year), where the year of registration of death is used instead. Previous 
investigation has shown that, due to a lag in the processing of death information, 
number of deaths registered in that year is closer to the true value. 
 Information in the NMD on Indigenous status is only considered of sufficient 
completeness for reporting for New South Wales, Queensland, Western Australia, 
South Australia and the Northern Territory.  
 Comparisons have been made throughout with non-Indigenous Australians, with the 
analysis excluding those for whom Indigenous status was not given. The overall level 
of missing data on Indigenous status was 0.8% (Table 4.1). 
 More detailed data are available in Cancer in Aboriginal and Torres Strait Islander peoples 
of Australia: supplementary data tables on the AIHW website. 
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All cancers combined 
From 2007 to 2011, 2,197 Aboriginal and Torres Strait Islander people from New South 
Wales, Queensland, Western Australia, South Australia and the Northern Territory died 
from cancer (Table 4.1). This accounted for 19% of all deaths for this population group. This 
means on average about one Indigenous Australian died from cancer every day during this 
time in these states and territories.  
During the same period, the age-standardised mortality rate of all cancers combined for 
Indigenous Australians was 252 per 100,000 persons, which was significantly higher 
 (1.5 times) than for non-Indigenous Australians (172 per 100,000).  
Table 4.1: Mortality from all cancers combined(a), by Indigenous status, New South Wales, 
Queensland, Western Australia, South Australia and the Northern Territory, 2007–2011  
Indigenous status Number  Per cent of cancer deaths  Per cent of all deaths ASR
(b)
 95% CI 
Indigenous 2,197 1.5 19.4 251.7 239.4–264.4 
Non-Indigenous 144,791 97.8 29.6 172.4 171.5–173.3 
Not stated 1,120 0.8 21.4 . . . . 
Total 148,108 100.0 29.3 174.7 173.8–175.6 
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3. 
(b) Rates were directly age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
Note: Mortality data for 2007–2009 are final, 2010 are revised and 2011 are preliminary. Data for 2010 and 2011 are subject to revision. 
Source: AIHW National Mortality Database. 
Age 
A greater proportion of Indigenous Australians died from cancer at a younger age than  
non-Indigenous Australians (Table 4.2). For Indigenous Australians, 29% died from cancer 
before the age of 55 compared with 10% of non-Indigenous Australians. The relatively 
younger age structures for the Indigenous population may affect the lower proportion of 
cancer deaths in Indigenous Australians aged 75 and older (AIHW 2012b). 
For both Indigenous and non-Indigenous Australian population groups, there was a 
significant overall trend of increasing cancer mortality rate with increasing age. The  
age-specific mortality rates for all cancers combined were significantly higher for Indigenous 
Australians than non-Indigenous Australians for all age groups under 75 (Table 4.2). The 
high proportion of deaths for Indigenous Australians from chronic diseases including cancer 
is of concern to the Australian Government (AHMAC 2012). 
Sex 
The number of deaths among Aboriginal and Torres Strait Islander males and females were 
similar (1,137 and 1,060, respectively) but the age-standardised mortality rate for Indigenous 
males was 1.4 times that for Indigenous females (305 compared with 214 per 100,000) (Table 
4.2). 
The age-standardised mortality rates were significantly higher for Indigenous males and 
females than for non-Indigenous males and females (rate ratio of 1.4 and 1.6, respectively) 
(Table 4.2). 
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Table 4.2: Mortality from all cancers combined(a) by Indigenous status, age group and sex, New 
South Wales, Queensland, Western Australia, South Australia and the Northern Territory,  
2007–2011  
 
Indigenous  Non-Indigenous 
Number  Per cent  Rate
(b)
 95% CI  Number  Per cent  Rate
(b)
 95% CI 
Age groups (years) 
<45 248 11.3 12.3 10.8–13.9  4,392 3.0 9.5 9.3–9.8 
45–54 394 17.9 176.9 159.9–195.3  9,630 6.7 91.9 90.0–93.7 
55–64 570 25.9 447.8 411.8–486.1  22,779 15.7 261.7 258.3–265.1 
65–74 588 26.8 1,061.5 977.4–1150.8  34,890 24.1 634.6 628.0–641.3 
75+ 397 18.1 1,979.3 1,789.3–2,183.9   73,096 50.5 2,119.5 2,104.2–2,134.9 
Sex          
Males 1,137 51.8 305.2 283.3–328.1  82,591 57.0 220.0 218.5–221.5 
Females 1,060 48.2 214.4 199.8–229.6   62,200 43.0 135.4 134.3–136.5 
Total 2,197 100.0 251.7 239.4–264.4  144,791 100.0 172.4 171.5–173.3 
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3. 
(b) The rates for age groups (years) are expressed per 100,000 population. The rates for sex and the total were directly age-standardised to 
the Australian population as at 30 June 2001 and expressed per 100,000 population. 
Note: Mortality data for 2007–2009 are final, 2010 are revised and 2011 are preliminary. Data for 2010 and 2011 are subject to revision. 
Source: AIHW National Mortality Database. 
Cancer type 
The 10 most common causes of cancer deaths among Aboriginal and Torres Strait Islander 
peoples accounted for 68% of all cancer deaths in this population (Table D4.1). The top 10 
cancer rankings for Indigenous Australians differed from that for non-Indigenous 
Australians and all Australians (Table 4.3, online supplementary Table G4.3). Lung cancer 
was the most common cause of cancer-related death for both Indigenous and  
non-Indigenous Australians. Cancer types that ranked higher among Indigenous than  
non-Indigenous Australians include: 
 liver cancer (ranked second compared with ninth)  
 cervical cancer (ranked tenth compared with twenty-seventh) 
 oesophageal cancer (ranked seventh compared with twelfth) 
 stomach cancer (ranked ninth compared with thirteenth). 
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Table 4.3: The 10 leading causes of cancer deaths among Aboriginal and Torres Strait Islander 
peoples, New South Wales, Queensland, Western Australia, South Australia and the Northern 
Territory, 2007–2011  
 Indigenous  Non-Indigenous 
Cancer site/type Number Ranking  Number Ranking 
Lung (C33–C34) 549 1  27,678 1 
Liver (C22) 145 2  4,289 9 
Breast in females (C50) 140 3  9,586 4 
Unknown primary site (C77–C80) 131 4  8,119 5 
Bowel (C18–C20) 118 5  13,644 2 
Pancreas (C25) 112 6  7,938 6 
Oesophagus (C15) 106 7  4,020 12 
Prostate (C61) 72 8  10,754 3 
Stomach (C16) 65 9  3,674 13 
Cervix (C53) 52 10  793 27 
All cancers combined
(a)
 2,197 . .  144,791 . . 
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3. 
Notes 
1. Full list of cancer types can be found in online supplementary Table G4.2. 
2. Top 10 rankings of Indigenous, non-Indigenous and all Australians can be found in online supplementary Table G4.3. 
3. Mortality data for 2007–2009 are final, 2010 are revised and 2011 are preliminary. Data for 2010 and 2011 are subject to revision. 
Source: AIHW National Mortality Database. 
Comparison of the age-standardised mortality rates for the 10 leading causes of cancer 
deaths indicates that Indigenous Australians are more likely to die from cervical cancer (rate 
ratio 3.9), liver cancer (3.3), oesophageal cancer (2.3), lung cancer (1.9), stomach cancer (1.7), 
cancer of unknown primary site (1.6), pancreatic cancer (1.4) and breast cancer in females 
(1.3) than non-Indigenous Australians (Figure 4.1). 
The higher prevalence of risk factors for these cancers in this population group such as 
smoking, alcohol consumption and HPV infection rates may explain the higher rates of lung, 
liver and cervical cancers. Cancers of the lung and liver have a poor prognosis in both 
Indigenous and non-Indigenous Australians. However, Indigenous Australians are usually 
diagnosed with these cancers at a later stage, are less likely to receive adequate treatment 
and are more likely to die from these cancers than non-Indigenous Australians (Cunningham 
et al. 2008). 
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Notes 
1. Rates were directly age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
2. Breast cancer is for females only. UPS stands for unknown primary site. 
3. Cancer types are ordered based on top 10 cancer mortality numbers for Indigenous Australians. 
4. Mortality data for 2007–2009 are final, 2010 are revised and 2011 are preliminary. Data for 2010 and 2011 are subject to revision. 
5. The data for this figure are shown in Table D4.1. 
Source: AIHW National Mortality Database. 
Figure 4.1: Age-standardised mortality rates for the 10 leading causes of cancer deaths among 
Aboriginal and Torres Strait Islander peoples, New South Wales, Queensland, Western Australia, 
South Australia and the Northern Territory, 2007–2011 
Age 
Consistent with the overall findings, the age-specific mortality rate for Indigenous 
Australians compared with non-Indigenous Australians was significantly higher for lung 
cancer among all age groups, for liver cancer among those aged 45 and older, for cervical 
cancer among those aged less than 65, for oesophageal cancer and cancer of unknown 
primary site among those aged between 45 and 74 and for stomach cancer among those aged 
55–64 (Figure 4.2). 
Other findings of interest for Indigenous Australians compared with non-Indigenous 
Australians include significantly higher rates of pancreatic cancer among those aged 45–54 
and 55–64, and significantly lower rates of bowel cancer for those aged 75 and older. 
Sex 
Consistent with the overall findings, the age-standardised mortality rate was significantly 
higher (Figure 4.3): 
 for Indigenous males than non-Indigenous males for liver cancer (rate ratio of 3.1), 
oesophageal cancer (2.3), lung cancer (2.0), stomach (1.7) and unknown primary site (1.6)  
 for Indigenous females than non-Indigenous females for liver cancer (rate ratio of 4.1), 
cervical cancer (3.9), oesophageal cancer (2.6), lung cancer (1.9) and unknown primary 
site (1.7). 
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Other findings of interest include significantly higher rates of pancreatic cancer (rate ratio of 
1.6) and breast cancer (1.3) among Indigenous females than non-Indigenous females. Within 
the Indigenous population, Indigenous males had significantly higher rates of oesophageal 
cancer (2.9), lung cancer (2.0) and liver cancer (1.9) than Indigenous females. 
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Notes 
1. There are differences in the scale on the y-axis between cancer types. 
2. Rates are expressed per 100,000 population. 
3. Mortality data for 2007–2009 are final, 2010 are revised and 2011 are preliminary. Data for 2010 and 2011 are subject to revision. 
4. The data for this figure are shown in Table D4.2. 
Source: AIHW National Mortality Database. 
Figure 4.2: Age-specific mortality rates for the 10 leading causes of cancer deaths among Aboriginal 
and Torres Strait Islander peoples, by age group, New South Wales, Queensland, Western 
Australia, South Australia and the Northern Territory, 2007–2011 
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Notes 
1. There are differences in the scale on the y-axis between cancer types. 
2. Rates were directly age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
3. Mortality data for 2007–2009 are final, 2010 are revised and 2011 are preliminary. Data for 2010 and 2011 are subject to revision. 
4. The data for this figure are shown in Table D4.3. 
Source: AIHW National Mortality Database. 
Figure 4.3: Age-standardised mortality rates for the 10 leading causes of cancer deaths among 
Aboriginal and Torres Strait Islander peoples, by sex, New South Wales, Queensland, Western 
Australia, South Australia and the Northern Territory, 2007–2011 
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Clinical cancer groupings 
This section presents statistics on cancer mortality based on clinical cancer grouping 
categories. See Chapter 3 and Appendix E for information on clinical group.  
The three cancer clinical groupings with the highest number of deaths for Aboriginal and 
Torres Strait Islander peoples were respiratory (563 deaths), upper gastrointestinal  
(463 deaths) and ill-defined and unknown primary sites (197 deaths) (Table 4.4).  
The proportional distributions of cancer mortality by clinical cancer groupings differed 
between Indigenous and non-Indigenous Australians as follows: 
 a greater proportion of Indigenous Australians than non-Indigenous Australians died 
from respiratory (26% compared with 21%), upper gastrointestinal  
(21% compared with 15%), head and neck (8% compared with 2%), and gynaecological 
(6% compared with 4%) cancers 
 Indigenous Australians were less likely than non-Indigenous Australians to die from 
lymphohaematopoietic (7% compared with 11%), colorectal (6% compared with 10%), 
urogenital (6% compared with 12%), and skin (2% compared with 5%) cancers. 
Table 4.4: Mortality from cancer, by Indigenous status and clinical groupings, New South Wales, 
Queensland, Western Australia, South Australia and the Northern Territory, 2007–2011 
Clinical cancer grouping (ICD-10 codes) 
Indigenous  Non-Indigenous 
Number Per cent  Number Per cent 
Respiratory (C33–C34, C37–C38, C45) 563 25.6  30,096 20.8 
Upper gastrointestinal (C15–C17, C22–C25) 463 21.1  21,110 14.6 
Ill-defined and unknown primary sites (C26, C39, C48, C76–C79, C80) 197 9.0  13,352 9.2 
Head and neck (C01–C14, C30–C32) 167 7.6  3,288 2.3 
Lymphohaematopoietic (C81–C85, C88, C90–C96, D45, D46, D47.1, D47.3) 145 6.6  15,151 10.5 
Breast (C50) 140 6.4  9,664 6.7 
Colorectal (C18–C21) 125 5.7  13,870 9.6 
Gynaecological (C51–C59) 121 5.5  5,447 3.8 
Urogenital (C60–C68) 133 6.1  17,767 12.3 
Skin (C00, C43, C44, C46) 40 1.8  7,111 4.9 
Neurological (C70–C72) 38 1.7  4,131 2.9 
Multiple primary (C97) 25 1.1  1,932 1.3 
Thyroid and other endocrine (C73–C75) 19 0.9  562 0.4 
Bone and other connective tissue (C40–C41, C47, C49) 19 0.9  1,219 0.8 
Eye (C69) 2 0.1  91 0.1 
Total
(a)
 2,197 100.0   144,791 100.0 
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3. 
Note: Mortality data for 2007–2009 are final, 2010 are revised and 2011 are preliminary. Data for 2010 and 2011 are subject to revision. 
Source: AIHW National Mortality Database. 
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Excess cancer deaths 
Indigenous Australians were 1.5 times as likely to die from cancer as non-Indigenous 
Australians (Table 4.1). Another way to express the over-representation of cancer deaths for 
Indigenous Australians is to compare the observed number of cancer deaths with the 
number of expected cancer deaths if the non-Indigenous age-specific mortality rates were to 
apply to the Indigenous population. A positive number indicates an excess in cancer deaths 
in Indigenous Australians, while a negative number indicates that there were less  
cancer-related deaths than would be expected if similar rates applied to both populations 
(see Appendix B). Note that the numbers of excess deaths for individual cancer types are not 
expected to sum to the number of excess case for all cancers. 
If the non-Indigenous mortality rate was applied to the Indigenous population, there would 
be an expected 1,459 deaths rather than the observed 2,197 deaths (Table D4.4). This means 
that overall there were 738 excess cancer deaths among Aboriginal and Torres Strait Islander 
peoples than would be expected. Aboriginal and Torres Strait Islander peoples with cancer 
are diagnosed at a later stage and are less likely to receive adequate treatment and this may 
in part explain the excess deaths in this population. (Cunningham et al. 2008). 
For Aboriginal and Torres strait Islander peoples, the number of excess cancer cases varied 
by cancer type (Figure 4.4). Lung cancer accounted for the largest number of excess death 
(443 excess), followed by liver cancer (131 excess), cancer of unknown primary site and 
oesophageal cancer (both 97 excess). 
More detailed data on the number of excess Aboriginal and Torres Strait Islander deaths by 
cancer type, age group and sex are available in Cancer in Aboriginal and Torres Strait Islander 
peoples of Australia: supplementary data tables on the AIHW website. 
 
Notes 
1. Excess deaths are the observed deaths minus the expected deaths. 
2. Breast cancer is for females only. UPS stands for unknown primary site. 
3. All cancers Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3. 
4. Excess deaths are derived by applying the age-specific rates from the non-Indigenous population to the age distribution of the Indigenous 
population. The numbers of excess deaths for individual cancer types are not expected to sum to the number of excess deaths for all 
cancers. 
5. Mortality data for 2007–2009 are final, 2010 are revised and 2011 are preliminary. Data for 2010 and 2011 are subject to revision. 
6. The data for this figure are shown in Table D4.4. 
Source: AIHW Australian Cancer Database 2009. 
Figure 4.4: Excess cancer deaths for the 10 leading causes of cancer deaths among Aboriginal and 
Torres Strait Islander peoples, New South Wales, Queensland, Western Australia, South Australia 
and the Northern Territory, 2007–2011 
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Associated cause of death  
The data presented so far in this chapter apply to deaths for which cancer was the 
underlying cause of death. However, information about diseases or conditions contributing 
to the death (multiple causes of death) is also available. In this section, the number of people 
who died from any cause where cancer was also mentioned as an associated cause of death 
(see Box 4.1) is presented.  
Box 4.1: What is an associated cause of death? 
A Medical Certificate of Cause of Death (death certificate) enables a medical practitioner to 
record all medical conditions instrumental in causing the death. The ABS codes the 
information recorded on the death certificates. The coding process considers the sequence of 
occurrence of each disease or health condition, removes duplicates and applies logical rules 
to select the underlying and associated causes (see Multiple causes of death (AIHW 2012g)). 
Underlying cause of death refers to the disease, injury, accident or violence that initiated the 
sequence of events leading directly to death.  
Associated causes of death refers to any other conditions or events that were instrumental in 
causing death, including conditions that occurred immediately before death or close to the 
time of death or conditions that occurred between the underlying and immediate causes.  
Between 2007 and 2011, 605 Aboriginal and Torres Strait Islander people died with cancer 
recorded as an associated cause of death (Table 4.5). Of the deaths where cancer was an 
associated cause, 61% had cancer also recorded as the underlying cause of death. 
Table 4.5: Underlying causes of death where cancer was an associated cause of death, by 
Indigenous status, New South Wales, Queensland, Western Australia, South Australia and the 
Northern Territory, 2007–2011  
 Indigenous  Non-Indigenous  Total
(a)
 
Underlying cause of death (ICD-10 codes) No.  Per cent  No.  Per cent  No.  Per cent 
Cancer (C00–C97, D45, D46, D47.1, D47.3) 368 60.8  28,311 57.2  28,887 57.2 
Cardiovascular disease (I00–I99) 82 13.6  10,391 21.0  10,567 20.9 
Endocrine and metabolic disease (E00–E90) 32 5.3  1,299 2.6  1,343 2.7 
Respiratory system disease (J00–J99) 34 5.6  2,948 6.0  3,014 6.0 
Digestive disease (K00–K93) 23 3.8  1,251 2.5  1,288 2.6 
Other diseases (All remaining ICD-10 codes) 12 2.0  548 1.1  568 1.1 
Certain infectious and parasitic diseases (A00–B99) 13 2.1  692 1.4  711 1.4 
Genitourinary system diseases (N00–N99) 11 1.8  706 1.4  723 1.4 
Nervous system disease (G00–G99) 7 1.2  998 2.0  1,012 2.0 
Skin and subcutaneous tissue diseases (L00–L99) 6 1.0  280 0.6  288 0.6 
Mental and behavioural disorder (F00–F99) 10 1.7  1,266 2.6  1,281 2.5 
External causes (V00–V98) 7 1.2  810 1.6  826 1.6 
Total
(b)
 605 100.0   49,500 100.0   50,508 100.0 
(a) Includes deaths for which information on Indigenous status was not available. 
(b) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3. 
Note: Mortality data for 2007–2009 are final, 2010 are revised and 2011 are preliminary. Data for 2010 and 2011 are subject to revision. 
Source: AIHW National Mortality Database. 
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5 Survival after a diagnosis of cancer 
Key findings 
Between 1999 and 2007 in New South Wales, Queensland, Western Australia and the 
Northern Territory: 
 The 5-year crude survival for Indigenous Australians was 40% for all cancers combined, 
which was significantly lower than for non-Indigenous Australians (52%). 
 Compared with their non-Indigenous counterparts, the 5-year crude survival rate for 
Indigenous Australians was significantly lower: 
– for all age groups 
– for both males and females 
– for those living in all remoteness areas 
– for lung cancer (7% compared with 11%), breast cancer in females (70% compared 
with 81%), bowel cancer (47% compared with 53%), prostate cancer (63% compared 
with 72%) and cervical cancer (51% compared with 67%). 
The mortality-to-incidence ratio suggests that cancer survival among Indigenous Australians 
was similar to that for people in the regions of Southern Europe, Polynesia and Micronesia. 
Indigenous Australians diagnosed with any cancer between 2003 and 2007 had a 97% higher 
risk of death from any cause by 2010 than non-Indigenous Australians, after adjusting for 
age, sex and geographic remoteness (hazard ratio of 1.97). 
About survival 
 The main data source was the ACD, with information on deaths (from any cause) 
sourced from the NDI. 
 Data provided are for cancer-related crude survival estimates for Aboriginal and 
Torres Strait Islander peoples for the period 1999–2007 (note: for the multivariate 
regression analysis, data on deaths from all causes are used due to data availability). 
 Information in the NMD on Indigenous status is considered of sufficient completeness 
for reporting for New South Wales, Queensland, Western Australia and the Northern 
Territory.  
 Comparisons have been made throughout with non-Indigenous Australians, with the 
analysis excluding those for whom Indigenous status was not stated.  
 Crude survival estimates were calculated using the cohort method, instead of the 
period method, as it provides more precise estimates (that is, estimates with narrower 
CIs). See Appendix B for more information. 
 Crude survival is the proportion of people alive at a specified point in time subsequent 
to the diagnosis of cancer. This report’s main measure is 5-year crude survival, which 
refers to the proportion of people alive 5 years after their diagnosis.  
 The ASGC RA (ABS 2006) was used to make comparisons by remoteness status (see 
Appendix A for more details) 
 More detailed data are available in Cancer in Aboriginal and Torres Strait Islander peoples 
of Australia: supplementary data tables on the AIHW website. 
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All cancers combined 
Aboriginal and Torres Strait Islander peoples diagnosed with cancer between 1999 and 2007 
had a 61% chance of surviving 1 year and a 40% chance of surviving for at least 5 years after 
a cancer diagnosis (Table 5.1). Indigenous Australians had significantly lower  
5-year crude survival than non-Indigenous Australians (40% compared with 52%).  
Table 5.1: Five-year crude survival for all cancers combined(a) by Indigenous status, New South 
Wales, Queensland, Western Australia and the Northern Territory, 1999–2007 
Survival 
Indigenous  Non-Indigenous 
Crude survival (%) 95% CI  Crude survival (%) 95% CI 
1-year survival 60.8 59.6–62.0  74.0 73.8–74.1 
5-year survival 40.2 38.9–41.5  51.9 51.7–52.0 
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, with the exception of those C44 codes that indicate basal cell 
and squamous cell carcinoma of the skin. 
Source: AIHW Australian Cancer Database 2007. 
Age 
For both Indigenous and non-Indigenous population groups, the 5-year crude survival from 
cancer tended to fall with age. For all age groups, the survival estimates for Indigenous 
Australians were significantly lower than those for non-Indigenous Australians (Table 5.2).  
Sex 
Both Indigenous males and females diagnosed with cancer had significantly lower 5-year 
survival rates than their non-Indigenous counterparts (34% compared with 48% for males 
and 46% compared with 56% for females) (Table 5.2). Within the Indigenous population, 
Indigenous females diagnosed with cancer were 1.3 times as likely to survive 5 years past 
diagnosis as their male counterparts. 
Remoteness 
Indigenous Australians living in all remoteness areas had significantly lower 5-year crude 
survival than their non-Indigenous counterparts (Table 5.2). Because cancer survival for 
Indigenous Australians tended to decrease with remoteness, the differences in survival 
between the two population groups increased with increasing remoteness.  
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Table 5.2: Five-year crude survival for all cancers combined(a) by Indigenous status, age group, sex 
and remoteness area, New South Wales, Queensland, Western Australia and the Northern 
Territory, 1999–2007 
 
Indigenous 
 
Non-Indigenous 
Crude survival (%) 95% CI 
 
Crude survival (%) 95% CI 
Age group (years) 
<50 57.3 54.9–59.6  78.1 77.8–78.4 
50–59 38.5 35.9–41.1  67.6 67.2–67.9 
60–69 36.7 34.2–39.3  58.9 58.6–59.2 
70+ 22.5 20.3–24.8  33.7 33.5–33.9 
Sex 
Males 34.3 32.5–36.0  48.2 48.0–48.4 
Females 45.8 44.0–47.6  56.4 56.2–56.6 
Remoteness area 
Major cities 49.4 47.0–51.9  52.5 52.4–52.7 
Inner regional 44.5 41.3–47.6  50.8 50.5–51.1 
Outer regional 35.5 33.0–38.0  49.4 48.9–49.9 
Remote and very remote 32.2 30.0–34.5  54.4 53.3–55.5 
Total 40.2 38.9–41.5  51.9 51.7–52.0 
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, with the exception of those C44 codes that indicate basal cell 
and squamous cell carcinoma of the skin. 
Source: AIHW Australian Cancer Database 2007. 
Cancer type 
The 5-year crude survival rates were calculated for the most commonly diagnosed cancers 
among Aboriginal and Torres Strait Islander peoples (see Chapter 3 for full list).  
Among the most commonly diagnosed cancers, 5-year crude survival for Indigenous 
Australians was significantly lower than that for their non-Indigenous counterparts (Figure 
5.1) for lung cancer (7% compared with 11%), breast cancer in females (70% compared with 
81%), bowel cancer (47% compared with 53%), prostate cancer (63% compared with 72%) 
and cervical cancer (51% compared with 67%). 
To maintain appropriate levels of privacy and confidentiality, 5-year survival could not be 
presented for: 
 liver and pancreatic cancers (ranked ninth and tenth respectively) 
 unknown primary site (ranked fifth) by age, sex and remoteness area. 
Of these individual cancer types, 1-year crude survival for Indigenous Australians was 
significantly lower for liver cancer (21% compared with 33%) and pancreatic cancer (11% 
compared with 20%) (Table D5.1). Further information on 1-year survival is provided in the 
Cancer in Aboriginal and Torres Strait Islander peoples of Australia: supplementary data tables on 
the AIHW website.  
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Notes 
1. Breast cancer is for females only. NHL stands for non-Hodgkin lymphoma. UPS stands for unknown primary site. 
2. Data on liver cancer and pancreatic cancer (ranked ninth and tenth respectively) cannot be released due to the small number of cases. 
3. Figure is ordered based on top 10 cancer incidence numbers for Indigenous Australians. 
4. The data for this figure are shown in Table D5.1. 
Source: AIHW Australian Cancer Database 2007. 
Figure 5.1: Five-year crude survival for selected most commonly diagnosed cancers in Aboriginal 
and Torres Strait Islander peoples, New South Wales, Queensland, Western Australia and the 
Northern Territory, 1999–2007 
Age 
The 5-year crude survival rates generally fell with age irrespective of Indigenous status. 
Similar to the overall findings, 5-year crude survival estimates for Indigenous Australians 
were significantly lower than for non-Indigenous Australians for breast cancer in females 
among all age groups, bowel cancer among those aged under 60, cervical cancer among 
those aged under 50, prostate cancer among those aged 50 and older and lung cancer among 
those aged 50 to 69 (Figure 5.2). 
Other findings of interest included significantly lower survival rates for Indigenous 
Australians than non-Indigenous Australians for non-Hodgkin lymphoma among those aged 
under 70 and uterine cancer among those aged 60‒69. 
Sex 
Similar to the overall findings, 5-year crude survival was significantly lower for (Figure 5.3): 
 Indigenous males than non-Indigenous males for bowel cancer (45% compared with 
52%) and prostate cancer (63% compared with 72%) 
 Indigenous females than non-Indigenous females for lung cancer (7% compared with 
13%), breast cancer (70% compared with 81%) and cervical cancer (51% compared with 
67%). 
Remoteness 
Consistent with the overall findings, 5-year crude survival was significantly lower for those 
living in (Figure 5.4):  
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 Inner regional for breast cancer in females and prostate cancer  
 Outer regional for breast cancer in females  
 Remote and very remote areas for breast cancer in females, prostate cancer, cervical cancer, 
bowel cancer and non-Hodgkin lymphoma. 
 
Notes  
1. Data for Aboriginal and Torres Strait Islander peoples for lung cancer (<50 year), prostate cancer (<50 years), cervical cancer (60–69 and 
70+ years), uterine cancer (70+ years) cannot be released due to small number of cases. 
2. Data on cancer of unknown primary site, liver cancer and pancreatic cancer (ranked fifth, ninth and tenth respectively) cannot be released 
due to the small number of cases. 
3. There are differences in the scale on the y-axis between cancer types. 
4. The data for this figure are shown in Table D5.2.  
Source: AIHW Australian Cancer Database 2007. 
Figure 5.2: Five-year crude survival for selected most commonly diagnosed cancers in Aboriginal 
and Torres Strait Islander peoples, by age group, New South Wales, Queensland, Western 
Australia and the Northern Territory, 1999–2007 
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Notes  
1. Data on cancer of unknown primary site, liver cancer and pancreatic cancer (ranked fifth, ninth and tenth for incidence, respectively) cannot 
be released due to the small number of cases. 
2. There are differences in the scale on the y-axis between cancer types. 
3. The data for this figure are shown in Table D5.3.  
Source: AIHW Australian Cancer Database 2007. 
Figure 5.3: Five-year crude survival for selected most commonly diagnosed cancers in Aboriginal 
and Torres Strait Islander people, by sex, New South Wales, Queensland, Western Australia and 
the Northern Territory, 1999–2007 
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Notes 
1. MC stands for Major cities, IR stands for Inner regional, OR stands for Outer regional and R+VR stands for Remote and very remote. 
2. Data for Aboriginal and Torres Strait Islander peoples for lung cancer for Inner regional areas and for non-Hodgkin lymphoma for Inner 
regional areas cannot be released due to the small number of cases. 
3. Data on cancer of unknown primary site, liver cancer and pancreatic cancer (ranked fifth, ninth and tenth respectively) cannot be released 
due to the small number of cases. 
4. There are differences in the scale on the y-axis between cancer types. 
5. The data for this figure are shown in Table D5.4 
Source: AIHW Australian Cancer Database 2007. 
Figure 5.4: Five-year crude survival for selected most commonly diagnosed cancers in Aboriginal 
and Torres Strait Islander peoples, by remoteness area, New South Wales, Queensland, Western 
Australia and the Northern Territory, 1999–2007 
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survival disadvantage is through a Cox proportional hazards regression analysis, which 
compares the risk of death (from all causes) for Indigenous Australians who had been 
diagnosed with cancer with that for non-Indigenous Australians (see Box 5.1).  
Box 5.1: Cox proportional hazard regression analysis 
This analysis allows the association between Indigenous status and the presence of cancer 
to be measured while accounting for the influence of factors such as sex, age and 
remoteness status. Factors such as individual screening or testing behaviours which might 
affect the survival analyses could not be taken into account (such as, participating in breast, 
cervical or bowel screening, or PSA testing for prostate cancer) due to data availability.  
In this model, individuals diagnosed with cancer between 2003 and 2007 were followed to 
date of death or to the 31 December 2010, whichever came first. Death from any cause 
rather than a cancer-specific death was used due to data availability. The results are 
presented as hazard ratios that show how many times higher the probability of death 
occurs in one group than in the other group. A hazard ratio greater than 1 suggests that 
people with that factor have a worse survival compared with the chosen reference group. 
Ninety-five per cent CIs are presented as an indication of statistical precision. If the interval 
does not cross the value of one then it is interpreted as having a statistically significant 
impact (that is, not due to chance) (Kalbfleisch & Prentice 1980). More information about the 
Cox proportional hazards regression analysis is in Appendix B. 
After adjusting for age, sex and residential remoteness, Indigenous Australians diagnosed 
with any cancer between 2003 and 2007 had a 97% higher risk of death from any cause by 
2010 than non-Indigenous Australians (hazard ratio of 1.97) (Table 5.3). 
Table 5.3: Cox proportional hazards regression analysis, hazard ratio of death from any cause, all 
persons diagnosed with cancer between 2003 and 2007 and followed until death or 31 December 
2010 (whichever came first), New South Wales, Queensland, Western Australia and the Northern 
Territory 
Factors Number Hazard ratio 95% CI 
Indigenous status    
 Non-Indigenous (reference group) 266,346 1.00  
 Indigenous  3,355 1.97 1.88–2.06 
Sex    
 Female (reference group)  120,028 1.00  
 Male  149,673 1.11 1.10–1.12 
Age    
 Increase in relative risk    
 for each year after age 50  1.048 1.047–1.048 
Remoteness area    
 Major cities (reference group)  179,569 1.00  
 Inner regional  59,037 1.03 1.02–1.05 
 Outer regional  25,808 1.14 1.12–1.16 
 Remote and very remote  5,287 1.25 1.20–1.30 
Note: Analysis excludes people who did not state their Indigenous status. 
Source: AIHW Australian Cancer Database 2007. 
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Sex 
Indigenous males diagnosed with any cancer between 2003 and 2007 had a 101% higher risk 
of dying from any cause by 2010 than non-Indigenous males (hazard ratio of 2.01). For the 
same period, Indigenous females diagnosed with any cancer had a 94% higher risk of dying 
from any cause than non-Indigenous females (1.94) (Table 5.4).  
Table 5.4: Cox proportional hazards regression analysis, hazard ratio of death from any cause, by 
sex, diagnosed with cancer between 2003 and 2007 and followed until death or 31 December 2010 
(whichever came first), New South Wales, Queensland, Western Australia and the Northern 
Territory 
Factors 
Males  Females 
Number Hazard ratio 95% CI  Number Hazard ratio 95% CI 
Indigenous status 
 Non-Indigenous  
 (reference group)  148,002 1.00   118,344 1.00  
 Indigenous 1,671 2.01  1.89– 2.14  1,684 1.94 1.81–2.08 
Age         
 Increase in relative risk  
 
     
 for each year after age 50  1.043  1.043–1.044   1.052 1.051–1.053 
Remoteness area        
 Major cities (reference 
 group)  97,569 1.00   82,000 1.00  
 Inner regional  34,076 1.03  1.02–1.05  24,961 1.04 1.01–1.06 
 Outer regional  14,918 1.15  1.13–1.18  10,890 1.12 1.09–1.15 
 Remote and very remote  3,110 1.28  1.22–1.34  2,177 1.20 1.13–1.29 
Note: Analysis excludes people who did not state their Indigenous status. 
Source: AIHW Australian Cancer Database 2007. 
Cancer type 
The Cox proportional hazards regression analysis was done for the five most commonly 
diagnosed cancers in Aboriginal and Torres Strait Islander peoples (see Chapter 3 for full 
list). Of these cancers (Figure 5.5): 
 breast cancer in females had the highest hazard ratio. Indigenous females diagnosed 
with breast cancer between 2003 and 2007 had a 100% higher risk of dying from any 
cause by 2010 than non-Indigenous females (hazard ratio of 2.00). 
 For the same period, Indigenous males diagnosed with prostate cancer had an 83% 
higher risk of dying from any cause than non-Indigenous males (1.83). 
 For the same period, Indigenous Australians diagnosed with bowel cancer had a 43% 
higher risk of dying from any cause than non-Indigenous Australians (1.43). 
 For the same period, Indigenous Australians diagnosed with cancer of unknown 
primary site had a 31% higher risk of dying from any cause than non-Indigenous 
Australians (1.31). 
 lung cancer, while being the most commonly diagnosed cancer for Indigenous 
Australians, had the lowest hazard ratio (1.24). 
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The high hazard ratio for breast cancer in females and prostate cancer may possibly be 
explained by lower participation in screening by Aboriginal and Torres Strait Islander 
peoples, which may result in delayed detection leading to poorer outcomes (see Chapter 9, 
Roder 2005; Roder 2007; AIHW 2012e, 2012f, 2013b).  
The lower hazard ratio for lung cancer and cancer of unknown primary site may possibly be 
explained by the nature of these diseases. Overall, people diagnosed with these cancers 
generally have poorer survival rates irrespective of Indigenous status, as a high proportion 
of diagnoses are made at the advanced stage where treatment is less effective (AIHW 2011c). 
Therefore, the difference between these two population groups is less likely to be prominent.  
 
Notes:  
1. Breast cancer is for females only. UPS stands for unknown primary site.  
2. The data for this figure are shown in Table D5.5, Table D5.6, Table D5.7, Table D5.8, Table D5.9 and Table 5.3. 
Source: AIHW Australian Cancer Database 2007. 
Figure 5.5: Cox proportional hazards regression analysis for selected cancers, hazard ratio of death 
from any cause, all persons diagnosed with cancer between 2003 and 2007 and followed until death 
or 31 December 2010 (whichever comes first), New South Wales, Queensland, Western Australia 
and the Northern Territory 
International context 
This section discusses the cancer survival prospects of Aboriginal and Torres Strait Islander 
peoples in Australia in an international context using the mortality-to-incidence ratio (MIR). 
The MIR is used as a proxy measure for survival because conventional survival estimates for 
different countries are not directly comparable. This ratio indicates the number of deaths 
relative to the number of new cases diagnosed during a particular year. For example, an MIR 
of 0.30 would indicate that there were 30 deaths for every 100 new cases of cancer diagnosed. 
If survival is low, then the ratio would be closer to 1.00. In contrast, if survival is higher, the 
ratio would be closer to zero (see Appendix B for more information). 
The MIR for Aboriginal and Torres Strait Islander peoples in Australia was calculated using 
2004–2008 age-standardised mortality and incidence rates for all cancers combined from 
AIHW National Mortality Database and Australian Cancer Database 2009, restricted to New 
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South Wales, Queensland, Western Australia and the Northern Territory. The data for all 
cancers combined encompass a narrower range of cancers than is generally considered in 
this report (includes ICD-10 as C00–C97, excluding C44 (non-melanoma skin cancer); see 
Appendix C for further information).  
MIRs for countries and regions including Australia were calculated using rates estimated for 
2008 from the GLOBOCAN database (Ferlay et al. 2010). All the rates were age-standardised 
to the World Standard Population (Doll et al. 1966).  
The MIR for Aboriginal and Torres Strait Islander peoples in Australia was 0.5, which 
suggests survival among this population group was similar to survival for people in 
Southern Europe, Polynesia and Micronesia (Table 5.5). Difference in survival across the 
world could relate not only to the underlying number of cancer cases and deaths, but also to 
differences in the availability and quality of treatment, availability and completeness of 
cancer surveillance programs, cancer coding and registration practices, and characteristics of 
cancer diagnosed (AIHW 2012d). 
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Table 5.5: International comparisons of mortality-to-incidence ratios for all cancers combined(a) 
Country or region Mortality: ASR Incidence: ASR Mortality-to-incidence ratio 
Australia 102.8 314.1 0.33 
Northern America 105.1 299.9 0.35 
New Zealand 110.7 309.2 0.36 
Western Europe 108.1 286.6 0.38 
Northern Europe 114.5 269.1 0.43 
Southern Europe 112.0 244.4 0.46 
Indigenous Australians 168.0  330.4 0.51 
Polynesia 109.1 209.8 0.52 
Micronesia 86.1 157.5 0.55 
Caribbean 99.9 172.6 0.58 
South America 100.3 171.8 0.58 
World 105.6 180.8 0.58 
Central and Eastern Europe 125.9 210.6 0.60 
Central America 82.0 134.4 0.61 
Eastern Asia 120.1 188.4 0.64 
Western Asia 92.2 133.7 0.69 
Southern Africa 133.2 189.6 0.70 
South-Eastern Asia 99.5 141.4 0.70 
South-Central Asia 74.5 104.6 0.71 
Northern Africa 78.0 103.2 0.76 
Melanesia 106.8 138.5 0.77 
Western Africa 85.4 107.6 0.79 
Eastern Africa 99.9 122.8 0.81 
Middle Africa 76.4 91.8 0.83 
(a) Includes cancers coded in ICD-10 as C00–C97, excluding C44 (that is, non-melanoma skin cancer), D45, D46, D47.1 and D47.3. 
Notes 
1. The ratios shown (except for Indigenous Australians) are based on estimates for 2008 by the International Agency for Research on Cancer 
(IARC) and are based on data from about 3 to 5 years earlier. The Indigenous Australians ratio is calculated using 2004–2008 New South 
Wales, Queensland, Western Australia and the Northern Territory data from the AIHW National Mortality Database and Australian Cancer 
Database 2009. 
2.  The mortality-to-incidence ratio equals the age-standardised mortality rate divided by the age-standardised incidence rate. The rates from 
GLOBOCAN were age-standardised by the IARC. All the rates were age-standardised to the World Standard Population (Doll et al. 1966).  
3. Australian data from GLOBOCAN includes Indigenous, non-Indigenous and not stated. 
Source: Ferlay et al. 2010, AIHW National Mortality Database and AIHW Australian Cancer Database 2009. 
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6 Prevalence of cancer 
Key findings 
At the end of 2007 in New South Wales, Queensland, Western Australia and the Northern 
Territory: 
 1,882 Aboriginal and Torres Strait Islander people were alive who had been diagnosed 
with cancer within the previous 5 years. 
 Five-year prevalence was significantly lower among Indigenous Australians than  
non-Indigenous Australians; this pattern was consistent for all age groups and by sex. 
 The five most prevalent cancers diagnosed among Aboriginal and Torres Islander 
peoples within the previous 5 years were breast cancer in females (325 people), 
melanoma of the skin (203), bowel (185), prostate (156) and lung (124) cancers. 
 Compared with their non-Indigenous counterparts, 5-year prevalence was significantly 
higher for cervical cancer (rate ratio 2.1), lung cancer (1.5) and uterine cancer (1.5).  
About prevalence 
 Prevalence refers to the number of people alive who have been diagnosed with cancer. 
 The main data source was the 2007 ACD, with information on deaths (from any cause) 
sourced from the NDI. 
 Limited-duration prevalence is presented and refers to the number of people alive who 
had been diagnosed with cancer within a given period.  
 The 26-year prevalence is the longest duration that can be calculated based on the 
available incidence data from 1982 to 2007. 
 Information in the 2007 NMD on Indigenous status is considered of sufficient 
completeness for reporting for New South Wales, Queensland, Western Australia and 
the Northern Territory.  
 Comparisons have been made throughout with non-Indigenous Australians, with the 
analysis excluding those for whom Indigenous status was not stated.  
 More detailed data are available in Cancer in Aboriginal and Torres Strait Islander peoples 
of Australia: supplementary data tables on the AIHW website. 
All cancers combined 
At the end of 2007, there were 3,305 Aboriginal and Torres Strait Islander people alive who 
had been diagnosed with cancer in the previous 26 years. Of these, 2,691 were diagnosed in 
the previous 10 years and 1,882 were diagnosed in the previous 5 years (Table 6.1).  
All age-standardised rates in three specified prevalence periods were significantly lower for 
Indigenous Australians compared with non-Indigenous Australians. Five-year prevalence 
among Indigenous Australians was 991 per 100,000 compared with 1,270 per 100,000 for  
non-Indigenous Australians. The remainder of this chapter focuses on 5-year prevalence.  
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Table 6.1: Limited-duration prevalence for all cancers combined(a), New South Wales, Queensland, 
Western Australia and the Northern Territory, as at the end of 2007  
Prevalence 
Indigenous  Non-Indigenous 
Number ASR
(b)
 95% CI  Number ASR
(b)
 95% CI 
5-year prevalence 1,882 991.2 938.2–1,046.1  177,092 1,269.5 1,263.5–1,275.4 
10-year prevalence 2,691 1,450.8 1,385.7–1,517.9  269,428 1,931.9 1,924.5–1,939.2 
26-year prevalence 3,305 1,855.3 1,779.5–1,933.1  332,590 2,381.7 2,373.6–2,389.9 
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, with the exception of those C44 codes that indicate basal cell 
and squamous cell carcinoma of the skin. 
(b) Rates were directly age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
Source: AIHW Australian Cancer Database 2007. 
Age 
The age-specific 5-year prevalence for all cancers combined rose with age for both 
Indigenous and non-Indigenous Australians (Table 6.2). The 5-year prevalence was 
significantly lower among Indigenous than non-Indigenous Australians for all age groups. 
Sex 
The age-standardised 5-year prevalence for all cancers combined was significantly lower for 
Indigenous Australians than for non-Indigenous Australians for both males (1,091 compared 
with 1,444 per 100,000) and females (938 compared with 1,132 per 100,000) (Table 6.2). 
Table 6.2: Five-year prevalence for all cancers combined(a), by Indigenous status, age group and sex, 
New South Wales, Queensland, Western Australia and the Northern Territory, as at the end of 2007 
 
Indigenous  Non-Indigenous 
Number Rate
(b)
 95% CI  Number Rate
(b)
 95% CI 
Age group (years) 
<45 471 127.0 115.8–139.0  17,385 215.7 212.5–219.0 
45–54 393 991.3 895.7–1094.3  23,164 1,266.2 1250.0–1282.7 
55–64 429 1,952.4 1,772.0–2,146.1  42,519 2,863.8 2,836.6–2,891.1 
65–74 383 4,015.3 3,623.2–4,438.3  47,095 5,141.7 5,095.3–5,188.3 
75+ 206 4,813.1 4,178.2–5,517.1  46,929 5,817.8 5,765.3–5,870.7 
Sex        
Males 849 1,091.0 999.5–1,187.3  95,379 1,444.3 1,435.1–1,453.6 
Females 1,033 937.6 872.7–1,005.5  81,713 1,131.9 1,124.1–1,139.8 
Total 1,882 991.2 938.2–1,046.1  177,092 1,269.5 1,263.5–1,275.4 
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, with the exception of those C44 codes that indicate basal cell 
and squamous cell carcinoma of the skin. 
(b) The rates for age groups (years) are expressed per 100,000 population. The rates for sex and the total were directly age-standardised to 
the Australian population as at 30 June 2001 and expressed per 100,000 population. 
Source: AIHW Australian Cancer Database 2007. 
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Cancer type 
As at the end of 2007, the 10 most prevalent cancers for Indigenous Australians differed from 
those which non-Indigenous Australians experienced (Table D6.1). Cancer types that were 
more prevalent in the Indigenous population than in the non-Indigenous population include: 
 breast cancer in females (ranked first compared with second)  
 cervical cancer (ranked eighth in prevalence compared with seventeenth). 
Comparison of the age-standardised 5-year prevalence for the 10 most prevalent cancers 
(Figure 6.1) indicates that Indigenous Australians have significantly: 
 higher rates of cervical cancer (rate ratio 2.1), lung cancer (1.5) and uterine cancer (1.5) 
 lower rates of thyroid cancer (rate ratio 0.8), breast cancer in females (0.8), bowel cancer 
(0.7), kidney cancer (0.7), non-Hodgkin lymphoma (0.6) and prostate cancer (0.4). 
 
Notes 
1. Rates were directly age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
2. Breast cancer is for females only. NHL stands for non-Hodgkin lymphoma. 
3. Figure is ordered based on top 10 cancer prevalence numbers for Indigenous Australians. 
4. The data for this figure are shown in Table D6.1. 
Source: AIHW National Mortality Database. 
Figure 6.1: Five-year prevalence of the 10 most prevalent cancers in Aboriginal and Torres Strait 
Islander peoples, New South Wales, Queensland, Western Australia and the Northern Territory, as 
at the end of 2007 
Age 
Consistent with the overall findings, the age-specific 5-year prevalence for Indigenous 
Australians, compared with non-Indigenous Australians (Figure 6.2), was: 
 significantly higher for lung cancer among those aged 45–54 and 65–74, cervical cancer 
and uterine cancer among those aged 45–54 
 significantly lower for prostate cancer among those aged 45 and older, bowel cancer 
among those aged 45 to 74, breast cancer in females and melanoma of the skin among 
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those aged less than 65, non-Hodgkin lymphoma among those aged 45 to 64 and thyroid 
cancer among those aged less than 55. 
Other cancers of interest include higher rates of melanoma of the skin among those aged 75 
and older. 
Sex 
Consistent with the overall findings, the age-standardised 5-year prevalence for Indigenous 
Australians, compared with non-Indigenous Australians (Figure 6.3), was: 
 significantly higher for Indigenous males for lung cancer, and for Indigenous females for 
uterine cancer and cervical cancer  
 significantly lower for both males and females for bowel cancer and non-Hodgkin 
lymphoma, for males with prostate cancer, and for females with breast cancer, thyroid 
cancer and melanoma of the skin.  
Within the Indigenous population, Indigenous males had higher prevalence rates of 
melanoma of the skin and lung cancer, while Indigenous females had higher rates of thyroid 
cancer. 
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Notes 
1. Data for Aboriginal and Torres Strait Islander peoples for prostate cancer (0–44 years), thyroid cancer (75+ years) and kidney cancer (75+ 
years) cannot be released due to small number of cases. 
2. There are differences in the scale on the y-axis between cancer types. 
3. The rates are expressed per 100,000 population.  
4. The data for this figure are shown in Table D6.2. 
Source: AIHW Australian Cancer Database 2007. 
Figure 6.2: Five-year prevalence of the 10 most prevalent cancers in Aboriginal and Torres Strait 
Islander peoples, by age group, New South Wales, Queensland, Western Australia and the 
Northern Territory, as at the end of 2007 
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Notes 
1. There are differences in the scale on the y-axis between cancer types. 
2. Rates were directly age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
3. The data for this figure are shown in Table D6.3. 
Source: AIHW Australian Cancer Database 2007. 
Figure 6.3: Five-year prevalence of the 10 most prevalent cancers in Aboriginal and Torres Strait 
Islander peoples, by sex, New South Wales, Queensland, Western Australia and the Northern 
Territory, as at the end of 2007 
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7 Hospitalisations for cancer 
Key findings 
From 2006–07 to 2010–11 in New South Wales, Victoria, Queensland, Western Australia, 
South Australia and public hospitals in the Northern Territory: 
 14,086 Aboriginal and Torres Strait Islander people were hospitalised for a principal 
diagnosis of cancer. 
 Indigenous Australians tended to have lower hospitalisation rates than other Australians 
for a principal diagnosis of cancer (113 compared with 170 per 10,000). 
 Indigenous Australians spent on average 9.6 days in hospital following a principal 
diagnosis of cancer, compared with 7.7 days on average for other Australians. 
 Indigenous Australians living in all geographic remoteness areas were less likely than 
other Australians to be hospitalised with a principal diagnosis of cancer. 
 Indigenous Australians were more likely to be hospitalised for cervical (rate ratio 3.0), 
liver (2.1) and lung (1.6) cancers than other Australians. 
About hospitalisations 
 Data provided are for cancer-related hospitalisations for Aboriginal and Torres Strait 
Islander peoples between 2006–07 and 2010–11 financial years. 
 Cancer hospitalisations are defined as an admitted patient hospitalisation in which a 
cancer was recorded as the principal diagnosis. 
 The main data source was the National Hospital Morbidity Database (NHMD).  
 Note that the data from the NHMD refer to hospitalisations, not individuals (see 
Appendix C and AIHW Australian hospital statistics reports (AIHW 2012c). 
 Information in the NHMD on Indigenous status is only considered of sufficient 
completeness for reporting for New South Wales, Victoria, Queensland, Western 
Australia, South Australia and public hospitals in the Northern Territory.  
 Comparisons have been made throughout with other Australians, including those of 
unknown Indigenous status. This is different to other chapters, because assessment of 
the demographic profile of the ‘not stated’ shows a similar profile to non-Indigenous. 
The level of missing data on Indigenous status is 11% (see Indigenous identification in 
hospital separations data—quality report for more details (AIHW 2010a). 
 Admission practices differ between states and territories and can change over time. For 
example, in public hospitals in New South Wales and South Australia, patients who 
receive same-day chemotherapy services are considered as outpatients rather than 
admitted patients (AIHW 2009). 
 The Australian Standard Geographical Classification Remoteness Area (ABS 2006) was 
used to make comparisons by remoteness status (see Appendix A for more details). 
 More detailed data are available in Cancer in Aboriginal and Torres Strait Islander peoples 
of Australia: supplementary data tables on the AIHW website. 
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All cancers combined 
Between 2006–07 and 2010–11, there were 25,403 cancer-related hospitalisations for 
Aboriginal and Torres Strait Islander peoples (Table 7.1). Of these hospitalisations, 14,086 
were for a principal diagnosis of cancer and 11,317 were hospitalisations for other  
cancer-related treatment and care (which includes special screening examinations, follow-up 
after surgery or treatment and chemotherapy).  
Other Australians were almost twice as likely to have cancer-related hospitalisations as 
Indigenous Australians (367 compared with 194 per 10,000). A similar pattern was observed 
for hospitalisations for a principal diagnosis of cancer (170 compared with 113). The 
discussion throughout the remainder of this chapter refers to hospitalisations data where the 
principal diagnosis was cancer.  
While Indigenous Australians had fewer cancer hospitalisations, they experienced longer 
age-standardised length of stay than other Australians (9.6 days compared with 7.7 days). 
Note that average length of stay is calculated based on overnight hospitalisations and 
excludes same-day hospitalisations. Indigenous Australians may have longer 
hospitalisations as they might have to travel into cities for treatment (see Box 7.1), although 
other factors could include case severity and additional conditions.  
Box 7.1: Issues facing Indigenous Australians living in remote areas 
A greater proportion of Indigenous than non-Indigenous Australians live in remote areas of 
Australia (ABS 2008). Indigenous Australians living in remote areas can face issues with 
accessing health-care services within their community (Humphreys & Wakerman 2008), 
meaning that they need to travel to receive treatment. As a result, Indigenous Australians 
may face longer hospitalisations as they cannot receive other care in the community 
(Australian Indigenous HealthInfoNet 2013). 
Table 7.1: Hospitalisations for all cancers combined by Indigenous status, New South Wales, 
Victoria, Queensland, Western Australia, South Australia and public hospitals in the Northern 
Territory, 2006–07 to 2010–11 
Type of cancer hospitalisation 
Indigenous  Other Australians 
Number ASR
(a)
 ALOS
(b)(c)
  Number  ASR
(a)
 ALOS
(b)(c)
 
Principal diagnosis of cancer 14,086 113.0 9.6  1,895,294 170.1 7.7 
Other cancer-related hospitalisations 11,317 80.7 . .  2,184,249 197.0 . . 
 Same-day chemotherapy 9,165 64.4 . .  1,550,695 139.6 . . 
All cancer-related hospitalisations
(d)
 25,403 193.8 . .  4,079,543 367.0 . . 
All hospitalisations  1,443,300 8,361.7 . .  38,063,302 3,549.6 . . 
(a) Rates were directly age-standardised to the Australian population as at 30 June 2001 and are expressed per 10,000 population. 
(b) Directly age-standardised to the national all cancer hospitalisation population 2006–07 to 2010–11. 
(c) Average length of stay (ALOS) excludes same day hospitalisations. 
(d) Pertain to hospitalisations in which (i) the principal diagnosis is cancer (ICD-10-AM codes C00–C97, D45, D46, 47.1 and D47.3), or (ii) the 
principal diagnosis is a health service or treatment that may be related to treatment of cancer. 
Source: AIHW National Hospital Morbidity Database. 
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Age 
A greater proportion of Indigenous Australians were hospitalised with a principal diagnosis 
of cancer at a younger age than non-Indigenous Australians. Forty-eight per cent of 
Indigenous Australians were hospitalised before the age of 55 compared with 21% for  
non-Indigenous Australians (Table 7.2). The relative proportion of hospitalisations of 
Indigenous Australians tended to fall with age, which was the reverse of the trend in relation 
to other Australians. 
The age-specific hospitalisation rate increased with age for both groups, but Indigenous 
Australians had lower hospitalisation rates for all age groups compared with other 
Australians across all age groups (Table 7.2). 
The overall average length of stay for hospitalisations was longer for Indigenous Australians 
for all age groups (Table 7.2).  
Sex 
The number of hospitalisations of Aboriginal and Torres Strait Islander peoples was equally 
distributed among males and females. However, the age-standardised hospitalisation rate 
was higher for Indigenous males than Indigenous females (129 compared with 102 per 
10,000). 
Both Indigenous males and females had lower hospitalisations following a principal 
diagnosis of cancer than other Australians. However, when hospitalised, Indigenous males 
and females experienced longer average length of stay than other Australian males and 
females. The difference in length of stay between the respective population groups was 
greater for males than females (Table 7.2).  
Remoteness area 
A smaller proportion of Indigenous Australians hospitalised with a principal diagnosis of 
cancer lived in Major cities than other Australians (30% compared with 68%), and a greater 
proportion lived in Remote and very remote areas (27% compared with 1%) (Table 7.2). 
Indigenous Australians living in all geographical remoteness areas were less likely to be 
hospitalised following a principal diagnosis of cancer, but had an longer average length of 
stay than other Australians living in the same areas. 
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Table 7.2: Hospitalisations for all cancers combined(a), by Indigenous status and age group, New 
South Wales, Victoria, Queensland, Western Australia, South Australia and public hospitals in the 
Northern Territory, 2006–07 to 2010–11  
 
Indigenous Australians  Other Australians 
Number Per cent Rate
(b)
 ALOS
(c)
  Number  Per cent Rate
(b)
 ALOS
(c)
 
Age group (years) 
<45 3,642 25.9 16.8 9.5  172,239 9.1 27.5 6.7 
45–54 3,087 21.9 129.2 8.7  219,679 11.6 155.3 6.8 
55–64 3,564 25.3 259.5 9.4  418,147 22.1 357.3 7.3 
65–74 2,491 17.7 414.9 9.3  480,914 25.4 646.7 8.0 
75+ 1,302 9.2 491.9 10.6  604,315 31.9 925.4 8.7 
Sex 
Males 7,024 49.9 129.0 10.1  1,092,663 57.7 209.1 7.9 
Females 7,062 50.1 101.5 8.7  802,629 42.3 137.9 7.7 
Remoteness area
(d)
 
Major cities 4,268 30.3 125.6 9.5  1,286,113 68.0 183.7 7.9 
Inner regional 2,879 20.5 137.4 8.4  408,687 21.6 186.9 7.5 
Outer regional 3,195 22.7 127.0 9.4  169,255 9.0 175.4 7.9 
Remote and very remote 3,721 26.5 119.0 9.7  26,607 1.4 165.8 8.2 
Total 14,086 100.0 113.0 9.6  1,895,294 100.0 170.1 7.7 
(a) All cancers combined pertain to ICD-10-AM codes of C00–C97, D45, D46, D47.1 and D47.3. 
(b) The rates for age groups (years) are expressed per 100,000 population. The rates for sex, remoteness area and the total were directly age-
standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
(c) ALOS excludes same-day hospitalisations. 
(d) There were 23 Indigenous hospitalisations and 4,432 other Australian hospitalisations that could not be ascribed to a remoteness area. 
Note: Rates for remoteness were calculated using 2006 estimated residential population due to data availability. This assumes that the population 
in each remoteness area has remained constant over the 5 years. New estimated residential population by Indigenous status and 
remoteness areas will be released by June 2014 (see Chapter 1) and may impact on the ASR presented here. 
Source: AIHW National Hospital Morbidity Database. 
Cancer type 
The 10 cancers most commonly recorded as the primary reason for hospitalisation among 
Aboriginal and Torres Strait Islander peoples accounted for 57% of all cancer 
hospitalisations. The top 10 cancer rankings for hospitalisations for Indigenous Australians 
differed from that for other Australians (Table D7.1). Cancer types that were ranked higher 
in the Indigenous population than in the other Australian population include: 
 lung cancer (ranked second compared with seventh) 
 acute lymphoblastic leukaemia (ranked eighth compared with eighteenth) 
 cervical cancer (ranked ninth compared with twenty-eighth) 
 liver cancer (ranked tenth compared with twenty-second). 
Comparison of age-standardised hospitalisation rates shows that Indigenous Australians, 
when compared with other Australians (Figure 7.1) were: 
 about 3 times as likely to be hospitalised for cervical cancer, twice as likely to be 
hospitalised for liver cancer and 1.6 times as likely to be hospitalised for lung cancer 
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 were less likely to be hospitalised for non-melanoma skin cancer (rate ratio 0.3), non-
Hodgkin lymphoma (0.4), prostate cancer (0.4), acute lymphoblastic leukaemia (0.6), 
bowel cancer (0.6), breast cancer in females (0.7) and cancer of secondary site (0.9). 
Comparisons of average length of stay for individual cancer types showed that Indigenous 
Australians, compared with other Australians (Table D7.1) had:  
 shorter hospitalisations for acute lymphoblastic leukaemia  
 longer hospitalisations for all other top 10 cancers ranked for hospitalisations.  
 
Notes 
1. Rates were directly age-standardised to the Australian population as at 30 June 2001 and are expressed per 10,000 population. 
2. Breast cancer is for females only. 
3. Figure is ordered based on top 10 cancer hospitalisation numbers for Indigenous Australians. 
4. The data for this figure are shown in Table D7.1. 
Source: AIHW National Hospital Morbidity Database. 
Figure 7.1: Age-standardised hospitalisation rates for the 10 most common principal diagnoses of 
cancer, New South Wales, Victoria, Queensland, Western Australia, South Australia and public 
hospitals in the Northern Territory, 2006–07 to 2010–11 
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Age 
Consistent with the overall findings, the age-specific hospitalisation rates for Indigenous 
Australians, compared with other Australians (Figure 7.2), were:  
 higher for lung and cervical cancers among those aged less than 75, and for liver cancer 
among those aged between 45 and 74 
 lower for non-melanoma skin cancer, non-Hodgkin lymphoma and prostate cancer 
among all age groups, for breast cancer in females and acute lymphoblastic leukaemia 
among those aged less than 75, for bowel cancer among those aged 45 and older and for 
cancer of secondary site among those aged less than 45 and those aged 75 and older. 
Other cancers where Indigenous Australians had higher age-specific hospitalisation rates 
than non-Indigenous Australians include acute lymphoblastic leukaemia among those aged 
75 and older and cancer of secondary site among those aged 45–54.  
Sex 
Consistent with the overall findings, the age-standardised hospitalisation rate (Figure 7.3) 
was: 
 higher for both Indigenous males and females for liver and lung cancers than for other 
Australians, and for Indigenous females for cervical cancer than for other females 
 lower for both Indigenous males and females for non-melanoma skin cancer, non-
Hodgkin lymphoma, cancer of secondary site, bowel cancer and acute lymphoblastic 
leukaemia than other Australians, and for Indigenous males for prostate cancer than 
other males, and for Indigenous females for breast cancer than other females. 
Within the Indigenous population, Indigenous males had higher hospitalisation rates for 
liver, lung and bowel cancers and non-melanoma skin cancer than Indigenous females. 
Remoteness area 
Consistent with the overall findings, the age-standardised hospitalisation rates for 
Indigenous Australians, compared with other Australians (Figure 7.4), were: 
 higher for those living in all remoteness areas for cervical and liver cancers, and higher 
for those living in Inner regional, Outer regional and Remote and very remote areas for lung 
cancer 
 lower for those living in all remoteness areas for non-melanoma skin cancer, non-
Hodgkin lymphoma, prostate cancer, bowel cancer and acute lymphoblastic leukaemia 
and for those living in Major cities for breast cancer in females.  
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Notes 
1. There are differences in the scale on the y-axis between cancer types. 
2. Rates are expressed per 10,000 population. 
3. The data for this figure are shown in Table D7.2. 
Source: AIHW National Hospital Morbidity Database. 
Figure 7.2: Age-specific hospitalisation rates for the 10 most common principal diagnoses of cancer, 
by age group, New South Wales, Victoria, Queensland, Western Australia, South Australia and 
public hospitals in the Northern Territory, 2006–07 to 2010–11 
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Notes 
1. There are differences in the scale on the y-axis between cancer types. 
2. Rates were directly age-standardised to the Australian population as at 30 June 2001 and are expressed per 10,000 population. 
3. The data for this figure are shown in Table D7.3. 
Source: AIHW National Hospital Morbidity Database. 
Figure 7.3: Age-standardised hospitalisation rates for the 10 most common principal diagnoses of 
cancer, by sex, New South Wales, Victoria, Queensland, Western Australia, South Australia and 
public hospitals in the Northern Territory, 2006–07 to 2010–11 
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Notes 
1. MC stands for Major cities, IR stands for Inner regional, OR stands for Outer regional and R+VR stands for Remote and very remote. 
2. There are differences in the scale on the y-axis between cancer types. 
3. Rates were directly age-standardised to the Australian population as at 30 June 2001 and are expressed per 10,000 population 
4. The data for this figure are shown in Table D7.4. 
Source: AIHW National Hospital Morbidity Database. 
Figure 7.4: Age-standardised hospitalisation rates for the 10 most common principal diagnoses of 
cancer, by remoteness area, New South Wales, Victoria, Queensland, Western Australia, South 
Australia and public hospitals in the Northern Territory, 2006–07 to 2010–11 
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Fewer cancer hospitalisations 
Another way to detect the under-representation of cancer hospitalisations for Indigenous 
Australians is to compare the number of observed hospitalisations with expected numbers if 
the other Australian age-specific hospitalisation rate was applied to the Indigenous 
population. A positive number indicates an excess in cancer hospitalisations cases than 
would be expected, while a negative number indicates that there were less cancer 
hospitalisations than expected (see Appendix B). The numbers of excess hospitalisations for 
individual cancer types are not expected to sum to the number of excess case for all cancers. 
If the hospitalisation rate for other Australians was applied to the Indigenous population, 
there would be an expected 19,800 hospitalisations rather than the observed 14,086 
hospitalisations (Figure 7.5). This means that for Indigenous Australians there were 5,714 
fewer hospitalisations than would have been expected from the other Australians 
hospitalisation rate (Table D7.5). The difference varied by cancer type (Figure 7.5) including:  
 non-melanoma skin cancer, which had the largest difference, with 2,808 fewer 
hospitalisations than expected 
 lung, cervical and liver cancers, where the reverse pattern applies, with more 
hospitalisations than expected for Indigenous Australians. 
More detailed data on the number of excess hospitalisations among Indigenous Australians 
by cancer type, age group and sex are available in Cancer in Aboriginal and Torres Strait 
Islander peoples of Australia: supplementary data tables on the AIHW website.  
 
Notes 
1. Excess hospitalisations are the observed number of hospitalisations minus the expected number of hospitalisations. 
2. All cancers pertain to hospitalisations in which the principal diagnosis is cancer (ICD-10-AM codes C00–C97, D45, D47.1 and D47.3). 
3. Breast cancer is for females only. NHL stands for non-Hodgkin lymphoma. ALL stands for acute lymphoblastic leukaemia. 
3. Excess hospitalisations are derived by applying the age-specific rates from the other Australians population to the age distribution of the 
Indigenous population. The numbers of excess hospitalisations for individual cancer types are not expected to sum to the number of excess 
hospitalisations for all cancers. 
4. The data for this figure are shown in Table D7.5. 
Source: AIHW National Hospital Morbidity Database. 
Figure 7.5: Excess cancer hospitalisations for the 10 most common principal diagnoses of cancer, 
New South Wales, Victoria, Queensland, Western Australia, South Australia and public hospitals 
in the Northern Territory, 2006–07 to 2010–11 
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Additional diagnoses 
This section looks at common additional diagnoses resulting in hospitalisation due to all 
cancers combined. An additional diagnosis is a condition or complaint that either coexists 
with the principal diagnosis or arose during the treatment. An additional diagnosis is 
reported if the condition affects patient management. 
The most common additional diagnoses for Aboriginal and Torres Strait Islander peoples 
admitted to hospital with a principal diagnosis of cancer were endocrine, nutritional and 
metabolic diseases (Table 7.3). Comparison of the age-standardised hospitalisation rate 
showed that, compared to other Australians, Indigenous Australians were: 
 1.5 times as likely to have an additional diagnosis of mental and behavioural disorders 
 1.4 times as likely to have an additional diagnosis of endocrine, nutritional and metabolic 
diseases and disease of the respiratory system.  
Table 7.3: Hospitalisations for all cancers combined(a) by additional diagnosis groups and 
Indigenous status, New South Wales, Victoria, Queensland, Western Australia, South Australia 
and public hospitals in the Northern Territory, 2006–07 to 2010–11 
Additional diagnosis (ICD-10-AM codes) 
Indigenous Australians  Other Australians 
No
(b)(c)
 Per cent ASR
(d)
  No
(b)(c)
 Per cent ASR
(d)
 
Endocrine, nutritional and metabolic diseases  
(E00–E89) 3,045 21.6 26.4  204,953 10.8 18.3 
Diseases of the circulatory system (I00–I99) 2,372 16.8 22.2  201,147 10.6 17.9 
Diseases of the blood and blood-forming organs and 
certain disorders involving the immune mechanism 
(D50–D89) 2,055 14.6 15.5  192,216 10.1 17.3 
Diseases of the digestive system (K00–K93) 1,977 14.0 15.8  189,140 10.0 16.9 
Diseases of the genitourinary system (N00–N99) 1,455 10.3 13.2  124,352 6.6 11.1 
Diseases of the respiratory system (J00–J99) 1,452 10.3 12.5  97,180 5.1 8.7 
Certain infectious and parasitic diseases (A00–B99) 1,425 10.1 10.6  91,419 4.8 8.2 
Mental and behavioural disorders (F00–F99) 891 6.3 7.1  52,426 2.8 4.7 
Injury, poisoning and certain other consequences of 
external causes (S00–T98) 846 6.0 6.3  74,707 3.9 6.7 
Diseases of the nervous system (G00–G99) 711 5.0 5.4   51,280 2.7 4.6 
Total hospitalisations for principal diagnosis of 
cancer  14,086 100.0 113.0  1,895,294 100.0 170.1 
(a) All cancers combined pertain to ICD-10-AM codes of C00–C97, D45, D46, D47.1 and D47.3. 
(b) A hospitalisation can have more than one additional diagnosis or can have no additional diagnosis, hence the numbers do not add up to the 
total number of hospitalisations where cancer is the principal diagnosis. 
(c) If more than one additional diagnosis on the 4-digit level in each group (3-digit level) is listed to a principal diagnosis of cancer, then only one 
is counted. 
(d) Rates are standardised to the Australian population as at 30 June 2001 and expressed per 10,000 population. 
Source: AIHW National Hospital Morbidity Database. 
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8 Expenditure on cancer 
Key findings 
In the 2010–11 financial year: 
 Total expenditure on cancer and cancer-related hospitalisations for Aboriginal and 
Torres Strait Islander peoples was estimated to be $58 million. 
 Hospital expenditure per person for Indigenous Australians was about half that of non-
Indigenous Australians for all cancers combined. 
 Cancer of a secondary (metastatic) site accounted for the highest proportion of the total 
hospital expenditure on cancer for Indigenous Australians. 
 Hospital expenditure per person was higher for Indigenous Australians than  
non-Indigenous Australians for cervical cancer (ratio of 2.0), cancer of unknown primary 
site (1.4), oesophageal cancer (1.2) and liver cancer (1.2). 
About expenditure 
 The main data sources were the AIHW National Hospital Morbidity Database 
(NHMD), the AIHW Public Hospitals Establishments Database (PHED) and the 
National Hospital Costs Data Collection (NHCDC).  
 Data provided are the estimated cost of hospital admitted patient services for cancer 
among Aboriginal and Torres Strait Islander peoples for 2010–11. 
 Expenditure estimates are based on both public and private hospital admitted patient 
services.  
 It is not possible to allocate all expenditure on health goods and services by disease. 
For some areas, expenditure is aimed at providing broad health infrastructure and/or 
services such as capital expenditure and general aids and appliances expenditure 
(where the costs are not part of hospital admitted patient services costs). For some 
other areas of expenditure, such as over-the-counter pharmaceuticals and non-
admitted patient services, there is a lack of available data that would enable a link of 
the broad expenditure costs to a particular disease. 
 Information on hospital admitted patient services relates to hospitalisations for which 
cancer was the primary, rather than an additional, diagnosis. Thus, the data provided 
give a conservative estimate of total admitted patient services expenditure on cancer 
patients. 
 Data presented in this chapter have been adjusted for estimated Indigenous under-
identification. Information on the adjustment method is provided in Expenditure on 
health for Aboriginal and Torres Strait Islander people 2010–11 (AIHW 2013e).The level of 
under-identification of Indigenous peoples in the data set varied by jurisdiction and 
remoteness area.  
 Due to the methodology used to estimate expenditure, the data apply to all states and 
territories, and comparisons have been made throughout with non-Indigenous 
Australians, unlike previous chapters.  
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All cancers combined 
In 2010–11, the total expenditure on all cancer-related hospitalisations for Aboriginal and 
Torres Strait Islander peoples was estimated to be $58 million, which includes $53 million on 
hospitalisations where cancer was the principal diagnosis and $5 million on cancer-related 
treatment and services (Table 8.1). The total expenditure on all cancer-related 
hospitalisations for Indigenous Australians accounted for 1.4% of that for all Australians. 
Furthermore: 
 hospital expenditure on all cancer-related hospitalisations as a proportion of hospital 
expenditure on all diseases was 3.2% for Indigenous Australians, compared with 9.1% 
for non-Indigenous Australians 
 hospital expenditure per person for Indigenous Australians was about half that of non-
Indigenous Australians for all cancers combined (ratio of 0.5) 
 hospital expenditure per person on cancer-related treatment and services (such as special 
screening examinations, chemotherapy and follow-up after treatment) for Indigenous 
Australians was less than one-third of that for non-Indigenous Australians (ratio of 0.3). 
Cancer type 
Hospital expenditure was calculated for the top 10 cancers for incidence, mortality and 
hospitalisation for Aboriginal and Torres Strait Islander peoples (see chapters 3, 4 and 7). 
Compared with non-Indigenous Australians, per person hospital expenditure on Indigenous 
Australians for individual cancers was:  
 higher for cervical cancer (ratio of 2.0), cancer of unknown primary site (1.4), 
oesophageal cancer (1.2) and liver cancer (1.2) 
 lower for non-melanoma skin cancer (ratio 0.1), prostate cancer (0.2), bowel cancer (0.3), 
non-Hodgkin lymphoma (0.3), pancreatic cancer (0.4), cancer of secondary site (0.5), 
stomach cancer (0.5), breast cancer in females (0.6), lung cancer (0.8) and acute 
lymphoblastic leukaemia (0.9). 
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Table 8.1: Estimated expenditure on hospitalisations(a)(b), by principal diagnosis and Indigenous 
status(c), in public and private hospitals, 2010–11 
Principal diagnosis 
Expenditure ($ million)  Expenditure ($) per person
(d)
 
Indigenous 
Non-
Indigenous Total 
Indigenous  
share (%)
(e)
  Indigenous 
Non-
Indigenous Ratio 
Cancer of secondary site 
(C77–C79) 7.8 531.0 538.7 1.4  13.6 26.9 0.5 
Lung cancer (C33–C34) 4.8 197.4 202.2 2.4  8.5 10.0 0.8 
Bowel cancer (C18–C20) 3.5 424.6 428.1 0.8  6.1 21.5 0.3 
Breast cancer in females 
(C50) 2.6 160.3 162.9 1.6  4.5 8.1 0.6 
Acute lymphoblastic 
leukaemia (C91.0) 1.7 68.6 70.3 2.4  3.0 3.5 0.9 
Liver cancer (C22) 1.6 47.6 49.2 3.3  2.9 2.4 1.2 
Oesophageal cancer (C15) 1.7 48.7 50.5 3.4  3.0 2.5 1.2 
Prostate cancer (C61) 1.4 211.2 212.7 0.7  2.5 10.7 0.2 
Uterine cancer (C54–C55) 1.1 37.7 38.8 2.9  2.0 1.9 1.0 
Stomach cancer (C16) 1.0 72.0 73.1 1.4  1.8 3.7 0.5 
Cervical cancer (C53) 0.9 14.6 15.5 5.5  1.5 0.7 2.0 
Non-melanoma skin cancer 
(C44) 0.8 276.6 277.5 0.3  1.5 14.0 0.1 
Pancreatic cancer (C25) 0.8 74.1 74.9 1.1  1.4 3.8 0.4 
Non-Hodgkin lymphoma 
(C82–C85) 0.5 54.8 55.4 0.9  0.9 2.8 0.3 
Cancer of unknown primary 
site (C80) 0.5 11.9 12.3 3.9  0.8 0.6 1.4 
All other malignant 
neoplasms 22.5 1,207.4 1,229.9 1.8  39.6 61.2 0.6 
All cancers combined
(f)
 53.3 3,438.6 3,491.9 1.5  93.7 174.4 0.5 
Cancer-related treatment 
and services
(g)
 4.5 524.7 529.2 0.9  7.9 26.6 0.3 
All cancer-related 
hospitalisations 57.8 3,963.3 4,021.1 1.4  101.6 201.0 0.5 
All diseases 1,798.3 43,735.5 45,533.8 3.9  3,160.0 2,218.5 1.4 
(a) Includes hospitalisation data for all states/territories. 
(b) Hospitalisations for which care type was reported as Newborn with no qualified days, and records for Hospital boarders and Posthumous 
organ procurement have been excluded. 
(c) Admitted patient rates have been adjusted for Indigenous under-identification. 
(d) Expenditure per person estimates are calculated using the Australia-wide population for all expenditure areas. 
(e) Indigenous share is the expenditure on Indigenous Australians divided by the total expenditure. 
(f) Includes hospitalisations in which the principal diagnosis is cancer (ICD-10-AM codes of C00–C97, D45, D46, D47.1 and D47.3). 
(g) Includes hospitalisations in which the principal diagnosis is a cancer-specific health service or treatment (ICD-10-AM codes of Z08, Z12, 
Z40.0, Z51.0, Z51.1, Z54.1, Z54.2, Z80 and Z85). 
Source: AIHW National Hospital Morbidity Database, AIHW Public Hospitals Establishments Database and National Hospital Costs Data 
Collection. 
 
 66 Cancer in Aboriginal and Torres Strait Islander peoples of Australia: an overview 
9 National cancer screening programs 
Key findings  
BreastScreen Australia:  
Over the two years 2010–2011 for women age 50–69: 
 11,971 Aboriginal and Torres Strait Islander women participated in BreastScreen 
Australia. 
 The participation rate for Indigenous women in BreastScreen Australia was lower than 
the non-Indigenous participation rate (36% compared with 54%). 
 53% of breast cancers diagnosed in BreastScreen in Indigenous women were small (≤15 
mm). Comparatively, the proportion of small breast cancers detected in non-Indigenous 
women was significantly higher at 61%. 
National Cervical Screening Program 
Participation in cervical screening cannot be measured nationally by Indigenous status 
through national cytology data as there is currently no national mechanism for collecting 
Indigenous status in relation to these data.  
National Bowel Cancer Screening Program  
Between July 2011 and June 2012: 
 1,919 Aboriginal and Torres Strait Islander peoples participated in the National Bowel 
Cancer Screening Program (NBCSP), representing 0.6% of all participants. 
 Indigenous participants had a slightly higher positivity faecal occult blood test (FOBT) 
rate than non-Indigenous participants (10% compared with 7%). 
 Indigenous males were more likely to have a positive FOBT result than Indigenous 
females (11% compared with 9%). 
About national population screening programs 
 Australia has three national population screening programs: BreastScreen Australia, 
the National Cervical Screening Program (NCSP) and the NBCSP. 
 The aim of the programs is to reduce illness and death through early detection of  
pre-cancerous abnormalities and cancer and effective follow-up and treatment. 
Screening services are free to individuals in the target population (for breast and bowel 
screening) or they are covered by a Medicare rebate (for cervical screening). 
 Note that, except where otherwise specified, rates are expressed per 100 people (not 
per 100,000 people as used in other chapters) and are often referred to as a percentage.  
 Note, that the data presented may underestimate the level of screening occurring in 
Australia due to screening outside the program. For more information on cancer 
screening see Cancer in Australia 2012 (AIHW 2012f). 
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BreastScreen Australia 
About BreastScreen Australia 
 Information on BreastScreen Australia was extracted from the AIHW web release of 
participation data (AIHW 2013b). 
 BreastScreen Australia was established in 1991 and operates as a joint program of the 
Australian, state and territory governments. 
 Women undergo routine mammographic screening to detect unsuspected breast 
cancer. If screening identifies suspicious signs then investigation occurs.  
 BreastScreen Australia focuses on women aged 50–69 for 2-yearly screening 
mammograms, although women aged 40 and older are also eligible for testing under 
the program. 
 Information on Indigenous status is collected on the BreastScreen Australia form. 
While self-reported data (in this instance, Indigenous status) are generally reliable 
(AIHW 2010b), there could be some Indigenous women who are incorrectly assigned 
to non-Indigenous status. 
 Participation is measured over 2 years to align with the recommended screening 
interval (time between screening mammograms) of BreastScreen Australia.  
 The participation rate is based on the number of women screened (not the number of 
screening mammograms performed) as a proportion of the target population. 
Participation 
Over 2010 and 2011, 36% of Aboriginal and Torres Strait Islander women in the target age 
group (50–69 years) participated in screening through BreastScreen Australia. This 
participation rate was lower than their non-Indigenous counterparts (54%) (Table 9.1). 
Participation rates for Indigenous women in BreastScreen Australia have historically been 
lower than for non-Indigenous women (Table D9.1). Sociodemographic factors including 
remoteness area, socioeconomic status and differences in age distribution and screening 
period can partly explain this (CA 2012). 
Table 9.1: Participation in BreastScreen Australia by Indigenous status, females aged 50–69,  
2010–2011 
Indigenous status Number
(a)
 ASR
(b)
 
Indigenous 11,971 36.2 
Non-Indigenous 1,341,869 53.9 
Not stated 19,891 . . 
Australia
(c)
 1,373,731 54.6 
(a) The numbers of females aged 50–69 screened in the reporting period covering 1 January 2010 to 31 December 2011. 
(b) Rates are the number of females screened as a percentage of the eligible female population calculated as the average of the ABS’s 
estimated resident population and age-standardised to the Australian population at 30 June 2001 and are expressed per 100 population.  
(c) Includes females screened for whom information on Indigenous status was not available.  
Source: AIHW 2013b.  
 68 Cancer in Aboriginal and Torres Strait Islander peoples of Australia: an overview 
Many of the state and territory BreastScreen programs have developed, and continue to 
develop, strategies and initiatives to encourage greater participation by Aboriginal and 
Torres Strait Islander women (see BreastScreen Queensland 2009; BreastScreen SA 2003; 
BreastScreen WA 2008). Strategies include dedicated and appropriate communication 
resources, and block and group bookings for breast cancer screening for Aboriginal and 
Torres Strait Islander women. BreastScreen programs also liaise closely with Aboriginal and 
Torres Strait Islander health practitioners and Aboriginal and Torres Strait Islander 
community groups to increase the acceptance of screening. 
Breast cancer detection following screening 
The data in this section are for women who participated in breast cancer screening over 2010 
and 2011. Reference to detection relates to screen-detected cancers and is reported by the 
number of all-size cancers and small (≤15 mm) cancers detected per 10,000 women screened. 
Detection of breast cancer is routinely disaggregated into first and subsequent screening 
rounds, as women are more likely to have a breast cancer detected at the first visit than in 
subsequent visits. This is because the first visit may result in the detection of prevalent 
cancers that have been present for some time, while subsequent visits pick up incident 
cancers that have grown between screens (Kavanagh et al. 1999). However, as a result of the 
relatively small numbers, cancer detection by Indigenous status is presented for all screening 
rounds combined.  
All-size cancer detection 
In 2010 and 2011, 73 Aboriginal and Torres Strait Islander women had a breast cancer 
detected through BreastScreen Australia (Table 9.2). 
Table 9.2: All-size and small (≤15 mm) breast cancer detection by Indigenous status, females aged 
50–69, 2010–2011 
Cancer size  
Indigenous  Non-Indigenous 
Number
(a)
 AS Rate
(b)
 95% CI  Number
(a)
 AS Rate
(b)
 95% CI 
Small (≤15 mm) 39 32.6 23.1–44.8  4,073 28.8 28.0–29.7 
All-size 73 60.1 46.9–75.7  6,697 47.5 46.4–48.7 
(a) The number of females aged 50–69 screened in the reporting period covering 1 January 2010 to 31 December 2011. 
(b) Rates are the number of women with breast cancer detected per 10,000 women screened and directly age-standardised to the population of 
women attending a BreastScreen Australia service in 2008. 
Source: AIHW analysis of BreastScreen Australia data. 
Small-size cancer detection 
Of the 73 Aboriginal and Torres Strait Islander women diagnosed with breast cancer, 39 
were diagnosed with a breast cancer that was classified as small (≤15 mm) breast cancer. This 
represents 53% of all-size breast cancers diagnosed in Aboriginal and Torres Strait Islander 
women, which was significantly lower than the proportion of small breast cancers detected 
in non-Indigenous women (61%) (Table 9.3). This finding is in line with research that 
suggests that breast cancer in Indigenous women are diagnosed at a more advanced stage 
(Condon et al. 2003). 
Small cancers are associated with increased treatment options (NBOCC 2009) and improved 
survival (AIHW & NBCC 2007). 
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Table 9.3: Proportion of breast cancers detected through BreastScreen Australia in women aged  
50–69 that were small (≤15 mm), 2010–2011(a) 
Indigenous status Per cent
(b)
 95% CI
(c)
 
Indigenous 53.4 52.3–54.6 
Non-Indigenous 60.8 60.7–60.9 
(a) The numbers of females aged 50–69 screened in the reporting period covering 1 January 2010 to 31 December 2011. 
(b) Refers to the number of small (≤15 mm) invasive breast cancers detected as a proportion of all-size invasive breast cancers detected. 
(c) Details of the method for calculating the 95% CI around the proportion are in Appendix B. 
Source: AIHW analysis of BreastScreen Australia data. 
National Cervical Screening Program 
About the National Cervical Screening Program (NCSP) 
 Information on the NCSP are sourced from Cervical screening in Australia 2010–2011 
(AIHW 2013d). 
 The NCSP was established in 1991. 
 Women aged 20–69 are recommended to receive Papanicolaou smears (or Pap tests) 
every 2 years. Women should begin screening between 18 and 20 years or within 1 or 2 
years of becoming sexually active, whichever is the later. Pap tests may cease at the age 
of 70 for women who have had two normal results within the last 5 years (DoHA 
2012).  
 These recommendations apply to women who have received the HPV vaccine as well 
as unvaccinated women.  
Participation 
Participation in NCSP by Indigenous status cannot be measured nationally as there is 
currently no mechanism for collecting Indigenous status in cervical cytology registries 
(AIHW 2013d). Currently the cytology and pathology tests do not contain questions on 
Indigenous status. While there are no national data on participation of Indigenous women in 
the NCSP, some research indicates that these women are under-screened (Coory et al. 2002, 
Binns & Condon 2006).  
Queensland research found that for the period March 1999 to February 2001 the Indigenous 
participation rate was 30 percentage points lower than the non-Indigenous rate (Coory et al. 
2002); while Northern Territory research found that between 1997 and 2004 the participation 
of Indigenous women in the NCSP was about half the national rate (Binns & Condon 2006). 
Both studies found that Indigenous women from rural and remote areas participated at 
lower rates than those from urban regions. 
It has been recognised that Aboriginal and Torres Strait Islander women face cultural, 
linguistic and geographic barriers to cervical screening (DoHA 2004, Kirk et al. 1998). State 
and territory cervical screening programs have developed initiatives to increase participation 
of Indigenous women in cervical screening such as the employment of Aboriginal and Torres 
Strait Islander health practitioners and the development of principles, standards and 
guidelines for screening Aboriginal and Torres Strait Islander women (DoHA 2004). 
However, without being able to measure participation in cervical screening by Indigenous 
status, the overall effectiveness of these initiatives is not known. 
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National Bowel Cancer Screening Program 
About the National Bowel Cancer Screening Program (NBCSP) 
 Information on the NBCSP are sourced from National Bowel Cancer Screening Program 
monitoring report: July 2011–June 2012 (AIHW 2013f).  
 The NBCSP was implemented in 2006. 
 Invitation packs are mailed out to eligible people. These packs include a free faecal 
occult blood test (FOBT) kit that enables a person to take a sample of their faeces for 
mailing to the program’s pathology laboratory to be tested for traces of blood. 
 The NBCSP targets men and women aged 50, 55 and 65, with 60 years being added in 
July 2013. By 2017–18, the NBCSP will move toward biennial screening for all 
Australians aged between 50 and 74 years. 
 Identification of participants as Indigenous is not known at the time of invitation, and 
is only collected once a person becomes a participant. Therefore it is not possible to 
accurately determine the participation rate for this population group, as the number of 
Aboriginal and Torres Strait Islander people invited to participate is unknown. 
 The pathologist classifies an FOBT as positive if blood is detected in the sample. 
 Participants who have a positive FOBT test are recommended to have a colonoscopy 
procedure to look for polyps or cancerous growths in the bowel. 
 A colonoscopy is considered the most accurate method to investigate the colon and 
rectum, as it enables biopsy and subsequent histopathological diagnosis and can be 
used for identification and removal of polyps and adenomas (ACN 2005).  
 Removal of polyps at colonoscopy is a preventive measure that lowers the risk of 
future bowel cancers, as bowel cancers can initiate from polyps (Cappell 2005). 
Participation 
Between July 2011 and June 2012, 1,919 Aboriginal and Torres Strait Islander peoples 
participated in the NBCSP, representing 0.6% of all participants in this program (Table 9.4). 
Table 9.4: National Bowel Cancer Screening Program participants, by Indigenous status and age, 
July 2011–June 2012 
Indigenous status 50 years 55 years 65 years Total 
Indigenous 773 653 493 1,919 
Non-Indigenous 98,904 103,676 110,307 312,887 
Not stated 3,278 3,407 3,785 10,470 
Australia 102,955 107,736 114,585 325,276 
Note: NBCSP Indigenous status was reported by the participant on the returned Participant Details Form. Participants who did not indicate 
Indigenous status were included in the ‘Not stated’ column. 
Source: AIHW 2013f. 
It is not possible to determine participation rates by Indigenous status using the NBCSP data. 
However, the proportion of participants who identified as Indigenous in the NBCSP can be 
compared with the corresponding proportion from the 2011 Census. Comparison of the 
proportion of participants who identified as Indigenous in the NBCSP was lower than the 
comparable proportion identifying as Indigenous in the 2011 Census, indicating that not all 
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eligible Indigenous Australians participated in this program (or choose not to identify) 
(Table 9.5). For Indigenous participants: 
 a similar proportion of males and females participated in the NBCSP (0.6) 
 the proportion who participated fell with increasing age. This pattern was evident for 
both males and females. This trend differed for non-Indigenous Australians where 
participation rates were relatively constant across age groups. 
Table 9.5: Proportion of National Bowel Cancer Screening Program participants, compared 
with corresponding proportions from the 2011 Census, by Indigenous status, 
 July 2011–June 2012 
 NBCSP participants  2011 Census 
Age Indigenous Non-Indigenous Not stated  Indigenous Non-Indigenous Not stated 
 Males 
50 years 0.8 95.4 3.8  1.7 93.1 5.2 
55 years 0.6 95.6 3.8  1.5 93.4 5.1 
65 years 0.4 95.9 3.7  1.0 94.2 4.9 
Total 0.6 95.6 3.8  1.5 93.5 5.1 
 Females 
50 years 0.7 96.6 2.6  1.9 94.2 3.9 
55 years 0.6 96.7 2.7  1.6 94.5 4.0 
65 years 0.5 96.6 2.9  1.1 94.7 4.2 
Total 0.6 96.7 2.7  1.6 94.4 4.0 
 Persons 
50 years 0.8 96.1 3.2  1.8 93.7 4.5 
55 years 0.6 96.2 3.2  1.5 93.9 4.5 
65 years 0.4 96.3 3.3  1.0 94.4 4.5 
Total
(a)
 0.6 96.2 3.2  1.5 93.9 4.5 
(a) Total includes people aged 50, 55 and 65 years. 
Notes  
1. NBCSP percentages equal the number of people returning a completed FOBT who indicated their Aboriginal and Torres Strait Islander 
status as a proportion of all people returning an FOBT (regardless of whether they were correctly completed).  
2. NBCSP Indigenous status was reported by the participant on the returned participant details form. Participants who did not indicate 
Indigenous status were included in the ‘Not stated’ column. 
3. Indigenous status proportions as recorded at the 2011 Australian Census of Population and Housing are included for comparative purposes. 
Source: AIHW 2013f. 
Faecal occult blood test positivity rates 
Overall, Indigenous participants had a higher proportion of positive faecal occult blood tests 
(FOBT) than non-Indigenous participants (10% compared with 7%); this pattern occurred for 
each age group and by sex, except for Indigenous females aged 65 years who had a lower 
positivity rate (Table 9.6). Participants who receive a positive FOBT result are encouraged to 
discuss this result with their doctor, who can refer them for a colonoscopy, if appropriate. 
For Indigenous participants: 
 males were more likely to have a positive FOBT than females (11% compared with 9%). 
 people aged 55 were more likely to have a positive FOBT result (12%), compared with 
those aged 50 (9%) and those aged 65 (9%).  
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Table 9.6: Faecal occult blood test positivity rates (%), by Indigenous status, July 2011–June 2012 
Age Indigenous Non-Indigenous Not stated Total 
 Males 
50 years 7.7 6.0 8.0 6.1 
55 years 14.8
(a)
 7.1 9.9 7.2 
65 years 11.0
(a)
 9.3 11.7 9.4 
Total 10.9 7.6 9.9 7.7 
 Females 
50 years 9.8 5.4 6.1 5.5 
55 years 9.4 6.1 5.8 6.1 
65 years 6.6
(a)
 7.5 8.3 7.6 
Total 8.8 6.4 6.8 6.4 
 Persons 
50 years 8.8 5.7 7.1 5.8 
55 years 11.9 6.5 8.0 6.6 
65 years 8.6 8.4 10.2 8.5 
Total 9.8 6.9 8.5 7.0 
(a) Based on numerator < 20 or denominator < 300; interpret with caution. 
Notes 
1. Positivity equals the number of participants with positive FOBT results as a percentage of the total number of participants with valid results. 
A valid result was either positive or negative; inconclusive results were excluded. 
2. NBCSP Indigenous status was reported by the participant on the returned participant details form. Participants who did not indicate 
Indigenous status were included in the ‘Not stated’ column. 
Source: AIHW 2013f. 
Follow-up colonoscopy following a positive FOBT test 
Of those Indigenous participants whose FOBT result was positive, over half (61%) were 
reported to have received a follow-up colonoscopy (Table 9.7). This was lower than the 
non-Indigenous follow-up colonoscopy rate (73%) but the reporting of colonoscopy 
procedures to the NBCSP register is not mandatory. Further, reporting of colonoscopies may 
differ between the public and private health-care sectors, which may affect comparisons if 
Indigenous and non-Indigenous groups use these services at different rates. Therefore this 
comparison should be interpreted with caution. 
Table 9.7: Crude follow-up colonoscopy following a positive FOBT result, by Indigenous status, 
July 2011–June 2012 
  Indigenous Non-Indigenous Not stated Total 
50 years n.p. 70.8 45.7
(a)
 69.7 
55 years n.p. 72.7 53.9
(a)
 71.9 
65 years n.p. 74.3 57.5 73.6 
Total 60.7
(a)
 72.9 53.3 72.0 
(a) Based on numerator <20 or denominator <300; interpret with caution. 
Notes 
1. Percentages of colonoscopies performed equal the number of people who have had a colonoscopy recorded after a positive FOBT as a 
proportion of the total number of people with positive FOBT results.  
2. Reporting of colonoscopy follow-up is not mandatory. Therefore, actual numbers of participant colonoscopies may be underestimated. 
3. NBCSP Aboriginal and Torres Strait Islander status was reported by the participant on the returned participant details form. Participants who 
did not indicate Aboriginal and Torres Strait Islander status were included in the ‘Not stated’ column. 
Source: AIHW 2013f. 
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10 Burden of disease due to cancer 
Key findings 
In 2003 in Australia, according to The burden of disease and injury in Aboriginal and Torres Strait 
Islander Peoples 2003 report (Vos et al. 2007) which is the most recent Australian study 
looking at the burden of disease among Aboriginal and Torres Strait Islander peoples: 
 3.6% of total disease burden was in Aboriginal and Torres Strait Islander peoples, 
despite only comprising approximately 2.4% of the total Australian population. 
 Cancer, as a group, accounted for 8% of all Aboriginal and Torres Strait Islander peoples 
disability-adjusted life years (DALYs). 
 The rate of burden due to cancer in the Aboriginal and Torres Strait Islander population 
was 1.7 times the rate for the total Australian population. 
 Indigenous females had a greater proportion of the cancer burden compared with 
Indigenous males (54% compared with 46%). 
 Among individual cancer types, lung cancer was responsible for the greatest burden of 
disease for both Indigenous and the total Australian population. 
The latest global burden of disease study was for 2010, but this did not include separate 
results for Indigenous Australians (Murray et al. 2012). The AIHW is currently undertaking a 
project funded by the Department of Health and Ageing (DoHA) and the Australian 
National Preventive Health Agency, which will deliver new burden of disease results for 
Indigenous and all Australians (AIHW 2013c). 
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About burden of disease 
 Data were sourced from The burden of disease and injury in Aboriginal and Torres Strait 
Islander Peoples 2003 report (Vos et al. 2007). 
 One measure of burden of disease is DALYs, which estimate years of life lost due to 
premature death (YLL), as well as years of healthy life lost due to disability (YLD) from 
disease and injury. The more DALYs that are associated with a disease, the greater the 
burden.  
 To illustrate this concept, a person who has been healthy throughout their life but who 
dies suddenly 20 years earlier than expected would be regarded as having lost 20 years 
of healthy life—20 DALYs, while a person who lives to an old age but has been only 
‘half-well’ for 30 years, have 15 DALYs lost. See Appendix C for more information. 
 Comparisons have been made throughout with the total Australian population 
(including Indigenous, non-Indigenous and those whose Indigenous identification was 
not stated). Data on DALYs have been adjusted for Indigenous under-identification. 
 Data presented in this chapter are for disease burden in 2003. Although advanced 
statistical methods were used to produce the results, caution should be taken when 
interpreting these results, in part because of uncertainties about how incidence, 
mortality and other factors might be changing over time (AIHW 2012b).  
 The global burden of disease for cancer in 2010 was 188,487 DALYs, which is a rate of 
2,736 DALYs per 100,000 population. Cancer accounted for 7.6% of global DALYs, with 
the three most common cancers being trachea, bronchus and lung (accounting for 
1.3%), liver (0.8%) and stomach (0.7%) (Murray et al. 2012). 
All cancers combined 
In 2003, the total disease burden in Aboriginal and Torres Strait Islander peoples accounted 
for 3.6% of the total burden of disease for Australians, despite representing only 2.4% of the 
Australian population.  
Cancer contributed the equal third highest disease burden for Aboriginal and Torres Strait 
Islander peoples, accounting for 8% of all DALYs (Figure 10.1). In comparison, cancer was 
the leading cause of disease burden in the total Australian population, accounting for 19% of 
DALYs.  
While cancer was responsible for a lower proportion of disease burden for Indigenous 
Australians than the total Australian population, the burden due to cancer in the Indigenous 
population was 1.7 times the burden in the total Australian population (Table 10.1).  
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Notes 
1. Un-Injuries refers to unintentional injuries, In-Injuries refers to intentional injuries. 
2  Total Australians includes Indigenous, non-Indigenous and Indigenous status not stated populations. 
3. CVD stands for cardiovascular disease. 
4.  Data for this figure are shown in Table D10.1. 
Source: Vos et al. 2007. 
Figure 10.1: Leading causes of burden of disease, by Indigenous status, Australia, 2003  
Sex 
Aboriginal and Torres Strait Islander females experienced a greater proportion of the cancer 
burden than their male counterparts (54% compared with 46%) (Figure 10.2). Further, 
Indigenous females had a greater proportion of the cancer burden compared with females in 
the total Australian population (54% compared with 47%).  
Burden due to YLL and YLD 
The relatively poor prognosis from many cancers compared with other diseases generally 
means that most cancers are expected to contribute more YLL than YLD. For Indigenous 
Australians and the total Australian population, most of the burden due to cancer was due to 
premature death (94% and 82%, respectively).  
Cancer type 
The DALY rates for some cancers in the Indigenous population were higher than those in the 
total Australian population (Table 10.1). This applied to: 
 mouth and oropharyngeal cancers (rate ratio 3.8) 
 lung cancer (2.7) 
 leukaemia (1.4). 
The higher disease burden for mouth, oropharyngeal and lung cancers among Aboriginal 
and Torres Strait Islander peoples can largely be explained by the higher prevalence of risk 
factors such as smoking (Cunningham et al. 2008).  
Per cent
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Table 10.1: Cancer DALYs for selected causes, Indigenous Australians and the total Australian 
population, 2003 
Cancer type 
Indigenous Australians  Total Australians
(a)
  
DALY 
Per cent of 
total DALY 
DALY rate 
per 1,000
(b)
  DALY 
Per cent of 
total DALY 
DALY rate 
per 1,000
(b)
 
Rate 
ratio
(c)
 
Lung cancer 1,940 2.0 4.1  88,904 3.4 1.5 2.7 
Breast cancer 725 0.8 1.5  60,654 2.3 1.4 1.1 
Colorectal cancer 601 0.6 1.3  63,605 2.4 1.1 1.1 
Mouth & oropharyngeal 
cancers 530 0.6 1.1  13,464 0.5 0.3 3.8 
Leukaemia 358 0.4 0.8  19,956 0.8 0.5 1.4 
Total cancer burden 7,817 8.1 16.4  499,416 19.0 9.8 1.7 
(a) Includes Indigenous, non-Indigenous and Indigenous status not stated populations. 
(b) Age-standardised to the total Indigenous Australian population, 2003. 
(c) Indigenous Australians to total Australians rate ratio. 
Source: Vos et al. 2007. 
Sex 
The top 20 causes of overall burden in Indigenous Australians differed from the total 
Australian population. Cancer types that were ranked differently in the Indigenous 
population than in the total Australian population (Table D10.2) include: 
 lung cancer for Indigenous males (ranked twelfth compared with fourth) 
 breast cancer for Indigenous females (ranked fourteenth compared with sixth).  
When comparing within Indigenous Australians: 
 Indigenous males experienced a greater proportion of the burden for mouth cancer (61% 
compared with 39%), lung cancer and leukaemia (both 51% compared with 49%) than 
Indigenous females. A similar pattern was found for lung cancer in total Australians 
(Begg et al. 2007) 
 Indigenous females experienced a greater proportion of the burden for colorectal cancer 
(52% compared with 48%) compared with Indigenous males, which was the opposite 
pattern to what was found in total Australians (Begg et al. 2007). 
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Note: Data for this figure are shown in Table D10.3. 
Source: Vos T et al. 2007. 
Figure 10.2: Contribution (%) of leading causes of cancer burden of disease, by sex, Aboriginal and 
Torres Strait Islander peoples, Australia, 2003  
Burden due to YLL and YLD 
For all leading individual cancers, most of the burden due to cancer was due to premature 
death (Figure 10.3). Note that the Vos et al. 2007 study did not provide a comparison with 
total Australians for individual cancer types. However, data analysis in Begg et al. 2007 
found that most of the burden for total Australian population for individual cancer types 
was also due to premature death.  
Note: Data for this figure are shown in Table D10.4. 
Source: Vos et al. 2007. 
Figure 10.3: Leading cancer causes of burden of disease, by fatal (YLL) and non-fatal (YLD) 
components, Aboriginal and Torres Strait Islander peoples, Australia, 2003  
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Appendix A: Classifications 
Health classifications 
International Statistical Classification of Diseases and Related Health Problems
The International Statistical Classification of Diseases and Related Health Problems (ICD) is 
used to classify diseases and other health problems (including symptoms and injuries) in 
clinical and administrative records. Mortality data in this report used the Tenth Revision 
(ICD-10). Cancers coded under the ICD classification system provide information on primary 
site or, for haematological cancers, histology. 
International Statistical Classification of Diseases and Related Health 
Problems, Australian modification
The ICD-10 was modified for the Australian setting by the National Centre for Classification 
in Health (NCCH) with assistance from clinicians and clinical coders (referred to as the  
ICD-10-AM) (NCCH 2010). The ICD-10-AM has been used for classifying diagnoses in 
hospital records in all states and territories since 1999–00 (AIHW 2000) and is comparable 
with the ICD-10 at the higher levels. 
Area-based classifications 
Australian Standard Geographical Classification Remoteness Area  
The Australian Standard Geographical Classification Remoteness Area (ASGC RA) was used 
to assign areas across Australia to a remoteness category (ABS 2006). This classification 
divides all areas into five categories: Major cities, Inner regional, Outer regional, Remote and 
Very remote (AIHW 2004). For this report, some of these categories were collapsed due to the 
small number of cases in these subgroups.  
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Appendix B: Statistical methods and 
technical notes 
Age-specific rates 
Age-specific rates provide information on the incidence of a particular event in an age group 
relative to the total number of people at risk of that event in the same age group. It is 
calculated by dividing the number of cases occurring in each specified age group by the 
corresponding population in the same age group, expressed as a rate (for example, number 
per 100,000 population).  
Age-standardised rates 
Age-standardisation is a method used to eliminate the effect of differences in population age 
structures when comparing populations with different age structures, and where age affects 
the variable being compared. This is the case with cancer, which occurs more often among 
older Australians. Age-standardisation is used in this report when comparing rates across 
different periods of time, different geographical areas, different socioeconomic groups or 
other different populations, including Aboriginal and Torres Strait Islander peoples and  
non-Indigenous Australians. 
Calculating age-standardised rates 
There are two methods commonly used to adjust for age: direct and indirect standardisation. 
In this report, age-standardised rates are calculated using the direct standardisation 
approach presented by Jensen and colleagues (1991). To age-standardise using the direct 
method, the first step is to get population numbers and numbers of cases (or deaths) in age 
ranges—typically 5-year age ranges. The next step is to multiply the age-specific population 
numbers for the standard population (in this case the Australian population as at 30 June 
2001) by the age-specific incidence rates (or death rates) for the population of interest (such 
as those who lived in Major cities). The next step is to sum across the age groups and divide 
this sum by the total of the standard population to give an age-standardised rate for the 
population of interest. Finally, this is expressed per 1,000 or 100,000 as appropriate. 
The indirect standardisation approach is used to calculate expected number of cancer cases, 
deaths and hospitalisations in Aboriginal and Torres Strait Islander peoples in Australia. See 
Observed and expected numbers. 
Calculating age-standardised average length of stay (ALOS) 
Calculating age-standardised ALOS is a three-step process. Within each population of 
interest, the crude ALOS for each age category is derived first by dividing the number of 
patient days for each age category by the corresponding number of hospitalisations. The 
second step is to calculate the weights using the selected standard population. The weights 
are derived by dividing the number of hospitalisations for each age category by the overall 
total of the standard population. The standard population chosen is the Australian overnight 
hospitalisations population in 2006–07 to 2010–11 where the principal diagnosis was cancer 
(ICD-10-AM codes of C00–C97, D45, D47.1 and D47.3). The third step is to multiply the 
crude ALOS with the corresponding weights and then sum up to get the total  
age-standardised ALOS. 
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Confidence intervals 
The observed value of a rate may vary because of the influence of chance and natural 
variation. Therefore to provide an approximate indication of whether two rates are 
statistically different, 95% confidence intervals (CIs) or prediction interval can be calculated, 
and significant differences highlighted.  
A 95% CI describes a span of numbers around the estimate which has a 95% chance of 
including the true value. A narrow CI indicates good precision or little random error and, 
conversely, a wider CI indicates poorer precision.  
When comparing two groups, if the two CIs do not overlap, the reader can be confident that 
the difference between the groups is probably real, and not due to chance. Note, however, 
that overlapping CIs do not necessarily mean that the difference between two rates is 
definitely due to chance. Instead, an overlapping CI represents a difference in rates that is 
too small to allow differentiation between a real difference and one which is due to chance 
variation. It can, therefore, only be stated that no statistically significant differences were 
found, and not that no differences exist. Note that, while rates for Indigenous Australians 
often differ from those for non-Indigenous Australians, the smaller population of Aboriginal 
and Torres Strait Islander peoples in Australia has led to broader CIs that may overlap the 
CIs for non-Indigenous rates. 
The variances of the age-specific rates were calculated by assuming that the counts follow a 
Poisson distribution, as recommended in Jensen et al. (1991) and Breslow and Day (1987). 
When the age-specific rates are low relative to the population at risk, the variability in the 
observed counts is accepted to be Poisson. However, even if the age-specific rates are not 
low, Poisson distribution is still generally assumed (Brillinger 1986; Eayres et al. 2008). 
With one exception as mentioned in details below, the CIs of the age-standardised rates in 
this report were calculated using a method developed by Dobson et al. (1991). This method 
calculates approximate CIs for a weighted sum of Poisson parameters.  
Note that statistical independence of observations is assumed in the calculations of the CIs 
for this report. This assumption may not always be valid for episode-based data (such as 
data from the NHMD).  
Calculating CIs around the proportion of cancers detected through 
BreastScreen Australia that were small (≤15 mm) compared with all size 
Relative standard error of estimates (number and ratio) 
The relative standard error (RSE) of an estimate is a measure of the percentage errors likely 
to have occurred due to sampling. The RSE of an estimate is calculated as follows: 
   ( )  (
  
       
)      
Caution should be used when a RSE is between 25% and 50% and estimates with a RSE 
above 50% are considered unreliable. 
The RSE for the proportion was derived from the standard error of both the estimate for the 
numerator (X) and the denominator (Y) as follows: 
   (
 
 
)  √   ( )     ( )  
where X is a subset of Y and Y is an estimate of the number of people in a group.  
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CI for estimates (number and ratio) 
The 95% CI around the proportion estimates (P) or number estimates was derived as follows: 
             ( ) 
             ( ) 
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             (
 
 
) 
where UCL = upper confidence limit 
 LCL = lower confidence limit 
As with all statistical comparisons, care should be exercised in interpreting the results. A 
non-significant difference between two rates may indicate no true difference, or could 
indicate that numbers of observations are too small to detect a true statistically significant 
difference. Judgment should be exercised in deciding whether the size of the difference 
observed is of practical importance.  
Hazard ratio 
Hazard ratios are generated from the Cox proportional hazards regression that is used for 
person-time data multivariable modelling, although they are essentially the same as rate 
ratios (see Cox proportional hazards regression analysis and Rate ratio). A hazard ratio indicates 
how many times higher the probability of a condition or event is in one group of people 
exposed to the factor of interest than in another group of people who are not exposed to the 
same factor, after adjusting for other factors in the model. This gives an indication of the 
strength of the association and can help decide whether the factor of interest could be a cause 
of a condition or event.  
In this report, hazard ratios are presented in the multivariate survival analysis section. 
Individuals diagnosed with cancer between 2003 and 2007 were followed to date of death or 
to the 31 December 2010, whichever came first. Hazard ratios were calculated using the Cox 
proportional hazards regression model, adjusting for other factors which are highly 
correlated with Indigenous status such as age, sex and residential remoteness. A hazard ratio 
exceeding 1 suggests that people with that factor have worse survival compared with the 
reference group. Ninety-five per cent CIs are presented as an indication of accuracy. If the 
interval for a factor does not cross the value 1 then it can be safely interpreted as being of 
significant impact (Kalbfleisch & Prentice 1980). 
Mortality-to-incidence ratio 
Mortality-to-incidence ratios (MIRs) can be used to estimate survival from a particular 
disease for a population. The MIR is defined as the age-standardised mortality rate divided 
by the age-standardised incidence rate. For example, an MIR of 0.42 in a given year for all 
types of cancers means that for every 100 new cancer cases diagnosed that year, there were 
42 deaths due to cancer in the same year (though the deaths need not be of the same people 
as the cases). If people generally die from their cancer, and do so relatively soon after 
diagnosis (that is, the death rate is nearly as high as the incidence rate for that cancer), then 
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the MIR will be closer to 1.00. In contrast, if people tend to survive a long time after being 
diagnosed, then the MIR will be closer to zero.  
The MIR only gives a valid measure of the survival experience in a population if: 
• cancer registration and death registration are complete or nearly so, and 
• the incidence rate, mortality rate and survival proportion are not undergoing rapid 
changes that affect the MIR. 
Note that, in Chapter 5, the age-standardised mortality rate and incidence rate used for 
calculating MIR are different from the rates reported in incidence and mortality chapters, 
which derived from data with different inclusions. The MIR for Aboriginal and Torres Strait 
Islander peoples was calculated using the age-standardised mortality rate and incidence rate 
for all cancers combined between 2004 and 2008, derived from the NMD and ACD. Data are 
restricted to New South Wales, Queensland, Western Australia and the Northern Territory, 
which are considered to be of sufficient completeness and quality for reporting in both the 
NMD and the ACD. MIRs for countries and regions including Australia were calculated 
using data from GLOBOCAN database (Ferlay et al. 2010). Caution must be taken when 
interpreting these data from different sources. 
All the mortality and incidence rates used for calculating MIRs were age-standardised to the 
Doll et al. (1966) World Standard Population. The data for all cancers combined pertain to 
cancers coded in ICD-10 as C00–C97, excluding C44 (that is, non-melanoma skin cancer), and 
therefore encompass a narrower range of cancers than is generally considered in this report 
(see Appendix C). 
When comparing data from different countries use caution since a number of factors may 
influence observed differences. These factors include the underlying number of cancer cases 
or deaths, differences in the composition of the populations, cancer detection and screening, 
types of treatment provided and access to treatment services, and cancer coding and 
registration practices. In Australia, all states and territories have legislation that makes 
cancer a notifiable disease (see Appendix C) and the completeness of cancer data is relatively 
high in comparison to a number of countries or regions (Curado et al. 2007). 
Observed and expected numbers 
Another way to express the differences in cancer statistics between Aboriginal and Torres 
Strait Islander peoples in Australia and other population groups is to compare the observed 
numbers and expected numbers, which shows the differences according to the age 
distribution of Aboriginal and Torres Strait Islander peoples. A positive number of the 
difference between observed and expected numbers indicates an excess, while a negative 
number indicates that there were lower numbers than expected. In this report, comparisons 
of observed and expected numbers are made for cancer cases, cancer deaths and 
hospitalisations due to cancer. 
The expected numbers are equivalent to those used in indirect age-standardisation method, 
which are derived from age-specific rates from a standard population to the age distribution 
of the study population. In this report, the study population is Aboriginal and Torres Strait 
Islander peoples in Australia, and the standard population is another population group—
namely, non-Indigenous Australians for cancer cases and cancer deaths and other 
Australians for hospitalisations due to cancer (see Box 1.2 in Chapter 1 for more information 
on population groups used throughout this report).  
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For example, to calculate the expected number of cancer cases in Aboriginal and Torres Strait 
Islander peoples in Australia, the first step is to obtain age-specific cancer incidence rates in 
the standard population (in this case, non-Indigenous Australians). The second step is to 
obtain the population in each age group in the study population (in this case the population 
of Aboriginal and Torres Strait Islander peoples in Australia). The third step is to calculate 
the expected number of cases in each age group by multiplying each age-specific incidence 
rate in the age group in non-Indigenous Australians by the population in each corresponding 
age group in Indigenous Australians. The final step is to sum across the expected number of 
cases in each age group. 
Prevalence 
In this report, limited-duration prevalence for 5, 10 and 26 years is presented. The main 
prevalence measure is 5-year prevalence and this refers to the number of persons alive at the 
end of 2007 that had been diagnosed with the cancer type under consideration in Australia 
during the 5-year period from 2003 to the end of 2007. 
In this report, 26-year prevalence is the longest duration that can be calculated based on the 
earliest (1982) and latest (2007) years of available incidence data. People who were diagnosed 
with cancer between 1982 and 2007 and who were alive on 31 December 2007 would be 
counted in 26-year prevalence. It is presented in this report as an approximation of the 
number of people alive who have ever been diagnosed with cancer, known as complete 
prevalence. Limited-duration prevalence was selected given its advantages in the ease of 
interpretation and calculation. Given that most cancers are diagnosed in the later years of 
life, 26 years was deemed a sufficiently long period for approximating complete prevalence. 
Note that prevalence is measured by the number of people diagnosed with cancer, not the 
number of cancer cases. An individual who was diagnosed with two separate cancers will 
contribute separately to the prevalence of each cancer. Yet this individual will contribute 
only once to prevalence of all cancers combined. For this reason, the sum of prevalence for 
individual cancers will not equal the prevalence of all cancers combined. 
Rate ratio 
The rate ratio measures the relative difference between two population groups (for example, 
Indigenous and non-Indigenous Australians). It can be calculated based on crude rates,  
age-standardised rates and cumulative rates. Ratios greater than 1 indicate an excess in 
population group A, while ratios less than 1 indicate an excess in population group B.  
Survival 
All survival statistics in this report were produced using SAS statistical software.  
Relative survival 
Relative survival is a measure of the survival of people with cancer compared with survival 
in the general population. It is calculated by dividing observed survival by expected survival 
which refers to the proportion of people in the general population alive for a given amount 
of time and is calculated from life tables of the entire Australian population, assumed to be 
cancer-free. The numerator and denominator have been matched for age, sex, calendar year, 
and where applicable, remoteness and socioeconomic status.  
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Crude survival 
Crude survival (CS) is simply observed survival which refers to the proportion of people 
alive for a given amount of time after a diagnosis of cancer and is calculated from 
population-based cancer data. CS was used because the Indigenous life tables are currently 
unavailable, which prevents the calculation of expected survival for the general Indigenous 
population (which serves as the denominator for relative survival estimates). Crude survival 
statistics are calculated using software written by Dickman (2004). 
The cohort and period methods of survival analysis 
CS estimates have traditionally been calculated using the cohort method and this was chosen 
as the primary method for this report. In this method, a cohort of patients diagnosed with 
cancer is followed over time to estimate the proportion surviving for a selected time frame 
(e.g. 1, 5 or 10 years).  
An alternative approach to calculating survival estimates is the period method, developed by 
Brenner and Gefeller in 1996. This method calculates survival using a given follow-up or  
at-risk period. Survival estimates are based on the survival experience of people who were 
diagnosed before or during this period, and who were at risk of dying during this period. By 
its nature the period method is likely to produce more up-to-date estimates of survival than 
the cohort method. 
Multivariate survival analysis: Cox proportional hazards regression analysis 
Multivariable modelling is used to estimate the strength of the relationship of the factor of 
interest and a condition or event, while controlling for potential confounders. One of the 
common statistical modelling techniques of multivariate survival analysis is Cox 
proportional hazards regression analysis, which is used to assess the importance of various 
covariates in the survival times of individuals. The survival statistics generated from the 
model are presented as hazard ratios (see Hazard ratio). 
In this report, a Cox proportional hazards regression analysis model was used to compare 
the risk of death (from any cause) of Indigenous Australians diagnosed with cancer with that 
for non-Indigenous Australians. The modelling was performed using SAS statistical 
software. This model controlled for the effect of factors which are highly correlated with 
Indigenous status and were available in the database, such as age, sex and residential 
remoteness. However, it should be noted that individual screening or testing behaviours 
which might confound the survival analyses could not be considered (for example, 
participating in breast, cervical or bowel screening programs, or undergoing PSA testing for 
prostate cancer) due to these variables not being available in the data set analysed.  
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Appendix C: Data sources 
To provide a comprehensive picture of national cancer statistics in this report, a range of data 
sources were used, including AIHW and external data sources. These data sources are 
described in this appendix.  
Australian Cancer Database  
The Australian Cancer Database (ACD) contains information on Australians who were 
diagnosed with cancer (other than basal cell and squamous cell carcinomas of the skin) 
between 1982 and 2009. The AIHW compiles and maintains the ACD, in partnership with the 
Australasian Association of Cancer Registries. Data from this source are used in chapters 3, 5 
and 6. 
Cancer is a notifiable disease, meaning that each Australian state and territory has legislation 
that makes the reporting of all cancers (excluding basal cell and squamous cell carcinomas of 
the skin) mandatory. The registration of cases of cancer is a dynamic process such that 
records in the state and territory cancer registries may be modified if new information is 
received. Thus, records in the cancer registries are always open and they are updated as 
required. As a result, the number of cancer cases reported by the AIHW for any particular 
year may change slightly over time (AIHW 2012f).  
The data in the ACD are protected physically, electronically with built-in computer security 
systems and legislatively under the Australian Institute of Health and Welfare Act 1987 as well 
as under agreements with the state and territory cancer registries. More information about 
physical security and legislative protection of the ACD is in the National Cancer Statistics 
Clearing House protocol (AIHW 2010c).  
The Data Quality Statement for the Australian Cancer database 2009 can be found on the 
AIHW website at <http://meteor.aihw.gov.au/content/index.phtml/itemId/500417>. 
BreastScreen Australia data 
Data from BreastScreen Australia were used in Chapter 9 to indicate the number of 
Aboriginal and Torres Strait Islander women and non-Indigenous women who had a 
screening mammogram and the number of cancers detected through BreastScreen Australia. 
These data are supplied annually to the AIHW by state and territory BreastScreen programs 
for monitoring purposes. They are compiled by the AIHW and reports are produced 
annually (AIHW 2012e).  
The Data Quality Statement for the BreastScreen Australian data 2010–2011 can be found on 
the AIHW website at < http://meteor.aihw.gov.au/content/index.phtml/itemId/510961>. 
Burden of disease data 
Disability-adjusted life year, or DALY, quantifies the gap between a population’s actual 
health status and some ‘ideal’ or reference status, with time (either lived in health states or 
lost through premature death and illness) being the unifying ‘currency’ for combining the 
impact of mortality and non-fatal health outcomes.  
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A DALY for a disease or health condition is calculated as the sum of the years of life lost due 
to premature mortality (YLL) in the population and the equivalent ‘healthy’ years lost due to 
disability (YLD) for incident cases of the health condition. For example, if a person who has 
been healthy all their life suddenly dies of a heart attack 20 years early than expected, there is 
20 years of healthy life lost—20 DALYs. For a person who lives to a normal old age but has 
been only ‘half-well’ for 30 years, there are 15 DALYs lost.  
Estimates on DALYs for the Australian population can be found in The burden of disease and 
injury in Australia report (Begg et al. 2007). The Global Burden of Disease Study 2010 (Murray  
et al. 2012) provides more recent estimates on DALYs. However, neither of these two studies 
provides information on burden of disease for Indigenous Australians. The AIHW is 
currently undertaking a project to revise and update Australia’s burden of disease estimates, 
which will deliver new burden of disease results for Indigenous and non-indigenous 
Australians (AIHW 2013c). 
The burden of disease data in this report were sourced from the most recent Australian 
study looking at the burden of disease in Aboriginal and Torres Strait Islander peoples — 
The burden of disease and injury in Aboriginal and Torres Strait Islander Peoples 2003 report (Vos 
et al. 2007), which provides 2003 data. Data on the burden of disease in Aboriginal and 
Torres Strait Islander peoples due to cancer are in Chapter 10 of this report.  
Disease expenditure database 
The disease expenditure database provides costs that are derived by combining information 
from the AIHW National Hospital Morbidity Database (NHMD), the AIHW Public Hospitals 
Establishments Database (PHED) and an external data source, the National Hospital Costs 
Data Collection. The methodologies used to derive the estimated costs in Chapter 8 are 
similar but are not the same as those used to derive the estimates in the AIHW Disease 
expenditure database. For this report, it was necessary to adjust the estimates for Indigenous 
under-identification. In addition, the AIHW Disease expenditure database has been designed 
to cover whole health system costs of which hospitalisation costs are one component.  
Further information on the Disease expenditure database including its limitations can be 
found in the Data Quality Statement 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/512599>. 
GLOBOCAN 
The GLOBOCAN database, which is prepared by the International Agency for Research on 
Cancer (IARC), contains cancer incidence and mortality data from cancer registries around 
the world (Ferlay et al. 2010). The IARC uses these data to produce estimates for a ‘common 
year’. The most recent GLOBOCAN estimates for which data could be obtained are for 2008, 
with these estimates based on incidence data from about 3‒5 years earlier. GLOBOCAN data 
are presented in Chapter 5 of this report for all cancers combined.  
For the GLOBOCAN data, all cancers combined were defined as those coded as ‘C00 to C97’ 
in ICD-10, with the exception of code C44 which indicates non-melanoma skin cancer. Thus 
the definition used in those data is different from that used in most other sections of this 
report.  
In the GLOBOCAN database, age-standardised incidence and mortality rates are provided, 
with the data standardised to the 1966 WHO World Standard Population.  
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National Bowel Cancer Screening Program data 
Data from the National Bowel Cancer Screening Register were used in Chapter 9 to indicate 
the number of Indigenous and non-Indigenous Australians who participated in the National 
Bowel Cancer Screening Program (NBCSP) as well as to indicate the number of positive 
screening results. These data are supplied twice a year to the AIHW by the Department of 
Human Services (formerly Medicare Australia) for monitoring purposes. They are compiled 
by the AIHW and reports are produced annually (AIHW 2013f).  
The Data Quality Statement for the Australian Cancer database 2009 can be found on the 
AIHW website at <http://meteor.aihw.gov.au/content/index.phtml/itemId/500678>. 
National Death Index 
Cancer incidence data were linked to the National Death Index (NDI) to provide survival 
and prevalence information (chapters 5 and 6). The NDI is a database that is maintained by 
the AIHW; it contains information on all deaths in Australia since 1980. This database exists 
solely for linkage purposes for health and medical research, such as to gain mortality 
information on individuals in a particular cohort, or with a known disease state. Ethics 
approval is required for the NDI to be used for any particular research project.  
The Data Quality Statement for the NDI can be found on the AIHW website at  
<http://meteor.aihw.gov.au/content/index.phtml/itemId/480010>. 
National Hospital Morbidity Database  
Chapter 7 of this report used data from the National Hospital Morbidity Database (NHMD) 
to examine the number of cancer-related hospitalisations. The NHMD is compiled from data 
supplied by the state and territory health authorities. It is a collection of electronic 
confidentialised summary records for hospitalisations (that is, episodes of admitted patient 
care) in essentially all public and private hospitals in Australia. The data include 
demographic, administrative and clinical information, including patient diagnoses and other 
procedures 
Information on the NHMD on Indigenous status is considered of sufficient quality for 
analysis purposes for New South Wales, Victoria, Queensland, South Australia, Western 
Australia and the Northern Territory (public hospitals only). National totals include these six 
jurisdictions only.  
The hospitalisations data in this report exclude those hospitalisations for which the care type 
was reported as newborn (unqualified days only), or records for hospital boarder or 
posthumous organ procurement. Thus, it includes all other admitted care hospitalisations, 
including those with a care type of acute care, rehabilitation care and palliative care. 
The Data Quality Statement for the NHMD can be found on the AIHW website at 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/511338>. 
National Mortality Database 
Registration of deaths is the responsibility of the state and territory Registrars of Births, 
Deaths and Marriages. The ABS then collates and codes these data. The mortality data used 
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in this report were provided by the Registries of Births, Deaths and Marriages, the ABS and 
the National Coroners Information System. These data are maintained at the AIHW in the 
National Mortality Database (NMD). 
Data from the NMD are used in Chapter 4 to provide statistical information on mortality in 
Indigenous and non-Indigenous Australians due to cancer.  
In the NMD, both the year of occurrence of the death and the year in which the death was 
registered are provided. For this report, mortality data are shown based on the year of 
occurrence, except for the most recent year (namely, 2011) where the number of people whose 
death was registered is used. This is because in some instances, deaths may not be registered 
in the same year in which they occur. 
The Data Quality Statement for the NMD can be found here: 
<http://www.abs.gov.au/Ausstats/abs@.nsf/0/D4A300EE1E04AA43CA2576E800156A24?
OpenDocument>.  
Population data  
The ABS estimated (mid-year) resident population data were used to calculate rates 
throughout this report. These data were sourced from ABS Australian demographic statistics 
(cat. No. 3101.0) (ABS 2012a) as at 27 September 2012. Relevant years and states were 
selected based on numerator data availability. 
For the Indigenous comparisons, the ABS Indigenous experimental estimated (mid-year) 
resident populations were used (ABS 2009a). Those estimates were based on the 2006 Census 
of Population and Housing. Relevant years and states were selected based on numerator 
data availability. 
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Appendix D: Additional tables 
Additional tables for Chapter 3: Incidence of cancer 
Table D3.1: The 10 most commonly diagnosed cancers in Aboriginal and Torres Strait Islander 
peoples, New South Wales, Queensland, Western Australia and the Northern Territory, 2004–2008 
 Indigenous  Non-Indigenous 
Cancer site/type Number Ranking ASR 95% CI  Number Ranking ASR 95% CI 
Lung (C33–C34) 603 1 79.8 72.7–87.2  28,998 4 43.0 42.5–43.5 
Breast in 
females(C50) 438 2 82.1 73.8–91.0  35,851 3 103.6 102.5–104.7 
Bowel (C18–C20)  348 3 47.8 42.1–53.9  39,725 2 58.8 58.2–59.4 
Prostate (C61) 291 4 105.2 91.5–120.2  47,404 1 147.6 146.2–148.9 
Unknown primary site 
(C77–C80) 167 5 23.6 19.6–28.2  8,329 7 12.2 12.0–12.5 
Non-Hodgkin 
lymphoma (C82–C85) 125 6 14.2 11.3–17.5  10,945 6 16.3 16.0–16.6 
Cervix (C53) 121 7 18.0 14.5–22.0  2,185 22 6.5 6.3–6.8 
Uterus (C54–C55) 120 8 24.4 19.8–29.7  5,243 13 14.9 14.5–15.3 
Liver (C22) 118 9 15.3 12.3–18.9  3,429 18 5.1 4.9–5.3 
Pancreas (C25) 110 10 15.2 12.1–18.8  7,046 8 10.4 10.1–10.6 
All cancers 
combined
(a)
 3,875 . . 460.8 443.8–478.2  292,949 . . 434.4 432.8–436.0 
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, with the exception of those C44 codes that indicate basal cell 
and squamous cell carcinoma of the skin. 
Notes 
1. Full list of cancer types can be found in online supplementary Table G3.1. 
2. Top 10 rankings of Indigenous, non-Indigenous and All Australians can be found in online supplementary Table G3.2. 
3. Rates were directly age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
Source: AIHW Australian Cancer Database 2009. 
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Table D3.2: Age-specific incidence rates for the 10 most commonly diagnosed cancers in Aboriginal 
and Torres Strait Islander peoples, New South Wales, Queensland, Western Australia and the 
Northern Territory, 2004–2008  
Age group 
Indigenous  Non-Indigenous 
Number  Age-specific rate 95% CI  Number Age-specific rate 95% CI 
  Lung (C33–C34) 
<45 31 1.7 1.2–2.4  535 1.3 1.2–1.5 
45–54 123 65.8 54.7–78.5  2,113 23.7 22.7–24.8 
55–64 198 196.7 170.3–226.1  6,108 86.5 84.3–88.7 
65–74 168 375.9 321.2–437.2  9,132 207.1 202.9–211.4 
75+ 83 406.5 323.8–503.9  11,109 285.5 280.2–290.8 
  Breast in females (C50) 
<45 92 10.3 8.3–12.6  4,909 25.1 24.4–25.8 
45–54 128 131.9 110.0–156.8  8,746 195.6 191.6–199.8 
55–64 113 212.2 174.9–255.2  9,552 273.1 267.6–278.6 
65–74 80 320.9 254.4–399.4  6,637 296.4 289.3–303.6 
75+ 25 199.8 129.3–294.9  6,007 262.2 255.6–268.9 
  Bowel (C18–C20) 
<45 42 2.3 1.7–3.1   1,441 3.6 3.4–3.8 
45–54 62 33.2 25.4–42.5   3,553 39.9 38.6–41.3 
55–64 90 89.4 71.9–109.9   8,285 117.3 114.8–119.8 
65–74 91 203.6 163.9–250.0   11,747 266.4 261.6–271.3 
75+ 63 308.6 237.1–394.8   14,699 377.7 371.6–383.9 
  Prostate (C61) 
<45 . . . . . .   195 1.0 0.8–1.1 
45–54 25 27.8 18.0–41.0   3,335 75.3 72.8–77.9 
55–64 104 219.4 179.2–265.8   14,357 402.6 396.0–409.2 
65–74 107 541.4 443.7–654.2   16,643 767.0 755.4–778.8 
75+ 55 695.9 524.3–905.9   12,874 804.4 790.5–818.4 
  Unknown primary site (C77–C80) 
<45 20 1.1 0.7–1.7   234 0.6 0.5–0.7 
45–54 30 16.0 10.8–22.9   571 6.4 5.9–7.0 
55–64 40 39.7 28.4–54.1   1,193 16.9 15.9–17.9 
65–74 43 96.2 69.6–129.6   1,886 42.8 40.9–44.8 
75+ 34 166.5 115.3–232.7   4,445 114.2 110.9–117.6 
 Non-Hodgkin lymphoma (C82–C85) 
<45 37 2.0 1.4–2.8   1,162 2.9 2.8–3.1 
45–54 22 11.8 7.4–17.8   1,388 15.6 14.8–16.4 
55–64 26 25.8 16.9–37.8   2,292 32.4 31.1–33.8 
65–74 24 53.7 34.4–79.9   2,580 58.5 56.3–60.8 
75+ 16 78.4 44.8–127.3   3,523 90.5 87.6–93.6 
       (continued) 
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Table D3.2 (continued): Age-specific incidence rates for the 10 most commonly diagnosed cancers 
in Aboriginal and Torres Strait Islander peoples, New South Wales, Queensland, Western 
Australia and the Northern Territory, 2004–2008 
 Indigenous  Non-Indigenous 
Age group Number Age-specific rate 95% CI  Number  Age-specific rate 95% CI 
  Cervix (C53) 
<45 64 7.1 5.5–9.1   876 4.5 4.2–4.8 
45–54 31 31.9 21.7–45.3   438 9.8 8.9–10.8 
55–64 12 22.5 11.6–39.4   316 9.0 8.1–10.1 
65–74 9 36.1 16.5–68.5   247 11.0 9.7–12.5 
75+ 5 40.0 13.0–93.2   308 13.4 12.0–15.0 
  Uterus (C54–C55) 
<45 20 2.2 1.4–3.4   288 1.5 1.3–1.7 
45–54 33 34.0 23.4–47.8   832 18.6 17.4–19.9 
55–64 35 65.7 45.8–91.4   1,578 45.1 42.9–47.4 
65–74 22 88.2 55.3–133.6   1,317 58.8 55.7–62.1 
75+ 10 79.9 38.3–146.9   1,228 53.6 50.6–56.7 
  Liver (C22) 
<45 15 0.8 0.5–1.4   164 0.4 0.4–0.5 
45–54 25 13.4 8.7–19.7   538 6.0 5.5–6.6 
55–64 30 29.8 20.1–42.5   722 10.2 9.5–11.0 
65–74 31 69.4 47.1–98.4   846 19.2 17.9–20.5 
75+ 17 83.3 48.5–133.3   1,159 29.8 28.1–31.5 
  Pancreas (C25) 
<45 6 0.3 0.1–0.7   160 0.4 0.3–0.5 
45–54 24 12.8 8.2–19.1   503 5.7 5.2–6.2 
55–64 35 34.8 24.2–48.4   1,317 18.6 17.7–19.7 
65–74 24 53.7 34.4–79.9   1,897 43.0 41.1–45.0 
75+ 21 102.9 63.7–157.2   3,169 81.4 78.6–84.3 
 All cancers combined
(a)
 
<45 763 42.2 39.2–45.3   24,793 62.5 61.7–63.3 
45–54 815 435.8 406.4–466.8   35,028 393.6 389.5–397.7 
55–64 975 968.7 908.8–1031.4   65,690 929.9 922.8–937.1 
65–74 836 1,870.4 1,745.8–2,001.6   75,797 1,719.2 1,707.0–1,731.5 
75+ 486 2,380.3 2,173.3–2,601.6   91,640 2,354.9 2,339.7–2,370.2 
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, with the exception of those C44 codes that indicate basal cell 
and squamous cell carcinoma of the skin. 
Note: The rates are expressed per 100,000 population. 
Source: AIHW Australian Cancer Database 2009. 
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Table D3.3: Age-standardised incidence rates for the 10 most commonly diagnosed cancers in 
Aboriginal and Torres Strait Islander peoples, by sex, New South Wales, Queensland, Western 
Australia and the Northern Territory, 2004–2008 
Sex 
Indigenous  Non-Indigenous 
Number  ASR 95% CI  Number  ASR 95% CI 
  Lung (C33–C34) 
Males 341 109.4 96.0–123.9   18,186 58.6 57.7–59.5 
Females 262 58.8 51.3–67.1   10,812 30.1 29.6–30.7 
  Breast in females (C50) 
Males . . . . . .   . . . . . . 
Females 438 82.1 73.8–91.0   35,851 103.6 102.5–104.7 
  Bowel (C18–C20) 
Males 188 55.5 46.2–65.8   21,988 70.0 69.1–71.0 
Females 160 41.3 34.4–49.1   17,737 48.9 48.2–49.7 
  Prostate cancer (C61) 
Males 291 105.2 91.5–120.2   47,404 147.6 146.2–148.9 
Females . . . . . .   . . . . . . 
  Unknown primary site (C77–C80) 
Males 81 26.4 19.8–34.2   4,447 14.8 14.3–15.2 
Females 86 21.5 16.6–27.3   3,882 10.1 9.8–10.5 
  Non-Hodgkin lymphoma (C82-C85) 
Males 75 19.1 13.8–25.5   6,056 19.2 18.7–19.7 
Females 50 10.4 7.3–14.3   4,889 13.7 13.3–14.1 
  Cervix (C53) 
Males . . . . . .   . . . . . . 
Females 121 18.0 14.5–22.0   2,185 6.5 6.3–6.8 
  Uterus (C54–C55) 
Males . . . . . .   . . . . . . 
Females 120 24.4 19.8–29.7   5,243 14.9 14.5–15.3 
  Liver (C22) 
Males 76 21.3 15.9–27.8   2,431 7.7 7.4–8.0 
Females 42 10.4 7.1–14.5   998 2.7 2.6–2.9 
  Pancreas (C25)  
Males 60 16.3 11.7–21.8   3,655 11.8 11.4–12.2 
Females 50 13.8 9.9–18.6   3,391 9.1 8.8–9.4 
  All cancers combined
(a)
 
Males 1,931 549.1 519.1–580.1   165,103 524.7 522.2–527.3 
Females 1,944 399.9 379.8–420.8   127,846 361.0 359.0–363.0 
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, with the exception of those C44 codes that indicate basal cell 
and squamous cell carcinoma of the skin. 
Note: Rates were directly age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
Source: AIHW Australian Cancer Database 2009. 
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Table D3.4: Age-standardised incidence rates for the 10 most commonly diagnosed cancers in 
Aboriginal and Torres Strait Islander peoples, by remoteness area, New South Wales, Queensland, 
Western Australia and the Northern Territory, 2004–2008 
Remoteness area 
Indigenous  Non-Indigenous 
Number ASR 95% CI   Number ASR 95% CI  
  Lung (C33–C34) 
Major cities 160 40.4 34.1–47.4  18,583 20.4 20.0–20.7 
Inner regional 106 39.9 32.4–48.5  6,524 21.2 20.6–21.8 
Outer regional 151 48.7 41.0–57.5  3,100 22.2 21.3–23.1 
Remote and very remote 182 45.2 38.6–52.6  647 26.1 24.0–28.4 
  Breast in females (C50) 
Major cities 145 66.7 55.9–79.0  24,579 80.2 79.1–81.3 
Inner regional 91 62.5 49.9–77.2  7,527 77.1 75.2–79.1 
Outer regional 110 66.4 54.2–80.4  3,304 71.5 68.8–74.2 
Remote and very remote 94 43.3 34.6–53.4  607 73.7 67.7–80.0 
  Bowel (C18–C20) 
Major cities 123 29.6 24.4–35.5  25,482 29.5 29.0–29.9 
Inner regional 78 28.3 22.2–35.6  9,304 31.8 31.0–32.6 
Outer regional 81 25.7 20.2–32.1  4,108 30.4 29.4–31.5 
Remote and very remote 62 14.7 11.1–19.1  722 30.9 28.5–33.4 
  Prostate (C61) 
Major cities 98 57.6 46.5–70.6  29,922 76.8 75.8–77.8 
Inner regional 81 62.2 49.1–77.7  11,571 81.3 79.6–83.1 
Outer regional 66 48.4 37.0–62.0  4,781 67.5 65.4–69.7 
Remote and very remote 44 22.7 16.2–30.7  892 67.1 62.5–71.9 
  Unknown primary site (C77–C80) 
Major cities 36 8.5 5.9–11.9  5,382 5.4 5.2–5.6 
Inner regional 18 7.1 4.1–11.3  1,902 5.8 5.5–6.1 
Outer regional 37 11.3 7.9–15.7  849 5.7 5.3–6.2 
Remote and very remote 75 17.1 13.3–21.6  151 6.0 5.0–7.1 
  Non-Hodgkin lymphoma (C82-C85) 
Major cities 44 9.6 6.8–13.1  7,289 9.7 9.5–10.0 
Inner regional 25 8.6 5.5–13.0  2,395 9.8 9.4–10.3 
Outer regional 29 8.3 5.3–12.1  1,012 9.0 8.3–9.6 
Remote and very remote 28 5.6 3.6–8.3  206 9.5 8.2–11.0 
  Cervix (C53) 
Major cities 24 9.9 6.1–15.0  1,523 5.5 5.2–5.8 
Inner regional 19 13.2 7.8–20.7  391 5.2 4.6–5.8 
Outer regional 34 18.4 12.7–25.9  207 5.3 4.5–6.2 
Remote and very remote 44 17.4 12.4–23.5  49 6.3 4.6–8.4 
       (continued) 
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Table D3.4 (continued): Age-standardised incidence rates for the 10 most commonly diagnosed 
cancers in Aboriginal and Torres Strait Islander peoples, by remoteness area, New South Wales, 
Queensland, Western Australia and the Northern Territory, 2004–2008 
 Indigenous  Non-Indigenous 
Remoteness area Number ASR 95% CI   Number ASR 95% CI 
  Uterus (C54–C55) 
Major cities 32 14.2 9.6–20.2  3,510 9.8 9.5–10.2 
Inner regional 15 11.9 6.5–19.7  1,130 9.5 8.8–10.1 
Outer regional 29 18.5 12.2–26.8  502 9.4 8.4–10.3 
Remote and very remote 43 20.2 14.4–27.5  91 10.3 8.1–12.7 
  Liver (C22) 
Major cities 37 9.1 6.3–12.7  2,520 3.2 3.1–3.4 
Inner regional 10 3.8 1.7–7.2  550 2.2 2.0–2.4 
Outer regional 28 8.7 5.7–12.7  295 2.4 2.1–2.8 
Remote and very remote 41 8.9 6.3–12.3  46 1.9 1.3–2.5 
  Pancreas (C25) 
Major cities 34 8.5 5.8–12.0  4,699 5.0 4.9–5.2 
Inner regional 19 7.1 4.2–11.3  1,502 4.8 4.5–5.1 
Outer regional 30 9.8 6.5–14.1  676 4.5 4.1–4.9 
Remote and very remote 26 6.4 4.1–9.4  133 5.4 4.5–6.5 
  All cancers combined
(a)
 
Major cities 1,139 269.3 253.2–286.1  191,504 252.5 251.2–253.8 
Inner regional 734 258.5 239.3–278.7  65,285 256.7 254.3–259.1 
Outer regional 924 284.6 265.9–304.3  29,175 243.0 239.7–246.2 
Remote and very remote 1,059 245.3 230.1–261.3  5,662 260.0 252.8–267.3 
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, with the exception of those C44 codes that indicate basal cell 
and squamous cell carcinoma of the skin. 
Note: Rates were directly age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
Source: AIHW Australian Cancer Database 2009. 
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Table D3.5: Number of observed, expected and excess new cases of the 10 most commonly 
diagnosed cancers in Aboriginal and Torres Strait Islander peoples, New South Wales, 
Queensland, Western Australia and the Northern Territory, 2004–2008 
Cancer site/type Observed number Expected number Excess cases
(a)
 
Lung (C33–C34) 603 288 315 
Breast in females(C50) 438 574 –136 
Bowel (C18–C20)  348 419 –71 
Prostate (C61) 291 462 –171 
Unknown primary site (C77–C80) 167 76 91 
Non-Hodgkin lymphoma (C82–C85) 125 144 –19 
Cervix (C53) 121 46 75 
Uterus (C54–C55) 120 70 50 
Liver (C22) 118 41 77 
Pancreas (C25) 110 68 42 
All cancers combined
(b)
 3,875 3,662 213 
(a) Excess new cases are the observed new cases minus the expected new cases. 
(b) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, with the exception of those C44 codes that indicate basal cell 
and squamous cell carcinoma of the skin. 
Note: The expected numbers are based on the indirect age-standardisation method. 
Source: AIHW Australian Cancer Database 2009. 
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Additional tables for Chapter 4: Mortality from 
cancer 
Table D4.1: Age-standardised mortality rates of the 10 leading causes of cancer deaths among 
Aboriginal and Torres Strait Islander peoples, New South Wales, Queensland, Western Australia, 
South Australia and the Northern Territory, 2007–2011  
 Indigenous  Non-Indigenous 
Cancer site/type Number Ranking ASR 95% CI  Number Ranking ASR 95% CI 
Lung (C33–C34) 549 1 63.6 57.5–70.0  27,678 1 33.2 32.8–33.6 
Liver (C22) 145 2 17.2 14.0–20.8  4,289 9 5.2 5.0–5.3 
Breast in females 
(C50) 140 3 27.5 22.5–33.1  9,586 4 21.4 21.0–21.9 
Unknown primary site 
(C77–C80) 131 4 15.7 12.6–19.1  8,119 5 9.6 9.4–9.8 
Bowel (C18–C20) 118 5 13.4 10.7–16.5  13,644 2 16.2 15.9–16.5 
Pancreas (C25) 112 6 12.9 10.3–16.0  7,938 6 9.4 9.2–9.7 
Oesophagus (C15) 106 7 10.8 8.5–13.4  4,020 12 4.8 4.6–4.9 
Prostate (C61) 72 8 30.6 22.8–39.9  10,754 3 29.9 29.3–30.5 
Stomach (C16) 65 9 7.4 5.4–9.9  3,674 13 4.4 4.2–4.5 
Cervix (C53) 52 10 7.1 5.2–9.5  793 27 1.8 1.7–2.0 
All cancers 
combined
(a)
 2,197 . . 251.7 239.4–264.4  144,791 . . 172.4 171.5–173.3 
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3. 
Notes 
1. Full list of cancer types can be found in online supplementary Table D4.2. 
2. Top 10 rankings of Indigenous, non-Indigenous and All Australians can be found in online supplementary Table G4.3. 
3. Rates were directly age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
4. Mortality data for 2007–2009 are final, 2010 are revised and 2011 are preliminary. Data for 2010 and 2011 are subject to revision. 
Source: AIHW National Mortality Database. 
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Table D4.2: Age-specific mortality rates for the 10 leading causes of cancer deaths among 
Aboriginal and Torres Strait Islander peoples, by age group, New South Wales, Queensland, 
Western Australia, South Australia and the Northern Territory, 2007–2011 
Age group 
Indigenous  Non-Indigenous 
Number Age-specific rate 95% CI  Number Age-specific rate 95% CI 
 Lung (C33–C34) 
<45 34 1.7 1.2–2.3   345 0.8 0.7–0.8 
45–54 101 45.4 36.9–55.1   1,693 16.2 15.4–16.9 
55–64 147 115.5 97.6–135.7   5,045 58.0 56.4–59.6 
65–74 175 315.9 270.8–366.3   8,162 148.5 145.3–151.7 
75+ 92 458.7 369.8–562.5   12,433 360.5 354.2–366.9 
 Liver (C22) 
<45 11 0.5 0.3–1.0   108 0.2 0.2–0.3 
45–54 27 12.1 8.0–17.6   452 4.3 3.9–4.7 
55–64 42 33.0 23.8–44.6   825 9.5 8.8–10.1 
65–74 39 70.4 50.1–96.2   1,093 19.9 18.7–21.1 
75+ 26 129.6 84.7–189.9   1,811 52.5 50.1–55.0 
 Breast in females (C50) 
<45 23 2.3 1.5–3.4   572 2.5 2.3–2.7 
45–54 29 24.9 16.7–35.8   1,372 26.0 24.6–27.4 
55–64 33 48.9 33.6–68.6   2,038 46.8 44.8–48.9 
65–74 25 81.1 52.5–119.8   1,954 70.0 66.9–73.2 
75+ 30 249.4 168.3–356.1   3,650 191.7 185.5–198.0 
 Unknown primary site (C77–C80) 
<45 12 0.6 0.3–1.0   141 0.3 0.3–0.4 
45–54 19 8.5 5.1–13.3   446 4.3 3.9–4.7 
55–64 35 27.5 19.2–38.2   1,004 11.5 10.8–12.3 
65–74 43 77.6 56.2–104.6   1,792 32.6 31.1–34.1 
75+ 22 109.7 68.7–166.1   4,736 137.3 133.4–141.3 
 Bowel (C18–C20) 
<45 16 0.8 0.5–1.3   358 0.8 0.7–0.9 
45–54 15 6.7 3.8–11.1   856 8.2 7.6–8.7 
55–64 34 26.7 18.5–37.3   2,158 24.8 23.8–25.9 
65–74 33 59.6 41.0–83.7   3,330 60.6 58.5–62.7 
75+ 20 99.7 60.9–154.0   6,942 201.3 196.6–206.1 
  Pancreas (C25) 
<45 3 0.2 0.0–0.4   126 0.3 0.2–0.3 
45–54 26 11.7 7.6–17.1   499 4.8 4.4–5.2 
55–64 31 24.4 16.5–34.6   1,340 15.4 14.6–16.2 
65–74 31 56.0 38.0–79.4   2,105 38.3 36.7–40.0 
75+ 21 104.7 64.8–160.0   3,868 112.2 108.6–115.7 
       (continued) 
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Table D4.2 (continued): Age-specific mortality rates for the 10 leading causes of cancer deaths 
among Aboriginal and Torres Strait Islander peoples, by age group, New South Wales, 
Queensland, Western Australia, South Australia and the Northern Territory, 2007–2011 
Age group 
Indigenous  Non-Indigenous 
Number Age-specific rate 95% CI  Number Age-specific rate 95% CI 
 Oesophagus (C15) 
<45 6 0.3 0.1–0.6   78 0.2 0.1–0.2 
45–54 27 12.1 8.0–17.6   312 3.0 2.7–3.3 
55–64 39 30.6 21.8–41.9   773 8.9 8.3–9.5 
65–74 22 39.7 24.9–60.1   1,070 19.5 18.3–20.7 
75+ 12 59.8 30.9–104.5   1,787 51.8 49.4–54.3 
 Prostate (C61) 
<45 n.p. n.p. n.p.   4 0.0 0.0–0.0 
45–54 n.p. n.p. n.p.   82 1.6 1.3–2.0 
55–64 13 21.8 11.6–37.2   692 15.9 14.7–17.1 
65–74 22 89.5 56.1–135.5   2,052 75.9 72.6–79.2 
75+ 34 423.4 293.2–591.7   7,924 513.1 501.8–524.5 
 Stomach (C16) 
<45 11 0.5 0.3–1.0   146 0.3 0.3–0.4 
45–54 8 3.6 1.6–7.1   300 2.9 2.5–3.2 
55–64 21 16.5 10.2–25.2   577 6.6 6.1–7.2 
65–74 13 23.5 12.5–40.1   804 14.6 13.6–15.7 
75+ 12 59.8 30.9–104.5   1,847 53.6 51.1–56.1 
 Cervix (C53) 
<45 20 2.0 1.2–3.1   120 0.5 0.4–0.6 
45–54 10 8.6 4.1–15.8   135 2.6 2.1–3.0 
55–64 12 17.8 9.2–31.0   167 3.8 3.3–4.5 
65–74 n.p. n.p. n.p.   122 4.4 3.6–5.2 
75+ n.p. n.p. n.p.   249 13.1 11.5–14.8 
 All cancers combined
(a)
 
<45 248 12.3 10.8–13.9   4,392 9.5 9.3–9.8 
45–54 394 176.9 159.9–195.3   9,630 91.9 90.0–93.7 
55–64 570 447.8 411.8–486.1   22,779 261.7 258.3–265.1 
65–74 588 1,061.5 977.4–1150.8   34,890 634.6 628.0–641.3 
75+ 397 1,979.3 1789.3–2183.9   73,096 2,119.5 2104.2–2134.9 
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3. 
Notes 
1. The rates are expressed per 100,000 population. 
2. Mortality data for 2007–2009 are final, 2010 are revised and 2011 are preliminary. Data for 2010 and 2011 are subject to revision. 
Source: AIHW National Mortality Database. 
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Table D4.3: Age-standardised mortality rates for the 10 leading causes of cancer deaths among 
Aboriginal and Torres Strait Islander peoples, by sex, New South Wales, Queensland, Western 
Australia, South Australia and the Northern Territory, 2007–2011 
Sex 
Indigenous  Non-Indigenous 
Number  ASR 95% CI  Number  ASR 95% CI 
  Lung (C33–C34) 
Males 312 89.7 77.8–102.7   17,160 45.1 44.5–45.8 
Females 237 45.8 39.5–52.7   10,518 23.5 23.1–24.0 
  Liver (C22) 
Males 95 23.1 17.6–29.5   2,890 7.5 7.2–7.8 
Females 50 12.4 8.8–16.9   1,399 3.0 2.9–3.2 
  Breast in females (C50) 
Males . . . . . .   . . . . . . 
Females 140 27.5 22.5–33.1   9,586 21.4 21.0–21.9 
  Unknown primary site (C77–C80) 
Males 67 18.2 13.0–24.3   4,257 11.4 11.1–11.7 
Females 64 13.8 10.2–18.2   3,862 8.0 7.8–8.3 
  Bowel (C18–C20) 
Males 60 15.3 10.9–20.8   7,568 20.0 19.6–20.5 
Females 58 12.0 8.7–16.0   6,076 13.0 12.7–13.3 
  Pancreas (C25) 
Males 55 12.3 8.6–16.8   4,129 10.8 10.4–11.1 
Females 57 13.0 9.5–17.3   3,809 8.2 7.9–8.5 
  Oesophagus (C15) 
Males 73 17.1 12.4–22.7   2,912 7.6 7.3–7.8 
Females 33 6.0 4.0–8.7   1,108 2.3 2.2–2.5 
  Prostate (C61) 
Males 72 30.6 22.8–39.9   10,754 29.9 29.3–30.5 
Females . . . . . .   . . . . . . 
  Stomach (C16) 
Males 39 10.4 6.5–15.4   2,310 6.1 5.9–6.4 
Females 26 5.2 3.1–8.1   1,364 2.9 2.8–3.1 
  Cervix (C53) 
Males . . . . . .   . . . . . . 
Females 52 7.1 5.2–9.5   793 1.8 1.7–2.0 
  All cancers combined
(a)
 
Males 1,137 305.2 283.3–328.1   82,591 220.0 218.5–221.5 
Females 1,060 214.4 199.8–229.6   62,200 135.4 134.3–136.5 
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3. 
Notes 
1. Rates were directly age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
2. Mortality data for 2007–2009 are final, 2010 are revised and 2011 are preliminary. Data for 2010 and 2011 are subject to revision. 
Source: AIHW National Mortality Database. 
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Table D4.4: Number of observed, expected and excess cancer deaths of the 10 leading causes of 
cancer deaths among Aboriginal and Torres Strait Islander peoples, New South Wales, 
Queensland, Western Australia, South Australia and the Northern Territory, 2007–2011 
Cancer site/type Observed number Expected number  Excess deaths(a) 
Lung (C33–C34) 549 106 443 
Liver (C22) 145 14 131 
Breast in females (C50) 140 127 13 
Unknown primary site (C77–C80) 131 34 97 
Bowel (C18–C20) 118 58 60 
Pancreas (C25) 112 34 78 
Oesophagus (C15) 106 9 97 
Prostate (C61) 72 5 67 
Stomach (C16) 65 14 51 
Cervix (C53) 52 12 40 
All cancers combined
(b)
 2,197 1,459 738 
(a) Excess deaths are the observed deaths minus the expected deaths. 
(b) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3. 
Notes 
1. Mortality data for 2007–2009 are final, 2010 are revised and 2011 are preliminary. Data for 2010 and 2011 are subject to revision. 
2. The expected deaths are based on the indirect age-standardisation method. 
Source: AIHW National Mortality Database. 
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Additional tables for Chapter 5: Survival after a 
diagnosis of cancer 
Table D5.1: One-year and five-year crude survival for the 10 most commonly diagnosed cancers in 
Aboriginal and Torres Strait Islander peoples, New South Wales, Queensland, Western Australia 
and the Northern Territory, 1999–2007 
 
Indigenous 
 
Non-Indigenous 
Cancer site/type CS (%) 95% CI 
 
CS (%) 95% CI 
 1-year crude survival 
Lung (C33–C34) 26.8 24.0–29.6  35.6 35.2–36.0 
Breast in females (C50) 91.6 89.2–93.5  96.0 95.8–96.1 
Bowel (C18–C20) 75.0 71.0–78.6  78.9 78.5–79.2 
Prostate (C61) 86.2 81.9–89.6  92.5 92.3–92.7 
Unknown primary site (C77–C80) 14.1 11.3–17.2  17.2 16.7–17.7 
Non-Hodgkin lymphoma (C82–C85) 65.2 57.5–71.9  76.2 75.6–76.8 
Cervix (C53) 72.7 66.0–78.4  85.7 84.5–86.8 
Uterus (C54–C55) 85.1 78.8–89.7  90.0 89.3–90.6 
Liver (C22) 21.1 15.9–26.9  32.9 31.7–34.1 
Pancreas (C25) 11.0 7.6–15.3  19.7 19.0–20.3 
All cancers combined
(a)
 60.8 59.6–62.0  74.0 73.8–74.1 
 5-year crude survival 
Lung (C33–C34) 7.4 5.8–9.2  10.7 10.4–11.0 
Breast in females (C50) 69.9 66.1–73.3  81.3 81.0–81.6 
Bowel (C18–C20) 46.8 42.3–51.2  52.9 52.5–53.2 
Prostate (C61) 62.5 56.7–67.7  72.0 71.6–72.4 
Unknown primary site (C77–C80) 6.6 4.6–9.0  8.3 7.9–8.6 
Non-Hodgkin lymphoma (C82–C85) 49.2 41.2–56.7  55.4 54.6–56.1 
Cervix (C53) 51.2 44.1–57.9  67.2 65.7–68.7 
Uterus (C54–C55) 66.3 58.4–73.1  72.2 71.2–73.1 
Liver (C22) n.p. n.p.  12.1 11.3–13.0 
Pancreas (C25) n.p. n.p.  4.1 3.8–4.5 
All cancers combined
(a)
 40.2 38.9–41.5  51.9 51.7–52.0 
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, with the exception of those C44 codes that indicate basal cell 
and squamous cell carcinoma of the skin. 
Note: Survival for liver and pancreatic cancer are not shown due to data quality issues. 
Source: AIHW Australian Cancer Database 2007. 
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Table D5.2: Five-year crude survival for the 10 most commonly diagnosed cancers among 
Aboriginal and Torres Strait Islander peoples, by age group, New South Wales, Queensland, 
Western Australia and the Northern Territory, 1999–2007 
Age group 
(years) 
Indigenous 
 
Non-Indigenous 
CS (%) 95% CI   CS (%) 95% CI 
 Lung (C33–C34) 
<50 n.p. n.p.  20.9 19.2–22.6 
50–59 9.9 6.6–13.9  16.2 15.3–17.1 
60–69 6.9 4.4–10.2  13.9 13.3–14.5 
70+ 5.5 3.1–8.7  7.0 6.7–7.3 
 Breast in females (C50) 
<50 74.9 68.7–80.2  88.3 87.7–88.8 
50–59 71.5 64.2–77.5  88.3 87.8–88.8 
60–69 74.4 65.9–81.1  86.7 86.1–87.3 
70+ 48.8 38.5–58.3  62.1 61.3–62.9 
 
Bowel (C18–C20) 
<50 44.0 34.7–53.0  66.9 65.5–68.3 
50–59 48.1 38.3–57.3  65.6 64.6–66.5 
60–69 55.8 46.6–63.9  61.9 61.2–62.7 
70+ 39.5 31.2–47.6  42.7 42.2–43.2 
 Prostate (C61) 
<50 n.p. n.p.  91.6 89.7–93.1 
50–59 74.1 59.8–83.9  91.5 90.9–92.1 
60–69 77.2 68.6–83.7  85.9 85.4–86.4 
70+ 41.4 32.3–50.3  55.1 54.5–55.7 
 Unknown primary site (C77–C80) 
<50 n.p. n.p.  30.6 27.8–33.4 
50–59 n.p. n.p.  20.3 18.5–22.1 
60–69 n.p. n.p.  12.8 11.8–13.9 
70+ n.p. n.p.  3.6 3.4–3.9 
 Non-Hodgkin lymphoma (C82–C85) 
<50 66.7 53.9–76.8  80.6 79.1–82.0 
50–59 50.5 32.6–66.0  74.9 73.3–76.4 
60–69 46.6 30.1–61.6  63.2 61.7–64.8 
70+ n.p. n.p.  33.8 32.8–34.9 
 Cervix (C53) 
<50 60.4 51.4–68.2  82.5 80.8–84.2 
50–59 48.6 31.8–63.5  67.2 63.3–70.8 
60–69 n.p. n.p.  58.5 54.1–62.6 
70+ n.p. n.p.  34.1 30.8–37.6 
     (continued) 
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Table D5.2 (continued): Five-year crude survival for the 10 most commonly diagnosed cancers 
among Aboriginal and Torres Strait Islander peoples, by age group, New South Wales, 
Queensland, Western Australia and the Northern Territory, 1999–2007 
Age group 
(years) 
Indigenous  Non-Indigenous 
CS (%) 95% CI   CS (%) 95% CI 
 Uterus (C54–C55) 
<50 76.6 59.4–87.3  87.3 84.9–89.3 
50–59 83.8 69.0–91.9  86.5 85.0–88.0 
60–69 61.2 45.3–73.7  77.5 75.7–79.2 
70+ n.p. n.p.  53.4 51.5–55.2 
 Liver (C22) 
<50 n.p. n.p.  28.3 24.7–32.1 
50–59 n.p. n.p.  21.2 18.6–23.9 
60–69 n.p. n.p.  12.8 11.0–14.7 
70+ n.p. n.p.  5.1 4.3–6.0 
 Pancreas (C25) 
<50 n.p. n.p.  17 14.1–20.2 
50–59 n.p. n.p.  7.4 6.1–8.9 
60–69 n.p. n.p.  5.8 4.9–6.7 
70+ n.p. n.p.  1.9 1.7–2.2 
 All cancers combined
(a)
 
<50 57.3 54.9–59.6  78.1 77.8–78.4 
50–59 38.5 35.9–41.1  67.6 67.2–67.9 
60–69 36.7 34.2–39.3  58.9 58.6–59.2 
70+ 22.5 20.3–24.8  33.7 33.5–33.9 
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, with the exception of those C44 codes that indicate basal cell 
and squamous cell carcinoma of the skin 
Source: AIHW Australian Cancer Database 2007. 
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Table D5.3: Five-year crude survival for the 10 most commonly diagnosed cancers among 
Aboriginal and Torres Strait Islander peoples, by sex, New South Wales, Queensland, Western 
Australia and the Northern Territory, 1999–2007  
Sex 
Indigenous  Non-Indigenous 
CS (%) 95% CI  CS (%) 95% CI 
 Lung (C33–C34) 
Males 8.0 5.9–10.5  9.5 9.1–9.8 
Females 6.5 4.2–9.3  13.1 12.6–13.6 
 Breast in females (C50) 
Males . . . .  . . . . 
Females 69.9 66.1–73.3  81.3 81.0–81.6 
 Bowel (C18–C20) 
Males 44.7 38.3–50.8  51.8 51.3–52.3 
Females 49.1 42.5–55.4  54.2 53.6–54.7 
 Prostate (C61) 
Males 62.5 56.7–67.7  72.0 71.6–72.4 
Females . . . .  . . . . 
 Unknown primary site (C77–C80) 
Males n.p. n.p.  9.5 9.0–10.1 
Females n.p. n.p.  6.9 6.5–7.4 
 Non-Hodgkin lymphoma (C82–C85) 
Males 50.7 40.4–60.2  54.6 53.6–55.6 
Females 47.0 34.3–58.8  56.4 55.3–57.4 
 Cervix (C53) 
Males . . . .  . . . . 
Females 51.2 44.1–57.9  67.2 65.7–68.7 
 Uterus (C54–C55) 
Males . . . .  . . . . 
Females 66.3 58.4–73.1  72.2 71.2–73.1 
 Liver (C22) 
Males n.p. n.p.  12.3 11.3–13.4 
Females n.p. n.p.  11.6 10.0–13.2 
 Pancreas (C25) 
Males n.p. n.p.  3.9 3.5–4.4 
Females n.p. n.p.  4.3 3.9–4.9 
 All cancers combined
(a)
 
Males 34.3 32.5–36.0  48.2 48.0–48.4 
Females 45.8 44.0–47.6  56.4 56.2–56.6 
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, with the exception of those C44 codes that indicate basal cell 
and squamous cell carcinoma of the skin. 
Source: AIHW Australian Cancer Database 2007. 
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Table D5.4: Five-year crude survival for the 10 most commonly diagnosed cancers among 
Aboriginal and Torres Strait Islander peoples, by remoteness area, New South Wales, Queensland, 
Western Australia and the Northern Territory, 1999–2007  
Remoteness area 
Indigenous   Non-Indigenous 
CS (%) 95% CI   CS (%) 95% CI 
 Lung (C33–C34) 
Major cities 7.7 4.7–11.6  11.2 10.9–11.6 
Inner regional n.p. n.p.  10.4 9.8–10.9 
Outer regional 7.2 4.5–10.8  8.2 7.5–9.0 
Remote and very remote 8.8 5.7–12.6  10.8 8.9–12.9 
 
Breast in females (C50) 
Major cities 77.3 70.9–82.4  81.8 81.4–82.2 
Inner regional 70.2 61.3–77.5  80.5 79.8–81.2 
Outer regional 66.0 57.3–73.3  78.9 77.8–80.0 
Remote and very remote 63.8 55.9–70.6  80.7 77.9–83.2 
 Bowel (C18–C20) 
Major cities 53.9 45.7–61.4  53.8 53.4–54.3 
Inner regional 51.9 41.2–61.5  51.5 50.7–52.3 
Outer regional 46.7 37.7–55.1  49.6 48.4–50.8 
Remote and very remote 32.7 23.9–41.8  52.0 48.8–55.1 
 
Prostate (C61) 
Major cities 74.4 65.1–81.6  73.4 72.9–73.8 
Inner regional 49.7 36.6–61.6  70.0 69.3–70.8 
Outer regional 60.2 48.3–70.2  68.6 67.4–69.7 
Remote and very remote 57.8 43.2–69.9  73.8 71.0–76.4 
 Unknown primary site (C77–C80) 
Major cities n.p. n.p.  7.9 7.5–8.3 
Inner regional n.p. n.p.  8.9 8.1–9.7 
Outer regional n.p. n.p.  8.5 7.4–9.7 
Remote and very remote 6.2 3.8–9.4  10.2 7.4–13.5 
 Non-Hodgkin lymphoma (C82–C85) 
Major cities 51.4 36.6–64.3  55.5 54.6–56.4 
Inner regional n.p. n.p.  54.9 53.3–56.4 
Outer regional 51.9 33.2–67.7  54.5 52.0–56.9 
Remote and very remote 35.4 22.9–48.1  61.3 55.0–67.0 
 
Cervix (C53) 
Major cities 58.3 42.1–71.4  67.5 65.6–69.2 
Inner regional 54.5 35.8–69.9  65.3 61.6–68.6 
Outer regional 56.5 43.5–67.5  66.1 61.1–70.6 
Remote and very remote  37.2 25.2–49.1  76.8 65.7–84.7 
     (continued) 
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Table D5.4 (continued): Five-year crude survival for the 10 most commonly diagnosed cancers 
among Aboriginal and Torres Strait Islander peoples, by remoteness area, New South Wales, 
Queensland, Western Australia and the Northern Territory, 1999–2007  
(a) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, with the exception of those C44 codes that indicate basal cell 
and squamous cell carcinoma of the skin. 
Source: AIHW Australian Cancer Database 2007. 
Remoteness area 
Indigenous   Non-Indigenous 
CS (%) 95% CI   CS (%) 95% CI 
 
Uterus (C54–C55) 
Major cities 61.5 43.3–75.4  72.6 71.3–73.8 
Inner regional 77.7 54.9–89.9  70.5 68.3–72.5 
Outer regional 61.0 46.2–72.9  72.8 69.4–75.8 
Remote and very remote  69.8 55.3–80.4  76.2 67.4–83.0 
 Liver (C22) 
Major cities n.p. n.p.  13.4 12.4–14.5 
Inner regional n.p. n.p.  9.1 7.3–11.2 
Outer regional n.p. n.p.  6.3 4.4–8.8 
Remote and very remote n.p. n.p.  11.8 5.5–20.7 
 Pancreas (C25) 
Major cities n.p. n.p.  4.6 4.2–5.1 
Inner regional n.p. n.p.  3.1 2.5–3.8 
Outer regional n.p. n.p.  3.3 2.4–4.3 
Remote and very remote n.p. n.p.  n.p. n.p. 
 All cancers combined
(a)
 
Major cities 49.4 47.0-51.9  52.5 52.4-52.7 
Inner regional 44.5 41.3-47.6  50.8 50.5-51.1 
Outer regional 35.5 33.0-38.0  49.4 48.9-49.9 
Remote and very remote 32.2 30.0-34.5  54.4 53.3-55.5 
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Table D5.5: Cox proportional hazards regression analysis, hazard ratio of death from any cause, all 
persons diagnosed with lung cancer, diagnosed between 2003 and 2007 and followed until death or  
31 December 2010 (whichever came first), New South Wales, Queensland, Western Australia and 
the Northern Territory 
Factors Number Hazard ratio 95% CI 
Indigenous status    
 Non-Indigenous (reference group)  27,288 1.00  
 Indigenous 488 1.24  1.13–1.37 
Sex    
 Female (reference group)  10,122 1.00  
 Male  17,654 1.13  1.10–1.16 
Age    
 Increase in relative risk    
 for each year after age 50  1.024  1.022–1.025 
Remoteness area    
 Major cities (reference group)  18,114 1.00  
 Inner regional  6,115 1.10  1.06–1.13 
 Outer regional  2,882 1.17 1.13–1.23 
 Remote and very remote  665 1.16  1.06–1.26 
Note: Analysis excludes people who did not state their Indigenous status. 
Source: AIHW Australian Cancer Database 2007. 
Table D5.6: Cox proportional hazards regression analysis, hazard ratio of death from any cause, 
females diagnosed with breast cancer, diagnosed between 2003 and 2007 and followed until death 
or 31 December 2010 (whichever came first), New South Wales, Queensland, Western Australia and 
the Northern Territory 
Factors Number Hazard ratio 95% CI 
Indigenous status    
 Non-Indigenous (reference group)  34,125 1.00  
 Indigenous  377 2.00  1.63–2.44 
Age     
 Increase in relative risk    
 for each year after age 50  1.058  1.056–1.060 
Remoteness area    
 Major cities (reference group)  23,826 1.00  
 Inner regional  7,071 1.02  0.96–1.09 
 Outer regional  3,021 1.19  1.10–1.30 
 Remote and very remote  584 1.48  1.23–1.78 
Note: Analysis excludes people who did not state their Indigenous status. 
Source: AIHW Australian Cancer Database 2007. 
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Table D5.7: Cox proportional hazards regression analysis, hazard ratio of death from any cause, all 
persons diagnosed with bowel cancer, diagnosed between 2003 and 2007 and followed until death 
or 31 December 2010 (whichever came first), New South Wales, Queensland, Western Australia and 
the Northern Territory 
Factors Number Hazard ratio 95% CI 
Indigenous status    
 Non-Indigenous (reference group) 37,909 1.00  
 Indigenous  294 1.43  1.22–1.68 
Sex    
 Female (reference group)  17,094 1.00  
 Male  21,109 1.12  1.09–1.16 
Age    
 Increase in relative risk    
 for each year after age 50  1.037  1.036–1.039 
Remoteness area    
 Major cities (reference group)  25,068 1.00  
 Inner regional  8,818 1.07  1.04–1.11 
 Outer regional  3,700 1.18  1.12–1.23 
 Remote and very remote  617 1.26  1.12–1.41 
Note: Analysis excludes people who did not state their Indigenous status. 
Source: AIHW Australian Cancer Database 2007. 
Table D5.8: Cox proportional hazards regression analysis, hazard ratio of death from any cause, 
males diagnosed with prostate cancer, diagnosed between 2003 and 2007 and followed until death 
or 31 December 2010 (whichever came first), New South Wales, Queensland, Western Australia and 
the Northern Territory 
Factors Number Hazard ratio 95% CI 
Indigenous status    
 Non-Indigenous (reference group)  42,364 1.00  
 Indigenous  206 1.83  1.44–2.32 
Age    
 Increase in relative risk    
 for each year after age 50  1.115  1.113–1.118 
Remoteness area    
 Major cities (reference group)  27,741 1.00  
 Inner regional  10,099 1.11  1.06–1.16 
 Outer regional  4,027 1.29  1.22–1.38 
 Remote and very remote  703 1.29  1.11–1.50 
Note: Analysis excludes people who did not state their Indigenous status. 
Source: AIHW Australian Cancer Database 2007. 
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Table D5.9: Cox proportional hazards regression analysis, hazard ratio of death from any cause, all 
persons diagnosed with cancer of unknown primary site, diagnosed between 2003 and 2007 and 
followed until death or 31 December 2010 (whichever came first), New South Wales, Queensland, 
Western Australia and the Northern Territory 
Factors Number Hazard ratio 95% CI 
Indigenous status    
 Non-Indigenous (reference group)  8,330 1.00  
 Indigenous 151 1.31  1.08–1.59 
Sex    
 Female (reference group)  3,981 1.00  
 Male  4,500 0.95  0.90–0.99 
Age    
 Increase in relative risk    
 for each year after age 50  1.029  1.027–1.031 
Remoteness area    
 Major cities (reference group) 5,514 1.00  
 Inner regional  1,911 0.94  0.89–1.00 
 Outer regional  856 0.98  0.90–1.06 
 Remote and very remote  200 1.13  0.95–1.34 
Note: Analysis excludes people who did not state their Indigenous status. 
Source: AIHW Australian Cancer Database 2007. 
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Additional tables for Chapter 6: Prevalence of cancer 
Table D6.1: Five-year prevalence of the 10 most prevalent cancers in Aboriginal and Torres Strait 
Islander peoples, New South Wales, Queensland, Western Australia and the Northern Territory, as 
at the end of 2007  
Cancer site/type 
Indigenous  Non-Indigenous 
No. Ranking ASR
(a)
 95% CI  No. Ranking ASR
(a)
 95% CI 
Breast in females 
(C50) 325 1 166.2 145.9–188.2  30,810 2 220.2 217.7–222.7 
Melanoma of the skin 
(C43) 203 2 114.5 95.8–135.3  17,724 4 127.8 125.9–129.7 
Bowel (C18–C20) 185 3 121.4 101.8–143.2  25,859 3 184.4 182.1–186.7 
Prostate (C61) 156 4 114.1 95.0–135.5  36,450 1 258.3 255.6–261.0 
Lung (C33–C34) 124 5 78.6 63.6–95.6  7,395 5 52.9 51.7–54.1 
Uterus (C54–C55) 81 6 43.7 33.6–55.8  4,083 10 28.8 28.0–29.7 
Thyroid (C73) 79 7 26.9 20.6–34.4  4,826 7 35.7 34.7–36.8 
Cervix (C53) 72 8 25.9 19.4–33.8  1,655 17 12.4 11.8–13.0 
Non-Hodgkin 
lymphoma (C82–C85) 68 9 30.8 22.4–40.7  7,329 6 52.7 51.5–53.9 
Kidney (C64) 51 10 22.8 16.0–31.2  4,667 8 33.5 32.5–34.5 
All cancers 
combined
(b)
 1,882 . . 991.2 938.2–1046.1  177,092 . . 1,269.5 1,263.5–1,275.4 
(a) Rates were directly age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
(b) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, with the exception of those C44 codes that indicate basal cell 
and squamous cell carcinoma of the skin. 
Source: AIHW Australian Cancer Database 2007. 
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Table D6.2: Five-year prevalence of the 10 most prevalent cancers among Aboriginal and Torres 
Strait Islander peoples, by age group, New South Wales, Queensland, Western Australia and the 
Northern Territory, as at the end of 2007  
Age group 
(years) 
Indigenous  Non-Indigenous 
Number 
Age-specific 
rate
(a)
 95% CI  Number 
Age-specific 
rate
(a)
 95% CI 
 
Breast in females (C50) 
<45 53 28.8 21.6–37.7  3,119 78.5 75.8–81.3 
45–54 97 470.7 381.7–574.3  7,372 801.0 782.8–819.5 
55–64 83 712.3 567.4–883.0  8,686 1,177.6 1,152.9–1,202.6 
65–74 64 1,202.9 926.4–1,536.1  6,501 1,399.8 1,366.0–1,434.2 
75+ 28 1,074.9 714.2–1,553.5  5,132 1,089.1 1,059.5–1,119.3 
 
Melanoma of the skin (C43) 
<45 69 18.6 14.5–23.5  2,742 34.0 32.8–35.3 
45–54 32 80.7 55.2–113.9  2,724 148.9 143.4–154.6 
55–64 35 159.3 110.9–221.5  3,864 260.3 252.1–268.6 
65–74 30 314.5 212.2–449.0  3,733 407.6 394.6–420.8 
75+ 37 864.5 608.7–1,191.6  4,661 577.8 561.4–594.7 
 
Bowel (C18–C20) 
<45 27 7.3 4.8–10.6  831 10.3 9.6–11.0 
45–54 24 60.5 38.8–90.1  2,097 114.6 109.8–119.6 
55–64 44 200.2 145.5–268.8  5,402 363.8 354.2–373.7 
65–74 53 555.6 416.2–726.8  7,901 862.6 843.7–881.8 
75+ 37 864.5 608.7–1,191.6  9,628 1,193.6 1,169.9–1,217.7 
 
Prostate (C61) 
<45 . . . . . .  73 1.8 1.4–2.2 
45–54 9 47.3 21.6–89.7  1,749 192.4 183.5–201.6 
55–64 48 465.0 342.9–616.6  10,024 1,341.7 1,315.6–1,368.2 
65–74 69 1,635.9 1,272.8–2,070.3  14,000 3,100.6 3,049.5–3,152.4 
75+ 30 1,791.0 1,208.4–2,556.8  10,604 3,161.4 3,101.5–3,222.2 
 
Lung (C33–C34) 
<45 7 1.9 0.8–3.9  177 2.2 1.9–2.5 
45–54 27 68.1 44.9–99.1  559 30.6 28.1–33.2 
55–64 33 150.2 103.4–210.9  1,723 116.0 110.6–121.7 
65–74 43 450.8 326.2–607.2  2,501 273.1 262.5–284.0 
75+ 14 327.1 178.8–548.8  2,435 301.9 290.0–314.1 
 Uterus (C54–C55) 
<45 7 3.8 1.5–7.8  196 4.9 4.3–5.7 
45–54 24 116.5 74.6–173.3  529 57.5 52.7–62.6 
55–64 24 206.0 132.0–306.5  1,331 180.4 170.9–190.4 
65–74 18 338.3 200.5–534.7  1,093 235.3 221.6–249.7 
75+ 8 307.1 132.6–605.1  934 198.2 185.7–211.3 
       (continued) 
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Table D6.2 (continued): Five-year prevalence of the 10 most prevalent cancers among Aboriginal 
and Torres Strait Islander peoples, by age group, New South Wales, Queensland, Western 
Australia and the Northern Territory, as at the end of 2007  
Age 
group 
(years) 
Indigenous 
 
Non-Indigenous 
Number  Age-specific rate
(a)
 95% CI   Number Age-specific rate
(a)
 95% CI 
 Thyroid (C73) 
<45 44 11.9 8.6–15.9  1,603 19.9 18.9–20.9 
45–54 14 35.3 19.3–59.2  1,296 70.8 67.0–74.8 
55–64 16 72.8 41.6–118.2  977 65.8 61.7–70.1 
65–74 4 41.9 11.4–107.4  587 64.1 59.0–69.5 
75+ . . . . . .  363 45.0 40.5–49.9 
 
Cervix (C53) 
<45 38 20.7 14.6–28.4  649 16.3 15.1–17.6 
45–54 20 97.1 59.3–149.9  388 42.2 38.1–46.6 
55–64 8 68.7 29.6–135.3  260 35.2 31.1–39.8 
65–74 3 56.4 11.6–164.8  188 40.5 34.9–46.7 
75+ 3 115.2 23.7–336.6  170 36.1 30.9–41.9 
 
Non-Hodgkin lymphoma (C82–C85) 
<45 26 7.0 4.6–10.3  839 10.4 9.7–11.1 
45–54 9 22.7 10.4–43.1  1,014 55.4 52.1–58.9 
55–64 14 63.7 34.8–106.9  1,717 115.6 110.2–121.2 
65–74 13 136.3 72.6–233.1  1,793 195.8 186.8–205.0 
75+ 6 140.2 51.4–305.1  1,966 243.7 233.1–254.7 
 
Kidney (C64) 
<45 14 3.8 2.1–6.3  443 5.5 5.0–6.0 
45–54 10 25.2 12.1–46.4  661 36.1 33.4–39.0 
55–64 16 72.8 41.6–118.2  1,199 80.8 76.2–85.5 
65–74 10 104.8 50.3–192.8  1,205 131.6 124.2–139.2 
75+ . . . . . .   1,159 143.7 135.5–152.2 
 All cancers combined
(b)
 
<45 471 127.0 115.8–139.0  17,385 215.7 212.5–219.0 
45–54 393 991.3 895.7–1094.3  23,164 1,266.2 1250.0–1282.7 
55–64 429 1,952.4 1,772.0–2,146.1  42,519 2,863.8 2,836.6–2,891.1 
65–74 383 4,015.3 3,623.2–4,438.3  47,095 5,141.7 5,095.3–5,188.3 
75+ 206 4,813.1 4,178.2–5,517.1  46,929 5,817.8 5,765.3–5,870.7 
(a) Rates are expressed per 10,000 population. 
(b) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, with the exception of those C44 codes that indicate basal cell 
and squamous cell carcinoma of the skin. 
Note: The rates are expressed per 100,000 population. 
Source: AIHW Australian Cancer Database 2007. 
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Table D6.3: Five-year prevalence of the 10 most prevalent cancers among Aboriginal and Torres 
Strait Islander peoples, by sex, New South Wales, Queensland, Western Australia and the Northern 
Territory, as at the end of 2007
Sex 
Indigenous  Non-Indigenous 
Number ASR
(a)
 95% CI  Number ASR
(a)
 95% CI 
 Breast in females (C50) 
Males . . . . . .  . . . . . . 
Females 325 302.3 266.6–341.0  30,810 429.4 424.6–434.2 
 Melanoma of the skin (C43) 
Males 110 163.7 126.9–206.1  10,245 156.0 152.9–159.0 
Females 93 80.5 61.7–102.3  7,479 104.8 102.4–107.2 
 Bowel (C18–C20) 
Males 91 132.2 100.7–169.0  14,256 218.2 214.6–221.9 
Females 94 113.3 88.7–141.8  11,603 155.0 152.2–157.9 
 Prostate (C61) 
Males 156 268.6 221.6–321.5  36,450 546.6 541.0–552.3 
Females . . . . . .  . . . . . . 
 Lung (C33–C34) 
Males 75 119.9 88.8–156.8  4,418 67.5 65.5–69.6 
Females 49 50.7 36.6–68.0  2,977 40.7 39.2–42.2 
 Uterus (C54–C55) 
Males . . . . . .  . . . . . . 
Females 81 79.5 61.5–100.7  4,083 55.8 54.1–57.5 
 Thyroid (C73) 
Males 18 13.8 7.5–22.8  1,120 16.7 15.8–17.8 
Females 61 38.7 28.6–50.8  3,706 54.5 52.8–56.3 
 Cervix (C53) 
Males . . . . . .  . . . . . . 
Females 72 48.7 36.8–62.9  1,655 24.3 23.2–25.5 
 Non-Hodgkin lymphoma (C82–C85) 
Males 40 33.6 21.1–49.5  4,043 61.2 59.3–63.1 
Females 28 27.9 17.3–41.9  3,286 45.0 43.5–46.6 
 Kidney (C64) 
Males 30 32.7 19.1–50.7  3,069 45.9 44.3–47.6 
Females 21 15.7 9.1–24.8  1,598 22.2 21.1–23.3 
 All cancers combined
(b)
 
Males 849 1,091.0 999.5–1,187.3  95,379 1,444.3 1,435.1–1,453.6 
Females 1,033 937.6 872.7–1,005.5  81,713 1,131.9 1,124.1–1,139.8 
(a) Rates were directly age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
(b) Includes cancers coded in ICD-10 as C00–C97, D45, D46, D47.1 and D47.3, with the exception of those C44 codes that indicate basal cell 
and squamous cell carcinoma of the skin. 
Source: AIHW Australian Cancer Database 2007. 
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Additional tables for Chapter 7: Hospitalisations for 
cancer 
Table D7.1: Hospitalisations for the 10 most common principal diagnoses of cancer in Aboriginal 
and Torres Strait Islander peoples, New South Wales, Victoria, Queensland, Western Australia, 
South Australia and public hospitals in the Northern Territory, 2006–07 to 2010–11 
 Indigenous Australians  Other Australians 
Cancer site/type Number Ranking ASR
(a)
 ALOS
(b)(c)
  Number Ranking ASR
(a)
 ALOS
(b)(c)
 
Secondary site (C77–C79) 1,741 1 14.3 9.5  187,251 2 16.8 8.9 
Lung (C33–C34) 1,335 2 12.3 10.1  89,504 7 7.9 9.2 
Breast in females (C50) 963 3 13.7 6.4  115,089 5 20.4 4.4 
Bowel (C18–C20) 882 4 7.8 11.0  143,069 4 12.7 9.5 
Non-melanoma of skin (C44) 867 5 9.7 9.8  418,092 1 37.4 3.8 
Non-Hodgkin lymphoma 
(C82–C85) 475 6 3.3 11.5  93,030 6 8.4 8.7 
Prostate (C61) 470 7 11.8 7.4  157,690 3 29.1 5.2 
Acute lymphoblastic 
leukaemia (C91.0) 425 8 1.1 4.0  19,938 18 2.0 14.1 
Cervix (C53) 417 9 4.8 8.2  8,436 28 1.6 7.7 
Liver (C22) 384 10 3.1 8.9  16,762 22 1.5 7.7 
All cancers combined
(d)
 14,086 . . 113.0 9.6  1,895,294 . . 170.1 7.7 
(a) Rates were standardised to the Australian population as at 30 June 2001 and are expressed per 10,000 population. 
(b) Directly age-standardised to the hospitalisation population in 2006–07 to 2010–11. 
(c) ALOS excludes same-day hospitalisations. 
(d) Pertain to hospitalisations in which the principal diagnosis is cancer (ICD-10-AM codes C00–C97, D45, D46, D47.1 and D47.3. 
Source: AIHW National Hospital Morbidity Database. 
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Table D7.2: Hospitalisations for the 10 most common principal diagnoses of cancer in Aboriginal 
and Torres Strait Islander peoples, by age group, New South Wales, Victoria, Queensland, Western 
Australia, South Australia and public hospitals in the Northern Territory, 2006–07 to 2010–11 
Age group (years) 
Indigenous Australians  Other Australians 
Number  Age-specific rate
(a)
  Number Age-specific rate
(a)
 
 Secondary site (C77–C79) 
<45 257 1.2  14,267 2.3 
45–54 486 20.3  24,916 17.6 
55–64 501 36.5  45,124 38.6 
65–74 378 63.0  49,286 66.3 
75+ 119 45.0  53,658 82.2 
 Lung (C33–C34) 
<45 108 0.5  2,004 0.3 
45–54 274 11.5  7,065 5.0 
55–64 486 35.4  20,607 17.6 
65–74 330 55.0  29,244 39.3 
75+ 137 51.8  30,584 46.8 
 Breast cancer in females (C50) 
<45 179 1.7  15,854 5.1 
45–54 289 23.2  29,032 40.7 
55–64 272 37.4  31,609 53.8 
65–74 165 49.5  22,470 59.3 
75+ 58 36.0  16,124 42.4 
 Bowel (C18–C20) 
<45 167 0.8  5,915 0.9 
45–54 174 7.3  13,954 9.9 
55–64 273 19.9  31,582 27.0 
65–74 159 26.5  42,228 56.8 
75+ 109 41.2  49,390 75.6 
 Non-melanoma of skin (C44) 
<45 109 0.5  23,852 3.8 
45–54 158 6.6  45,568 32.2 
55–64 199 14.5  78,670 67.2 
65–74 179 29.8  94,531 127.1 
75+ 222 83.9  175,471 268.7 
 Non-Hodgkin lymphoma (C82–C85) 
<45 202 0.9  10,877 1.7 
45–54 62 2.6  13,343 9.4 
55–64 97 7.1  23,288 19.9 
65–74 87 14.5  22,560 30.3 
75+ 27 10.2  22,962 35.2 
       (continued) 
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Table D7.2 (continued): Hospitalisations for the 10 most common principal diagnoses of cancer in 
Aboriginal and Torres Strait Islander peoples, by age group, New South Wales, Victoria, 
Queensland, Western Australia, South Australia and public hospitals in the Northern Territory, 
2006–07 to 2010–11 
Age group (years) 
Indigenous Australians  Other Australians 
Number  Age-specific rate
(a)
  Number Age-specific rate
(a)
 
 Prostate (C61) 
<45 0 0.0  780 0.2 
45–54 50 4.4  12,201 17.4 
55–64 186 28.8  50,347 86.4 
65–74 157 58.8  55,473 152.2 
75+ 77 74.4  38,889 142.7 
  Acute lymphoblastic leukaemia (C91.0) 
<45 411 1.9  16,099 2.6 
45–54 7 0.3  1,308 0.9 
55–64 1 0.1  1,329 1.1 
65–74 0 0.0  829 1.1 
75+ 6 2.3  373 0.6 
  Cervix (C53) 
<45 233 2.2  3,022 1.0 
45–54 92 7.4  1,857 2.6 
55–64 40 5.5  1,522 2.6 
65–74 43 12.9  1,045 2.8 
75+ 9 5.6  990 2.6 
  Liver (C22) 
<45 56 0.3  1,463 0.2 
45–54 111 4.6  2,453 1.7 
55–64 99 7.2  4,140 3.5 
65–74 100 16.7  4,443 6.0 
75+ 18 6.8  4,263 6.5 
 All cancers combined
(b)
 
<45 3,642 16.8  172,239 27.5 
45–54 3,087 129.2  219,679 155.3 
55–64 3,564 259.5  418,147 357.3 
65–74 2,491 414.9  480,914 646.7 
75+ 1,302 491.9  604,315 925.4 
(a) Rates are expressed per 10,000 population. 
(b) All cancers combined pertain to ICD-10-AM codes of C00–C97, D45, D46, D47.1 and D47.3. 
Source: AIHW National Hospital Morbidity Database. 
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Table D7.3: Hospitalisations for the 10 most common principal diagnoses of cancer in Aboriginal 
and Torres Strait Islander peoples, by sex, New South Wales, Victoria, Queensland, Western 
Australia, South Australia and public hospitals in the Northern Territory, 2006–07 to 2010–11 
Sex 
Indigenous Australians  Other Australians 
Number  ASR
(a)
  Number  ASR
(a)
 
 Secondary site (C77–C79) 
Males 784 14.9  95,171 18.2 
Females 957 14.0  92,080 15.9 
 Lung (C33–C34) 
Males 653 14.1  54,126 10.4 
Females  682 11.0  35,377 5.9 
 Breast in females (C50) 
Males . . . .  . . . . 
Females  963 13.7  115,089 20.4 
 Bowel (C18–C20) 
Males 486 9.2  79,854 15.2 
Females  396 6.6  63,215 10.6 
 Non-melanoma of skin (C44) 
Males 507 13.2  248,424 48.2 
Females  360 7.1  169,668 28.5 
 Non-Hodgkin lymphoma (C82–C85) 
Males 294 3.5  54,121 10.3 
Females  181 3.0  38,909 6.7 
 Prostate (C61) 
Males 470 11.8  157,687 29.1 
Females . . . .  . . . . 
 Acute lymphoblastic leukaemia (C91.0) 
Males 255 1.2  11,720 2.3 
Females 170 1.0  8,218 1.7 
 Cervix (C53) 
Male  . . . .  . . . . 
Female 417 4.8  8,436 1.6 
 Liver (C22) 
Males 247 4.4  12,144 2.3 
Females 137 2.0  4,618 0.8 
 All cancers combined
(b)
 
Males  7,024 129.0  1,092,663 209.1 
Females 7,062 101.5   802,629 137.9 
(a) Rates were standardised to the Australian population as at 30 June 2001 and are expressed per 10,000 population. 
(b) All cancers combined pertain to ICD-10-AM codes of C00–C97, D45, D46, D47.1 and D47.3. 
Source: AIHW National Hospital Morbidity Database. 
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Table D7.4: Hospitalisations for the 10 most common principal diagnoses of cancer in Aboriginal 
and Torres Strait Islander peoples, by remoteness area(a), New South Wales, Victoria, Queensland, 
Western Australia, South Australia and public hospitals in the Northern Territory, 2006–07 to  
2010–11 
Remoteness area  
Indigenous Australians  Other Australians  
Number  ASR
(b)(c)
  Number ASR
(b)(c)
 
  Secondary site (C77–C79) 
Major cities 502 16.3  126,273 18.0 
Inner regional 364 17.7  41,454 18.9 
Outer regional 448 19.2  16,584 17.1 
Remote and very remote 425 14.4  2,449 15.0 
  Lung (C33–C34) 
Major cities 264 9.4  57,783 8.2 
Inner regional 314 16.2  20,359 9.1 
Outer regional 351 17.0  9,555 9.7 
Remote and very remote 405 15.6  1,621 10.5 
 Breast in females (C50) 
Major cities 272 14.2  82,057 22.4 
Inner regional 230 19.2  22,584 20.7 
Outer regional 221 16.6  8,874 18.7 
Remote and very remote 237 15.2  1,407 17.9 
 Bowel (C18–C20) 
Major cities 295 9.6  93,401 13.3 
Inner regional 205 10.2  33,540 15.1 
Outer regional 229 10.2  13,837 14.2 
Remote and very remote 152 5.0  2,030 13.0 
 Non-melanoma of skin (C44) 
Major cities 430 16.9  282,922 40.4 
Inner regional 244 14.0  90,739 41.2 
Outer regional 113 5.3  37,860 39.2 
Remote and very remote 79 2.8  6,280 39.1 
 Non-Hodgkin lymphoma (C85–C85) 
Major cities 163 4.3  64,178 9.2 
Inner regional 83 3.6  19,075 8.8 
Outer regional 104 3.8  8,138 8.4 
Remote and very remote 125 3.3  1,313 7.8 
(continued) 
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Table D7.4 (continued): Hospitalisations for the 10 most common principal diagnoses of cancer in 
Aboriginal and Torres Strait Islander peoples, by remoteness area(a), New South Wales, Victoria, 
Queensland, Western Australia, South Australia and public hospitals in the Northern Territory, 
2006–07 to 2010–11 
Remoteness area  
Indigenous Australians  Other Australians 
Number  ASR
(b)(c)
  Number ASR
(b)(c)
 
  Prostate (C61) 
Major city 150 13.2  105,423 32.3 
Inner regional 145 19.8  35,941 33.1 
Outer regional 98 12.9  13,658 27.6 
Remote and very remote 76 8.0  2,340 27.0 
 Acute lymphoblastic leukaemia (91.0) 
Major city 191 1.5  14,202 2.2 
Inner regional 63 1.2  3,912 2.2 
Outer regional 56 0.7  1,348 1.6 
Remote and very remote 114 1.1  268 1.7 
  Cervix (C53) 
Major city 105 3.8  5, 985 1.7 
Inner regional 62 4.1  1,492 1.5 
Outer regional 111 6.4  748 1.7 
Remote and very remote 138 7.2  121 1.5 
 Liver (C22) 
Major city 86 2.5  12,432 1.8 
Inner regional 37 2.3  2,852 1.3 
Outer regional 96 4.4  1,192 1.2 
Remote and very remote 165 5.5  211 1.3 
  All cancers combined
(d)(e)
 
Major city 4,268 125.6  1,286,313 183.7 
Inner regional 2,879 137.4  408,687 186.9 
Outer regional 3,195 127.0  169,255 175.4 
Remote and very remote 3,721 119.0  26,607 165.8 
(a) Classified using the ASGC RA (see Appendix A). 
(b) Rates were calculated using 2006 estimated residential population due to data availability. This assumes that the population in each 
remoteness area has remained constant over the 5 years. New estimated residential population by Indigenous status and remoteness areas 
will be released by June 2014 (see Chapter 1) and may impact on the ASR presented here.  
(c) Rates were directly age-standardised to the Australian population as at 30 June 2001 and are expressed per 10,000 population. 
(d) All cancers combined pertain to ICD-10-AM codes of C00–C97, D45, D46, D47.1 and D47.3. 
(e) There were 23 Indigenous hospitalisations and 4,432 other Australian hospitalisations that could not be ascribed to a remoteness area. 
Source: AIHW National Hospital Morbidity Database. 
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Table D7.5: Observed, expected and excess number of hospitalisations for the 10 most common 
principal diagnoses of cancer in Aboriginal and Torres Strait Islander peoples, New South Wales, 
Victoria, Queensland, Western Australia, South Australia and public hospitals in the Northern 
Territory, 2006–07 to 2010–11 
Cancer site/type Observed number Expected number
 
 Excess hospitalisations
(a)
 
Secondary site (C77–C79) 1,741 1,898 –157 
Lung (C33–C34) 1,335 757 578 
Breast in females (C50) 963 1,523 –560 
Bowel (C18–C20) 882 1,266 –384 
Non-melanoma of skin (C44) 867 3,675 –2,808 
Non-Hodgkin lymphoma (C82–C85) 475 1,081 –606 
Prostate (C61) 470 1,306 –836 
Acute lymphoblastic leukaemia (C91.0) 425 744 –319 
Cervix (C53) 417 138 279 
Liver (C22) 384 195 189 
All cancers combined
(b)
 14,086 19,800 –5,714 
(a) Excess hospitalisations are the observed number of hospitalisations minus the expected number of hospitalisations. 
(b) Pertain to hospitalisations in which the principal diagnosis is cancer (ICD-10-AM codes C00–C97, D45, D46, D47.1 and D47.3), 
Note: The expected numbers are based on the indirect age-standardisation method. 
Source: AIHW National Hospital Morbidity Database. 
  Cancer in Aboriginal and Torres Strait Islander peoples of Australia: an overview 121 
Additional tables for Chapter 9: National cancer 
screening programs 
Table D9.1: Participation rate of women aged 50–69 in BreastScreen Australia, by Aboriginal and 
Torres Strait Islander status, 1996–1997 to 2010–2011 
Reporting period Indigenous Non-Indigenous 
1996–1997 28.9 39.5 
1997–1998 32.0 42.4 
1998–1999  33.7 43.1 
1999–2000 34.9 43.2 
2000–2001 35.9 44.0 
2001–2002 36.4 44.5 
2002–2003 36.7 50.0 
2003–2004  35.4 55.7 
2004–2005 35.2 56.1 
2005–2006 36.4 56.9 
2006–2007  36.2 56.1 
2007–2008 36.4 54.8 
2008–2009  36.5 55.2 
2009–2010 36.2 54.9 
2010–2011 36.2 54.6 
Notes 
1. Some jurisdictions do not use the ‘not stated’ category. Therefore there are likely to be some Aboriginal and Torres Strait Islander women 
incorrectly assigned to non-Indigenous status. Limitations of Aboriginal and Torres Strait Islander data are detailed in Appendix B. 
2. Rates are the number of women screened as a percentage of the eligible female population calculated as the average of the ABS’s 
estimated resident population and age-standardised to the Australian population at 30 June 2001. 
3. Each reporting period covers 2 years. For example, 1996–1997 covers 1 January 1996 to 31 December 1997.  
4. BreastScreen is a dynamic database, with new records added and the quality of existing records improved over time. For this reason, there 
is the potential for revisions of these data. 
Source: AIHW analysis of BreastScreen Australia data. 
  
 122 Cancer in Aboriginal and Torres Strait Islander peoples of Australia: an overview 
Additional tables for Chapter 10: Burden of disease 
due to cancer 
Table D10.1: Leading causes of burden of disease, by Indigenous status, per cent, Australia, 2003 
Cause Indigenous Australians (%) Total Australians (%) 
Cardiovascular disease 17 18 
Mental disorders 15 13 
Chronic respiratory disease 8 7 
Diabetes 8 5 
Cancer 8 19 
Unintentional injuries 7 5 
Intentional injuries 5 2 
Other 32 31 
Note: Total Australians includes Indigenous, non-Indigenous and Indigenous status not stated populations. 
Source: Vos et al. 2007. 
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Table D10.2: Rank of leading causes of DALYs, by sex and Indigenous status, 2003 
Males  Females 
Condition 
Indigenous 
Australians 
Total 
Australians   Condition 
Indigenous 
Australians 
Total 
Australians 
Ischaemic heart disease 1 1   Anxiety and depression 1 1 
Type 2 diabetes 2 2   Type 2 diabetes 2 4 
Anxiety and depression 3 3   Ischaemic heart disease 3 2 
Suicide 4 8   Asthma 4 9 
Road traffic accidents 5 12   COPD 5 7 
COPD 6 6   Stroke 6 3 
Alcohol dependence and 
harmful use 7 14   Road traffic accident 7 22 
Asthma 8 13   
Alcohol dependence and 
harmful use 8 34 
Stroke 9 5   Lung cancer 9 8 
Homicide and violence 10 46   Homicide and violence 10 75 
Low birthweight 11 37   Low birthweight 11 33 
Lung cancer 12 4   Pneumonia 12 16 
Pneumonia 13 21   Suicide 13 24 
Inflammatory heart disease 14 32   Breast cancer 14 6 
Heroin or polydrug 
dependence 15 24   Rheumatic heat disease 15 74 
Schizophrenia 16 16   Deficiency anaemia 16 52 
Epilepsy 17 36   Schizophrenia 17 19 
Hepatitis 18 23   Otitis media 18 81 
Birth trauma and asphyxia 19 54   Heroin or polydrug dependency 19 55 
Otitis media 20 81   STD (not HIV/AIDS) 20 86 
Note: Total Australians includes Indigenous, non-Indigenous and Indigenous status not stated populations. 
Source: Vos et al. 2007. 
Table D10.3: : Contribution (%) of leading causes of cancer burden of disease, by sex, Aboriginal 
and Torres Strait Islander peoples, Australia, 2003  
Cause Males (%) Females (%) 
Breast 1 99 
Colorectal 48 52 
Leukaemia 51 49 
Lung 51 49 
Mouth 61 39 
Total 46 54 
Source: Vos et al. 2007. 
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Table D10.4: Leading cancer causes of burden of disease, by fatal (YLL) and non-fatal (YLD) 
components, Aboriginal and Torres Strait Islander peoples, per cent, Australia, 2003 
Cause Years of life lost (YLL) (%) Years of healthy life lost (YLD) (%) 
Breast 89 11 
Colorectal 93 7 
Leukaemia 95 5 
Lung 98 2 
Mouth 88 12 
Total 94 6 
Source: Vos et al. 2007. 
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Appendix E: Clinical cancer groupings 
This report provides incidence and mortality numbers based on clinical cancer groupings 
(that is, clinical categories). For example, prostate, testicular, bladder and kidney cancers are 
grouped into ‘urogenital cancers’ as these cancers are most often treated by an urologist. 
Similarly, all cancers of female genital organs are grouped into ‘gynaecological cancers’ as 
these cancers are most often treated by a gynaecologist or gynaecological oncologist. See 
Table E1 for classification of clinical cancer groupings. 
Table E1: The corresponding ICD-10 codes for clinical cancer groupings  
Clinical cancer grouping Corresponding ICD-10 codes 
Skin C00, C43, C44, C46 
Head and neck C01–C14, C30–C32 
Upper gastrointestinal C15–C17, C22–C25 
Colorectal C18–C21 
Respiratory C33–C34, C37–C38, C45 
Bone and other connective tissue C40–C41, C47, C49 
Breast C50 
Urogenital C60–C68 
Gynaecological C51–C59 
Eye C69 
Neurological C70–C72 
Thyroid and other endocrine C73–C75 
Lymphohaematopoietic C81–C85, C88, C90–C96, D45, D46, D47.1, D47.3 
Ill–defined and unknown primary sites C26, C39, C48, C76–C79, C80 
Multiple primary C97 
 
  
 126 Cancer in Aboriginal and Torres Strait Islander peoples of Australia: an overview 
Appendix F: Definition of cancer-related 
hospitalisations 
Data on hospitalisations include principal diagnosis—this is the reason determined to be 
chiefly responsible for the person’s hospitalisation. The principal diagnosis recorded is 
usually a disease (or injury or poisoning), but can also be a specific treatment of an already 
diagnosed condition, such as chemotherapy for cancer. These treatments are usually coded 
using Z-codes defined in ICD-10-AM Chapter 21 ‘Factors influencing health status and 
contact with health services’ (NCCH 2010). 
Due to the method in which the principal diagnosis for hospitalisations of cancer patients is 
coded, it is insufficient to simply select those hospitalisations for which cancer was recorded 
as the principal diagnosis—it must also include those hospitalisations where a treatment 
relating to cancer was recorded as the principal diagnosis.  
Many cancer–related interventions recorded as a principal diagnosis (such as Z51.1 
Chemotherapy or Z12 Special screening examination for neoplasm) are specific only to the 
investigation for, or treatment of, cancer. However, some (Z45.1 and Z45.2 Adjustment and 
management of infusion pumps or vascular devices) apply to a number of disease types. 
For some cancer–related interventions (such as same-day chemotherapy), the Australian 
Coding Standards (NCCH 2010) stipulate that the principal diagnosis is to be coded to reflect 
the treatment with the type(s) of cancer listed as an additional diagnosis. This standard does 
not apply, however, to all cancer–related interventions. 
Thus, for the purposes of examining the number of admitted patient hospitalisations that 
arose due to invasive cancer or were directly related to the investigation, treatment or care 
for cancer, ‘cancer–related hospitalisations’ were identified in this report as those 
hospitalisations in which:  
 the principal diagnosis was cancer (ICD-10-AM codes C00–C97, D45, D46, D47.1 and 
D47.3)  
or  
 the principal diagnosis was related to health services or treatment for cancer. This 
includes a principal diagnosis of one of the following cancer-specific ICD-10-AM 
Z-codes: 
– Z08 Follow-up examination after treatment for malignant neoplasms  
– Z12 Special screening examination for neoplasm  
– Z40.0 Prophylactic surgery  
– Z51.0 Radiotherapy session  
– Z51.1 Pharmacotherapy session for neoplasm  
– Z54.1 Convalescence following radiotherapy  
– Z54.2 Convalescence following chemotherapy  
– Z80 Family history of malignant neoplasm  
– Z85 Personal history of malignant neoplasm 
or  
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 a principal diagnosis of one of the following non-cancer specific ICD-10-AM Z codes 
with an additional diagnosis of cancer (ICD-10-AM codes C00–C97, D45, D46, D47.1 and 
D47.3): 
– Z29.1 Prophylactic immunotherapy  
– Z29.2 Other prophylactic chemotherapy  
– Z42.0 Follow-up care involving plastic surgery of head and neck  
– Z42.1 Follow-up care involving plastic surgery of breast  
– Z45.1 Adjustment and management of infusion pump  
– Z45.2 Adjustment and management of vascular access device. 
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Appendix G: Guide to online 
supplementary tables 
Additional tables are available as online Excel tables at <www.aihw.gov.au>. These tables 
contain detailed statistics, some of which are presented in summary form in the body of the 
report. Throughout the report, online additional tables are referred to with a ‘G’, for 
example, ‘See online supplementary Table G3.1’. 
There are eight Excel files, each representing a chapter from the report: 
 Chapter 3—Incidence of cancer 
 Chapter 4—Mortality from cancer 
 Chapter 5—Survival after a diagnosis of cancer 
 Chapter 6—Prevalence of cancer 
 Chapter 7—Hospitalisations for cancer 
 Chapter 8—Expenditure on cancer 
 Chapter 9—National cancer screening programs  
 Chapter 10—Burden of disease due to cancer. 
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Glossary 
This section provides a general description of the terms used in this report. The terms are defined in 
the context of this report; some terms may have other meanings in other contexts. 
Aboriginal or Torres Strait Islander: A person of Aboriginal and/or Torres Strait Islander 
descent who identifies as an Aboriginal and/or Torres Strait Islander. See also Indigenous. 
Additional diagnosis: A condition or complaint either coexisting with the principal 
diagnosis or arising during the episode of care. 
Administrative databases: Observations about events that are routinely recorded or 
required by law to be recorded. Such events include births, deaths, hospitalisations and 
cancer incidence. Administrative databases include the Australian Cancer Database, the 
National Mortality Database and the National Hospital Morbidity Database. 
Admitted patient: A person who undergoes a hospital’s formal admission process to receive 
treatment and/or care. Such treatment or care can occur in hospital and/or in the person’s 
home (as a ‘hospital-in-home’ patient).  
Age-specific rate: A rate for a specific age group. The numerator and denominator relate to 
the same age group.  
Age-standardisation: A method of removing the influence of age when comparing 
populations with different age structures. This is usually necessary because the rates of many 
diseases vary strongly (usually increasing) with age. The age structures of the different 
populations are converted to the same ‘standard’ structure; then the disease rates that would 
have occurred with that structure are calculated and compared. 
Associated cause of death: Cause, other than the underlying cause, that was instrumental in 
causing death, including conditions that occurred immediately before death or close to the 
time of death or conditions that occurred between the underlying and immediate causes 
(also see Underlying cause of death). 
Average length of stay (ALOS): The average (mean) number of patient days for admitted 
patient episodes. Patients admitted and separated on the same date are allocated a length of 
stay of 1 day. 
Burden of disease and injury: Term referring to the quantified impact of a disease or injury 
on an individual or population, using the disability-adjusted life year (DALY) measure. 
Cancer (malignant neoplasm): A large range of diseases in which some of the body’s cells 
become defective, begin to multiply out of control, can invade and damage the area around 
them, and can also spread to other parts of the body to cause further damage. 
Chemotherapy: The use of drugs (chemicals) to prevent or treat disease, with the term being 
applied for treatment of cancer rather than for other uses. 
Cohort method: A method of calculating survival that is based on a cohort or group of people 
diagnosed with cancer in a previous time period and followed over time. 
Comorbidity: When a person has two or more health problems at the same time. 
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Confidence interval (CI): A statistical term describing a range (interval) of values within 
which we can be ‘confident’ that the true value lies, usually because it has a 95% or higher 
chance of doing so. 
Crude rate: The number of events in a given period divided by the size of the population at 
risk in a specified time period.  
Crude survival (CS): The proportion of people alive at a specified point in time subsequent 
to the diagnosis of cancer. 
Disability-adjusted life years (DALYs): A year of healthy life lost, either through premature 
death or equivalently through living with disability due to illness or injury. It is the basis 
unit used in burden of disease and injury estimates.  
Death due to cancer: A death where the underlying cause is indicated as cancer. 
Expected survival: A measure of survival that reflects the proportion of people in the general 
population alive for a given amount of time. Expected survival estimates are crude estimates 
calculated from life tables of the general population by age, sex and calendar year. 
Heath expenditure: Includes expenditure on health goods and services (for example, 
medications, aids and appliances, medical treatment, public health, research) which 
collectively are termed current expenditure; and on health-related investment which is often 
referred to as capital expenditure.  
Hospitalisation: See Separation.  
Incidence: The number of new cases (of an illness or event, and so on) occurring during a 
given period. 
Indigenous: A person of Aboriginal and/or Torres Strait Islander descent who identifies as 
an Aboriginal and/or Torres Strait Islander. See also Aboriginal or Torres Strait Islander. 
International Statistical Classification of Diseases and Related Health Problems: The 
World Health Organization’s internationally accepted classification of death and disease. The 
tenth revision (ICD-10) is currently in use. ICD-10-AM is the Australian modification of ICD-
10; it is used for diagnoses and procedures recorded for patients admitted to hospitals (see 
Appendix A).  
Invasive: See Malignant. 
Length of stay: Duration of hospital stay, calculated by subtracting the date the patient was 
admitted from the day of separation. All leave days, including the day the patient went on 
leave, are excluded. A same-day patient is allocated a length of stay of 1 day. 
Life tables: Tables of annual probabilities of death in the general population. 
Limited-duration prevalence: The number of people alive at a specific time who have been 
diagnosed with cancer over a specified period (such as the previous 5 or 25 years). 
Malignant: A tumour with the capacity to spread to surrounding tissue or to other sites in 
the body.  
Metastasis: See Secondary cancer.  
Mortality due to cancer: The number of deaths which occurred during a specified period 
(usually a year) for which the underlying cause of death was recorded as cancer. 
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Mortality-to-incidence ratio (MIR): The ratio of the age-standardised mortality rate for 
cancer to the age-standardised incidence rate for cancer. 
New cancer case: See Incidence. 
Neoplasm: An abnormal (‘neo’, new) growth of tissue. Can be ‘benign’ (not a cancer) or 
‘malignant’ (a cancer). Also known as a tumour. 
Non-Indigenous: People who have declared they are not of Aboriginal or Torres Strait 
Islander descent.  
Observed survival: A measure of survival that reflects the proportion of people alive for a 
given amount of time after a diagnosis of cancer. Observed survival estimates are crude 
estimates calculated from population-based cancer data. 
Other Australians: Includes people who have declared that they are not of Aboriginal or 
Torres Strait Islander descent as well as those who have not stated their Indigenous status. 
Overnight patient: An admitted patient who receives hospital treatment for a minimum of  
1 night (that is, is admitted to, and separates from, hospital on different dates). 
Patient days: The number of full or partial days of stay for patients who were admitted for 
an episode of care and who underwent separation during the reporting period. A patient 
who is admitted and separated on the same day is allocated one patient day.  
Period method: A method of calculating survival that is based on the survival experience 
during a recent at-risk or follow-up time period. 
Population estimates: Official population numbers compiled by the ABS at both state and 
territory and statistical local area levels by age and sex, as at 30 June each year. These 
estimates allow comparisons to be made between geographical areas of differing population 
sizes and age structures (see Appendix A). 
Prevalence (or complete prevalence): The total number of people alive at a specific date who 
have ever been diagnosed with a particular disease such as cancer. 
Primary cancer: A tumour that is at the site where it first formed (also see Secondary cancer). 
Principal diagnosis: The diagnosis listed in hospital records to describe the problem that 
was chiefly responsible for the patient’s episode of care in hospital. 
Procedure: A clinical intervention that is surgical in nature, carries a procedural risk, carries 
an anaesthetic risk, requires specialised training and/or requires special facilities or 
equipment available only in the acute care setting. 
Relative survival: The ratio of observed survival of a group of persons diagnosed with 
cancer to expected survival of those in the corresponding general population after a specified 
interval following diagnosis (such as 5 or 10 years). 
Risk factor: Any factor that represents a greater risk of a health disorder or other unwanted 
condition or event. Some risk factors are regarded as causes of disease, others are not 
necessarily so. Along with their opposites, namely protective factors, risk factors are also 
known as ‘determinants’. 
Same-day patient: A patient who is admitted to, and separates from, hospital on the same 
date. 
Secondary cancer: A tumour that originated from a cancer elsewhere in the body. Also 
referred to as a metastasis.  
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Separation: An episode of care for an admitted patient which may include a total hospital 
stay (from admission to discharge, transfer or death) or a portion of a hospital stay that 
begins or ends in a change of type of care (for example, from acute to rehabilitation). In this 
report, separations are also referred to as hospitalisations.  
Statistical significance: An indication from a statistical test that an observed difference or 
association may be significant or ‘real’ because it is unlikely to be due just to chance. A 
statistical result is usually said to be ‘significant’ if it would occur by chance only once in 20 
times or less often (see Appendix F for more information about statistical significance). 
Stage: The extent of a cancer in the body. Staging is usually based on the size of the tumour, 
whether lymph nodes contain cancer, and whether the cancer has spread from the original 
site to other parts of the body. 
Survival: A general term indicating the probability of being alive for a given amount of time 
after a particular event, such as a diagnosis of cancer. 
Symptom: Any indication of a disorder that is apparent to the person affected.  
Underlying cause of death: The disease or injury that initiated the sequence of events 
leading directly to death.  
Years of healthy life lost due to disability (YLD): For each new case of cancer, YLD equals 
the average duration of the cancer (to remission or death) multiplied by a severity weight for 
cancer (which depends upon its disabling effect over the disease duration). 
Years of life lost (YLL): For each new case, YLL equals the number of years between 
premature death and the standard life expectancy for the individual. 
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